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Abstract 
 
With a globally ageing population diseases associated with this natural 
process are becoming major issues worldwide. Research into the process of 
ageing and its concomitant issues is rapidly expanding; the need for new tools 
and models to investigate this rapidly expanding arena of research is 
paramount. The discovery of a spontaneous mutation in the AS rat strain 
which introduces a premature stop mutation into the gene encoding protein 
kinase C  (PKC lead to the development of a model for one such age related 
disorder, Parkinson‟s disease. Consequently, this model has been selected to 
investigate age related changes in specific areas of the brain (the cerebellum, 
basal ganglia, cerebral cortex and brainstem). These regions were selected 
because they have previously been shown to demonstrate changes with age 
(cerebellum, cerebral cortex and basal Ganglia), they show differences 
between the AS and AS/AGU strains (basal ganglia) or they show differences in 
PKC knockout models (cerebellum). The Brainstem was selected as it shows 
little change due to age and shows no differences in PKC knockouts or 
AS/AGU rats. This study used established qPCR methods to measure a 
validated biomarker of ageing, CDKN2A (the transcript for p16INK4a) in the 
brains of these rats to determine whether this model is in fact a genuine 
model for accelerated ageing. This thesis demonstrates that CDKN2A 
expression, in combination with senescence-associated -galactosidase 
staining, provides clear evidence of accelerated ageing in the brains of 
AS/AGU rats when compared with the parent AS strain.  
These investigations were furthered by an investigation of members of 
the Sirtuin family of proteins. The changes in expression of these Sirtuins 
indicates that there may be increased levels of cellular stress, disruption of 
metabolism and DNA damage in the AS/AGU rats, this would be congruent 
with the accelerated ageing phenotype present in this strain. Furthermore, 
the levels of these Sirtuins were in line with the predictions from the MTR 
trinity in regards to the accelerated ageing phenotype. Whilst some of the 
changes in senescence and metabolic disruption may be attributable to the 
PKC mutation in the AS/AGU rats, it would appear that there is some 
element of accelerated ageing that is independent of this mutation. 
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1.  Introduction 
 
1.1  Ageing 
 
The process of ageing in humans is broadly defined as the 
accumulation of changes in a person over time (Bowen and Atwood, 2004). 
These changes come in physical, biological, chemical and psychological 
forms, ultimately transforming the appearance and personality of the 
individual. In fact, a more recent definition by Fulop et. al., has described it 
as a complex phenomenon encompassing a series of deficits which 
accumulate at different rates, in different ways, in each individual; 
furthermore within the individual this occurs at different rates in different 
organs and tissues (Fulop, et. al., 2010). At the molecular level, a 
combination of factors which includes genes and environmental processes 
define the lifespan of an organism (Jazwinski, et. al., 1998; Takahashi, et. 
al., 2000). This has been reinforced by the generation of genetically 
engineered animal models which demonstrate an accelerated ageing 
phenotype (Kuro-o, et. al., 1997). The influence of environmental factors is 
highlighted in the case of the biologically immortal hydra (e.g. Hydra 
vulgaris) (Martinez, 1998) which does not undergo senescence, although this 
has been recently disputed (Estep, 2010), but is still subject to trauma and 
infection. Similarly, the planarian flatworm possesses extensive telomere 
regenerative ability and a highly proliferative population of adult stem cells 
(Tan, et. al., 2012), but again they are susceptible to trauma and infection 
indicating that they are not truly immortal. Additionally, lifespans of these 
worms vary greatly between species, demonstrating that age is a product of 
both genetic and environmental determinants. The term ageing is used to 
describe the process of progression through lifespan and the consequent loss 
of dynamic regulation of interactions at cellular, tissue and organ levels in 
the organism (Monaghan, et. al., 2008). 
 
The maximum lifespan or age at which an organism is considered 
elderly varies dramatically according to inherited differences amid species 
(Austad, 2009), for example an elderly mouse would be around 3 years old, 
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whereas a human would be 70-80 years old. However, high levels of variation 
in intra-species lifespan suggest that genetic factors alone are not sufficient 
to explain organismal ageing, thus environmental factors must play a major 
role.  
 
The proportion of individuals aged 60 or over is currently increasing in 
almost every country in the world, resulting in an ageing population as a 
whole. Current estimates believe that the percentage of the world‟s 
population over 60 will increase to 22% by 2050, this is double the 11% level 
seen in 2000. This is a result of longer life expectancy, as we understand the 
ageing process more, our ability to provide new treatments and policies to 
enhance the lifespan further continues to increase. Despite the fact that old 
age is no longer considered a cause of mortality, due to the proximal reasons 
normally being identified and recorded, it is the most potent driver of 
mortality in the world today. The increase in our older generations brings 
with it an increase in problems, diseases and disorders associated with age; 
these are now beginning to dominate, becoming ever more prevalent and 
presenting novel challenges for healthcare and society in general. This 
increase has concomitantly resulted in increased research into these 
disorders, and into ageing in general. Consequently, as a result of our ageing 
society and the improvements in general health and healthcare, the World 
Health Organisation (WHO) included four age-related causes of death in the 
top ten leading causes of death globally in 2002: Ischaemic heart disease 
(12.6%), Cerebrovascular disease (9.7%), Chronic obstructive pulmonary 
disease (COPD, 4.8%) and airway/lung associated cancers (2.2%) (WHO, 
2004). 
 
The significance of ageing, and its influence on society, has been 
studied for over a century. August Weissman, who developed the germ-plasm 
theory of inheritance (Weissman, 1893) which suggested distinct germ and 
somatic cell lineages, suggested that senescence is beneficial for the 
population as it removed older and less productive members (Weissman, 
1889). However, Weissman never addressed the issue of senescence as its 
existence was an assumption made within his theory. The evolution of 
senescence is still debated today, with three main theories of its 
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emergence, although strong ties between the theories are evident. The first 
theory, championed by Haldane (Haldane, 1941) and Medawar (Medawar, 
1952), suggests that the force of evolutionary selection declines 
proportionately with age, in accordance with Fisher‟s reproductive value 
(Fisher, 1930) – a measure of contribution to future generations by any given 
individual. This includes the proposition that an accumulation of deleterious 
mutations would occur in older individuals, resulting in reduced survival and 
reproductive capability. The second theory is an extension of the first by 
Williams (Williams, 1957), this theory, typically termed antagonistic 
pleiotropy, suggests senescence is a consequence of positive selection of 
genetic factors which have a deleterious effect in later life, i.e. due to 
higher numbers of living individuals in younger age classes, mutations which 
present favourable fitness benefits during early years are selected for even if 
they are detrimental in old age. The third theory, termed „the disposable 
soma theory‟ focuses on the balance between limited resources, self-
maintenance and additional activities (in particular reproduction) (Kirkwood, 
1977; Kirkwood, 2002; Kirkwood and Holliday, 1979). This theory postulates 
that unrepaired damage to molecules, cells and tissues as a result of 
metabolism and stress, as well as other factors, result in a decline in 
function. This is damage which accumulates with age (Sgro and Partridge, 
1999; Westendorp and Kirkwood, 1998); this theory also emphasises the 
influence of biochemical mechanisms, which prevent or repair this damage, 
have on the rate of accumulation. Although these three theories have been 
proposed it seems evident that these are consequently an evolution of the 
first theory as more is understood about the processes involved.  
 
The natural process of ageing in mammals follows a very similar 
overall trend, with increases in the biological functionality during the early 
stages of life, peaking in early adulthood, and thus prime reproductive age, 
before a slow decline. The rate of decline is determined by many factors, 
from diet and exercise to genetics and environmental factors. Ultimately, 
these factors mean that chronological age is not necessarily the optimal 
method to determine an individual‟s actual “health age” this has lead to 
research into “biological age”, or bio-age, which is determined by 
biochemical, epigenetic and genetic factors. The definition of a biomarker 
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of ageing (BoA) is a marker which alone or in composite will be superior in 
predicting functional outcome at a later age than chronological age alone, in 
the absence of disease (Baker and Sprott, 1988). These BoA provide greater 
insight into the actual age of an individual. Again, animal models which 
demonstrate accelerated ageing phenotypes demonstrate the importance of 
bio-age versus chronological age (Kuro-o, et. al., 1997). Furthermore, it has 
been demonstrated that psychosocial effects influence ageing in man, with 
higher prevalence of ageing related diseases being associated with lower 
socioeconomic status. For example links between the lower end of the socio-
economic scale and increased levels of inflammatory markers, as well as 
increased biomarkers for cardiovascular disease (CVD) have been 
demonstrated (McGuinness, et. al., 2012). This further reinforces the link 
between these socio-economic factors and accelerated bio-ageing. Matters 
are further complicated by the discovery that different organs/tissues can 
age at different rates, with respect to bio-age. For example, age-related 
disorders of the heart occur at much younger ages than those of the brain. It 
is also evident that the choices people make heavily influence how and when 
they, or specific parts of them, age. Over exposure to high levels of 
ultraviolet (UV) radiation for example induces premature ageing in the skin 
(also known as photo-ageing) (Gilchrest, 1990), studies in C. elegans have 
demonstrated a direct link between UV exposure and shortened lifespan 
(Klass, 1977). Smoking has been linked to increases in age-related disease 
susceptibility (Valdes, et. al., 2005), however the true nature of the 
relationship between smoking and ageing is masked by environmental 
exposure to passive tobacco smoke and other environmental toxins including 
car exhaust fumes; this makes finding a true negative exposure control 
almost impossible. Poor diet choices can lead to metabolic and intestinal 
problems earlier in life than would normally be expected. The effect of over 
eating on lifespan has been demonstrated with shortening of life expectancy 
in several models including protozoans (Rudzinska, 1952), rotifers (Fanestil 
and Barrows, 1965), nematodes (Klass, 1977) and rats (Ross, 1961; Ross and 
Bras, 1975). In humans obesity has also being linked with risk for age-related 
diseases (Valdes, et. al., 2005). Taking all of these factors into consideration 
it is now obvious that many of the day to day decisions we make may seem 
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trivial at the time, but ultimately they can have a monumental influence on 
our healthspan (years of healthy living). 
 
Different tissues age in different ways, making age related 
comparisons between tissues difficult. By segregating body tissues into four 
main categories these differences can be minimised and catalogued. Firstly 
there is connective tissue; this tissue generally becomes stiffer increasing 
the rigidity surrounding the body‟s organs, blood supply and airways. 
Ultimately this reduces the flow of nutrients and oxygen to tissues and 
organs resulting in reduced capacity throughout. Secondly, muscle tissue, 
including all forms of muscle: smooth or involuntary muscle which is an 
integral part of the stomach, intestine and other organs; striated or 
voluntary muscle which is responsible for conscious movement of the limbs 
and skeleton; cardiac muscle, another type of involuntary muscle which is 
found exclusively in the heart. Muscle tissue tends to atrophy, or reduce in 
size with a concurrent diminishment of capacity. Thirdly, epithelial tissue 
which lines the internal passages of the body as well as covering the exterior 
and protecting other body tissue from direct exposure to the environment. 
Similarly to connective tissue, epithelial tissue becomes more rigid or less 
elastic and suffers from a reduced regenerative capacity. Finally Neuronal, 
or nerve, tissue which encompasses the brain, spinal cord and peripheral 
nervous system (PNS), this tissue rarely regenerates and is generally 
replaced with scar tissue when damaged. Similar to muscle neuronal tissue is 
at high risk from atrophy. There are also overall differences in mass of 
organs as these atrophy with age, the largest age related changes in reserve 
function occur in the heart, lungs and kidneys. 
 
1.2  The biochemistry of ageing 
 
Ultimately all of the changes apparent with ageing are explainable at 
the biochemical level, the occurrence of premature ageing syndromes and 
creation of animal models which appear to prematurely age is evidence of 
the overall genetic control of ageing (Kuro-o, et. al., 1997). Cells, similarly 
to whole organisms, undergo symptoms of ageing with degradation of DNA 
over time, changes in morphology and ultimately senescence and apoptosis; 
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whereupon they stop growing and replicating, then finally “self-destruct”. In 
general the process of cellular ageing can be analysed as two distinct 
phenotypes, the first being proliferative senescence where ordinarily diploid 
cells lose their ability to divide, in vitro this limit is around 50 cell divisions, 
this phenomenon is also known as the “Hayflick Limit” after the author, Dr 
Leonard Hayflick, who first described it (Hayflick and Moorhead, 1961).  
Although incapable of reproduction these senescent cells maintain metabolic 
activities and generally adopt the senescence associated secretory 
phenotype: flattening of cell, altered gene expression and secretion profile; 
as well as demonstrating positive staining for Senescence associated  
galactosidase (SA -gal) (Campisi, 2013). Removal of senescent cells has 
been demonstrated to protect against ageing disorders (Baker, et. al., 
2011), thus implicating cellular senescence in the generation of age related 
phenotypes. The second is ageing and death of an individual post-mitotic cell 
(Kurz, et. al., 2000). These post-mitotic cells are found in specific areas of 
the body which are unable to replenish by replication, or mitosis, these 
areas replenish themselves from the germline, or stem cell population. 
However, there is one exception to this, the brain and nervous system, 
which is unable to replenish dead cells by either mitosis or from a stem cell 
population. Despite this apparent disadvantage the effects of cell depletion 
are not apparent until old age when neurodegenerative disorders and 
memory loss become more common. 
 
Looking at age related changes in tissues and organs it becomes 
evident that the type of change is related to the biochemistry or senescent 
status of the cell. Those cells which undergo regular mitotic division suffer 
from a reduction in elasticity and reduced regenerative capacity; whilst cells 
which do not undergo mitosis, post-mitotic tissues, atrophy with age due to 
in inability to replace lost or damaged cells. The ultimate cause of atrophy is 
unknown, however it is most likely a combination of reduction in use (or 
decreased workload), reduced nutrient/oxygen supply or a reduction in 
stimulation (by nerves or hormones). 
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1.2.1 Cellular senescence 
 
The process of cellular senescence gives us insights into the “ageing” 
of the individual cell and the pathways which govern it. The process of 
ageing and cellular senescence have become closely entwined (Jeyapalan 
and Sedivy, 2008), however it must be noted that senescence can occur 
without the necessary onset of age related changes. Believed to be a 
defensive mechanism against onset of neoplastic transformation, the term 
senescence is used to refer to age related phenotypic changes, 
incorporating many biological, developmental and maturational processes, 
which do not necessarily precipitate apoptosis. These changes include 
irregular morphology, a flattened appearance, and increased nuclei size 
(Suh, et. al., 2002; Wagner and Jansen-Durr, 2000). Due to the range of 
these alterations the phenotype of cellular senescence is complex 
(Takahashi, et. al., 2000). Furthermore, expression of another biomarker in 
the form of SA gal is also characteristic of senescent cells (Dimri, et. al., 
1995). Senescence is accompanied by an inflammatory secretome (Sikora, 
et. al., 2010). The onset of cellular senescence can be triggered by a 
number of factors. Firstly, the Hayflick limit, after a set number of 
replications a cell effectively retires and becomes senescent, sometimes 
referred to as replicative senescence (Hayflick and Moorhead, 1961). This is 
extremely important, as the longer a cell is active and the more times it 
undergoes mitosis the more likely it is to incur increased DNA damage 
which may ultimately lead to disastrous consequences, for example 
tumourigenesis. This process is effectively over-watched by the telomere 
system. Telomeres are found at the ends of each chromosome and 
comprise a nucleo-protein complex around a region of repetitive nucleotide 
sequences (Blackburn and Gall, 1978). These protect the ends of the 
chromosomes from degradation, at the expense of becoming shortened 
themselves via the end replication problem (Counter, et. al., 1992; 
Olovnikov, 1973). This shortening however, serves as a biological clock 
indicating the replicative history of the cell; once the telomeres have 
shortened to a specific length the cell undergoes senescence and/or 
apoptosis to protect the entire organism (von Zglinicki, 1998). This process 
was originally believed to be irreversible however some studies have 
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demonstrated that the key senescence regulator p16INK4a has the ability to 
induce reversible cellular senescence dependent on its expression and 
interaction with the Retinoblastoma (Rb) protein (Beausejour, et. al., 
2003). Telomere dysfunction, or accelerated shortening of telomeres, has 
also been demonstrated to be at the centre of a number of clinically 
diverse disorders which all ultimately demonstrate a catastrophic tissue 
failure (i.e. loss of function); for example, bone marrow failure or 
idiopathic pulmonary fibrosis (Armanios and Blackburn, 2012). The average 
length of telomeres in a given cell population can now be measured by 
quantitative polymerase chain reaction (qPCR), giving a rough guide to the 
bio-age and life expectancy of that cell population (Cawthon, 2002). 
However, it has also been demonstrated that the shortest telomere length 
in any given cell is critical for determining the lifespan of that cell 
(Hemann, et. al., 2001). This shortening is overcome in stem cells, and 
other immortalised cell lineages, where telomere shortening is counter-
acted by an enzyme called telomerase, which adds repeats back on to the 
ends of chromosomes to preserve the integrity of the genome in these cells 
(Blackburn, et. al., 1989). In a similar fashion to normal cells, inhibiting 
telomerase activity in immortalised cells, for example stem cells or cancer 
cells, results in apoptosis (Zhang, et. al., 1999). 
 
The second factor influencing the onset of cellular senescence is 
oxidative stress (Serrano and Blasco, 2001). Increased levels of oxidative 
stress induce senescence associated mechanisms and can result in early 
onset of senescence as a protective mechanism within the cell. This 
oxidative stress most often derives from reactive oxygen species (ROS) (Lu 
and Finkel, 2008). This can of course be either temporary or permanent 
dependent on the level, duration and severity of the stress on the cell. In 
fact if the stress is sufficiently severe the cell can rapidly undergo 
apoptosis to prevent further damage to surrounding tissues (Johnson, et. 
al., 1996). Tissue hypoxia has been demonstrated to inhibit senescence; 
increasing tissue hypoxia with increasing age provides a potential override 
for the tumour suppressor function of cellular senescence (Welford and 
Giaccia, 2011). 
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A third possibility for inducing senescence comes from toxicology, as 
specific toxins or environmental factors can induce senescence. For 
example, lipopolysaccharide has been demonstrated to cause cellular 
senescence in lung alveolar epithelial cells at sub-lethal doses (Kim, et. al., 
2011a). Bacterial heat-stable enterotoxin has also been demonstrated to 
induce cell cycle arrest (Basu, et. al., 2013).  
 
Finally, senescence can be induced by genetic, or more likely 
epigenetic, changes which result in aberrant expression of genes. This 
process is most often found in response to DNA damage and telomere 
erosion. Some genes are critical for senescence and their induction under 
specific circumstances can be used as a biomarker, p53 (Tyner, et. al., 
2002) and p16INK4a (Jacobs and de Lange, 2004) are two such genes. Recent 
studies have also suggested that p21, part of the p53 cellular senescence 
pathway, may also be able to induce senescence independently of p53 
(Zuo, et. al., 2012). Oncogenes have also been demonstrated to induce 
senescence, for example the oncogene ras can induce senescence via p53 
and p16INK4a (Serrano, et. al., 1997); another oncogene raf has also been 
shown to induce senescence in human fibroblasts (Zhu, et. al., 1998). In 
some cases senescence can be induced not by aberrant expression, but by 
anomalous activation of specific proteins. 
 
Originally presented as two independent hypotheses (Campisi and 
d'Adda di Fagagna, 2007), the process of cellular senescence is now widely 
accepted to be critical for two seemingly unrelated functions. These are 
tumour control and ageing, although more and more research is tying these 
phenomena together revealing overlapping pathways and mechanisms. The 
close links between these two functions can be epitomised by mouse 
models with hyperactive p53; these mice do not suffer from tumours but do 
exhibit severe and multiple symptoms of accelerated ageing (Tyner, et. al., 
2002). 
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1.2.2 Post mitotic cells – ageing and death 
 
The exact definition of what constitutes a „post mitotic cell‟ remains 
debated, with some believing it to cover both senescent and quiescent cells 
while others suggest that it only covers cells which do not exhibit mitosis 
and cell division after foetal development. However, the most common 
definition, and the one referred to from this point forward, is one which 
states that post mitotic cells are mature cells which are no longer capable 
of reproducing, or in fact re-entering the normal cell cycle (Campisi and 
d'Adda di Fagagna, 2007). This excludes quiescent cells which are capable 
of re-entering the cell cycle even after extended periods of inactivity in 
the cell cycle. Post mitotic cells are found throughout the body and include 
neurons, cardiac myocytes, skeletal muscle cells and terminally 
differentiated cells e.g. gut epithelial cells and peripheral blood cells 
(Terman, et. al., 2009). Generally the major post mitotic tissues are 
considered to be neural, cardiac and skeletal muscle, as these tissues are 
rarely replaced and can, in some instances, be as old as the organism itself 
(Bhardwaj, et. al., 2006). Due to the lack of normal proliferation and cell 
cycle, these tissues can only undergo limited repair and regeneration 
(Campisi and d'Adda di Fagagna, 2007). Furthermore this limited 
regenerative capacity has been linked to recruitment of mitotic stem cells 
(or their progeny) in the brain (Emsley, et. al., 2005) and heart (Srivastava 
and Ivey, 2006). Skeletal muscle is capable of complete regeneration due 
to somatic stem cells resident within the skeletal muscle itself (Shi and 
Garry, 2006), these stem cells are also known as satellite cells (Cossu and 
Biressi, 2005; Mauro, 1961).  
 
Within post mitotic cells, highly modified expression of anti-
apoptotic and cell cycle regulators is apparent. In particular, high 
expression of B-cell lymphoma 2 (BCL2; a proto-oncogene) (Hockenbery, et. 
al., 1991), an anti-apoptotic protein membrane protein found within 
mitochondria, has been noted (Hockenbery, et. al., 1990). The cyclins, 
cyclin dependent kinases (CDKs) and CDK inhibitors are also differentially 
regulated in post mitotic cells providing the mechanism for maintaining the 
cells in a quiescent state (Yoshikawa, 2000). In fact it has been 
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demonstrated, both in neuronally differentiated cell lines and sympathetic 
neurons, that CDK inhibitors are necessary for cell survival (Park, et. al., 
1996). Retinoblastoma (Rb) and the proteins which control its 
phosphorylation appears to be key to maintaining the quiescent state (Lois, 
et. al., 1995) and preventing apoptosis (Park, et. al., 1998). The Rb protein 
itself is differentially expressed between areas of neurogenesis and post 
mitotic neurons (Slack, et. al., 1993); as are the Rb family member p107 
(also known as Retinoblastoma like 1, or RBL1) (Gill, et. al., 1998) and p130 
(a Rb related protein), which is expressed in quiescent cells and decreased 
in cells re-entering normal cell cycle (LeCouter, et. al., 1996). This is to be 
expected as phosphorylation of Rb is essential for progression into the 
synthesis (S) and mitotic (Mi) phases of the cell cycle. 
 
Due to their very nature, these post mitotic tissues are present 
throughout the lifespan of the organism (Terman, et. al., 2009). In the case 
of skeletal muscle, its regenerative capacity maintains the population and 
replaces cells as necessary. However, in neural tissue regeneration is very 
limited and is restricted to only a few key neurogenic areas. There are two 
constitutive areas of neurogenesis: the hippocampal dentate gyrus (Altman 
and Das, 1965) and the olfactory bulb (Altman, 1969). However, there have 
also been other areas identified which possess potential regenerative cells: 
neural stem cells (NSCs). For example a primary cell line derived from the 
striatum of mice could be induced to proliferate and differentiate into cells 
which were morphologically and antigenically similar to neurons and 
astrocytes (Reynolds and Weiss, 1992). Another study demonstrated a 
similar phenomenon in rat cells in culture (Palmer, et. al., 1995), however 
neither of these studies demonstrated this in vivo. 
 
The regeneration of neuronal tissue is believed to result from small 
key areas of multipotent stem cells, some of which can migrate large 
distances across the brain (Lois and Alvarez-Buylla, 1993). These cells are 
capable of differentiating into different neuronal lineages including 
neurons, astrocytes and oligodendrocytes depending on the supporting 
signals present (Johe, et. al., 1996). Some cell models have been 
developed to mimic these cells in order to study neurogenesis; two of the 
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most significant models to date are embryonal carcinoma (EC) cell lines, 
for example murine P19 cells treated with retinoic acid (Ra) (McBurney, et. 
al., 1988) and Ra treated human NTera2 cells (Andrews, 1984). Ra 
treatment of P19 cells results in a differentiated population consisting of 
several neural post mitotic cells including: microglia-like phagocytes 
(Aizawa, et. al., 1991), astrocytes-like cells (Jones-Villeneuve, et. al., 
1982) and oligodendrocytes (Staines, et. al., 1996). The interplay between 
this regenerative capacity and the ageing process in the brain is still not 
fully understood. 
 
1.2.3 DNA damage repair mechanisms 
 
Due to the lack of replication, and thus dilution of post-mitotic 
tissues maintenance and repair become essential mechanisms for the 
healthy cell and disruption of these mechanisms can be catastrophic for 
post-mitotic cells and tissues. One such set of repair and maintenance 
mechanisms is DNA damage repair. 
 
The integrity of the genome, and the DNA which encodes it, is 
absolutely critical for the survival of any organism. This is reflected in the 
level of resources attributed to its accurate replication, protection and 
repair mechanisms. In particular a very high level of resources and 
complexity is attributed to the repair and maintenance of DNA. The 
extensive nature of these mechanisms also reflects the potential insults the 
genome can endure for example from UV light (Ravanat, et. al., 2001), 
radiation (Ward, 1988), hydrolysis (Lindahl, 1993), replication errors 
(McCulloch and Kunkel, 2008), incorporation of altered nucleotides 
(Shimizu, et. al., 2003), ROS (Cadet, et. al., 1997), RNS (Burney, et. al., 
1999), viruses (Chen, et. al., 2014), toxins (Bedard and Massey, 2006), 
pharmaceuticals and mutagens (Irigaray and Belpomme, 2009; Wogan, et. 
al., 2004). DNA is also inexorably linked to ageing, it has been postulated 
that the DNA repair mechanisms also play into the ageing mechanisms 
through their activation; it is also obvious that advancing age adversely 
affects the DNA repair mechanisms slowing them down and making them 
less efficient. These mechanisms are also closely linked to the cell 
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senescence and apoptosis pathways, for example cells can undergo 
reversible senescence to initiate repair or apoptosis in the event of 
catastrophic damage. 
 
1.2.3.1 Mismatch repair 
 
The mismatch repair system detects and repairs mismatched bases 
introduced during DNA replication and missed by the proof-reading 
component of the polymerases. This also incorporates loops that are 
generated by slippage in the replication of repetitive sequences. This 
system is one of the simpler processes and is accomplished in three steps: 
recognition, excision and repair (Fukui, 2010; Li, 2008). This system also 
demonstrates homology with the bacterial system found in E. coli 
(Modrich, 2006), with two protein complexes called MutS and MutL which 
are responsible for recognition of site (Su and Modrich, 1986) and 
initiation of repair respectively (Galio, et. al., 1999). 
 
1.2.3.2 Base excision repair 
 
Base excision repair (BER) occurs when a single nucleotide, or a 
small section, becomes damaged and needs to be replaced, this system 
comes into effect when there is little overall disruption to the DNA helical 
structure (Zharkov, 2008). A key example of this repair mechanism is the 
excision and replacement of Uracil bases in DNA, but incorporates a broad 
range of base alterations and damage including some methylations. There 
have been twelve DNA glycosidases, the enzyme responsible for binding to 
the damaged base and excising it, identified to date each with a unique 
single or small set of targets representing a different type of base damage 
(Jacobs and Schar, 2011). This system effectively swings the damaged 
base outward from the helical structure allowing easy access and excision, 
creating an abasic/apyrimidic or AP site (Hitomi, et. al., 2007). These AP 
sites are then treated by apurinc/apyrmidinic endonuclease 1 to create a 
single strand break flanked by 3' -OH and 5'-deoxyribose phosphate ready 
to accept a replacement base (Abbotts and Madhusudan, 2010). However, 
there are several potential 3' and 5' termini that cannot be treated by this 
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mechanism giving rise to a diverse set of enzymes and processes to create 
the 3'-OH and 5'-deoxyribose phosphate necessary for repair (Caldecott, 
2008). Once the break is repaired the site is filled and the ends ligated, 
these repairs are segregated into short and long patch repairs, the former 
is initiated in response to single base replacements each type of repair 
has its own mechanism with long patch requiring more input from the DNA 
replication machinery (Fortini and Dogliotti, 2007).  
 
1.2.3.3 Nucleotide excision repair 
 
The Nucleotide excision repair (NER) pathway is a more versatile 
system capable of responding to larger scale DNA malformities, which 
induce helical disruptions. One of the most prominent of these repairs is 
pyrimidine dimers. Despite the principals being similar NER is far more 
complex than BER requiring around thirty proteins in a mutli-step 
approach involving recognition, local helical disruption, excision, repair 
and ligation (Shuck, et. al., 2008). These repair pathways are subdivided 
into two categories: global genome NER and transcription-coupled NER, 
the former conducts repairs throughout the genome whereas the latter 
focusses solely on the coding strand of actively transcribed genes. The 
difference between these pathways is found in the recognition step and 
the proteins that accomplish this task (Dexheimer and Mathews, 2013).  
 
1.2.3.4 Double stranded breaks 
 
Double stranded breaks are potentially lethal and can induce 
chromosomal deletions and aberrations, making the repair of these breaks 
essential for cell survival and genome stability (Khanna and Jackson, 
2001; van Gent, et. al., 2001). There are two mechanisms for repairing 
this kind of break the first, homologous recombination, is more accurate 
and less error prone as it repairs the break using the intact sister 
chromatid as a template (Li and Heyer, 2008). The second type, non-
homologous end joining, is quite error prone and involves direct ligation 
of the ends (Lieber, 2010). 
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As would be expected a great numbers of problems and diseases 
are a result of DNA damage and in particular of malfunction of these 
repair mechanisms, for example many cancers involve an alteration in the 
repair mechanisms, particularly defects in mismatch repair systems 
(Peltomaki, 2001). Furthermore, Xeroderma pigmentosum, Cockayne 
syndrome and Trichothiodystrophy are all linked to genetic abnormalities 
in nucleotide repair which all demonstrate overlapping symptoms with 
cancer and premature ageing (Cleaver, et. al., 2009; Vermeulen, et. al., 
1997). 
 
1.2.4 Biomarkers of ageing  
 
Biomarkers represent useful tools for the in vivo and in vitro 
measurement of various phenomena, in this regard ageing is no different. 
Biomarkers in ageing are different to standard biomarkers which detect or 
monitor diseases. These biomarkers are by their very definition natural and 
normal, therefore molecules which naturally change with age are the only 
potential candidates. In order to assess the validity of any biomarker with 
regard to ageing a well accepted definition was published by Baker and 
Sprott in 1988: “a biological parameter of an organism that either alone or 
in some multivariate composite will, in the absence of disease, better 
predict functional capacity at some later age than will chronological age” 
(Baker and Sprott, 1988). This definition came with a more specific set of 
criteria for the determination and measurement of such a biomarker. These 
criteria were, the first four are based on the original set published by Reff 
and Schneider (Reff and Schneider, 1982), 1) non-lethal; 2) highly 
reproducible; 3) displays significant alterations during relatively short time 
periods; 4) critical to effective maintenance of health and prevention of 
disease; 5) reflects a measurable parameter that can be predicted at a 
later age; 6) reflects some basic biological process of ageing and 
metabolism; 7) should have high reproducibility in cross-species 
comparisons (Baker and Sprott, 1988; Reff and Schneider, 1982). These 
criteria are very useful but do have their limitations, for example with 
regard to criteria 1, it may not always be possible to measure a biomarker 
non-lethally particularly in sensitive tissues like the brain. Criteria 3, it is 
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possible that some biomarkers may experience bursts of activity/level 
changes due to environmental insults, but otherwise change at a different 
rate; this also leads to criteria 5 which implies that the level of the 
biomarker will change linearly over time and track with chronological age, 
by the very definition of a BoA neither of these would be true. Finally 
criteria 6 states that a BoA should be involved in ageing and metabolism, 
this may not necessarily be directly true, the molecule may influence 
metabolism indirectly e.g. through control of the cell cycle.  
 
The search for biomarkers has been further hampered by the inter-
species differences in ageing. It is obvious from lifespans that all organisms 
do not age equally, in fact some like the hydra are effectively immortal 
(Martinez, 1998), these differences in ageing suggest a mechanism or 
mechanisms which areimplemented and regulated differentially between 
species. Furthermore, the genetic variation between species suggests 
marked differences in the genes and proteins involved in the ageing 
processes may also be present. Despite this some of the ageing databases 
describe common elements present in ageing, for example GenAGE 
[http://genomics.senescence.info/genes/microarray.php, accessed on 12th 
January 2015]. This suggests that a common core of ageing processes may 
exist, with a variety of inputs and/or outputs which are species specific. 
 
Due to the highly selective nature of the criteria for a BoA very few 
BoA exist. In fact only two meet the definition of a BoA and come close to 
completely fulfilling these criteria, CDKN2A product p16INK4a and telomere 
length, however in direct comparisons telomere length has been shown to 
be weaker than CDKN2A (Shiels, 2012). Additionally CDKN2A has been 
shown to be superior to chronological age (Koppelstaetter, et. al., 2008; 
McGlynn, et. al., 2009). In terms of age related changes many candidates 
have been identified, although few meet these stringent criteria, for 
example the AGEMAP programme in mice sought to examine the age 
related changes throughout the mouse lifespan. This study demonstrated 
that not only did many genes change in association with advancing age, but 
that changes were different between tissue types (Zahn, et. al., 2007). 
Several databases also exist which list genes that have been associated 
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with ageing in a variety of species, including rat and human; for example 
GenAge (Human) [http://genomics.senescence.info/genes/allgenes.php, 
accessed on 3rd January, 2015], AnAge (animal species) 
[http://genomics.senescence.info/species/, accessed on 3rdJanuary, 2015)  
 
1.3 Theories of ageing 
 
There are several different theories of ageing and how the processes 
involved are related and controlled. In general, these theories can be 
divided into two classes, programmed and stochastic. Theories in the 
programmed classification use the biological clock basis, where all events 
and genetic changes are, in general, a result of a pre-determined sequence. 
The stochastic theories cite environmental effects on organisms which 
induce cumulative damage resulting in ageing; this can come in the form of 
DNA damage, tissue or cell damage as a result of free radicals. 
 
From all of these theories of ageing it is evident that no single process 
or pathway is responsible for all of the effects and changes induced by 
advancing age, biological or chronological. Furthermore, these theories are 
not exclusively independent of one another; in fact several of these theories 
could be construed as advancements or amalgamations of previous theories. 
Currently, theories of ageing are classified into two categories: the 
programmed theories and the damage or error theories, the following 
theories are extrapolated from the categories suggested by Kunlin Jin (Jin, 
2010).  
 
1.3.1 The programmed theories 
 
The programmed theories follow the basic premise that ageing is 
predetermined in some form or other. This pre-determination can be 
minimally influenced by other factors but in general follows a 
predetermined route with specific events on a defined schedule. There are 
three main theories within this sub-category, these are outlined below: 
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1.3.1.1 Programmed longevity theory 
 
This theory stipulates that ageing, and all if its consequences, is a 
direct result of sequential activation/silencing of specific genes, in a 
programmed manner. This ultimately leads to senescence when the 
correct set of genes is activated due to age related defects becoming 
evident. Many believe that this theory includes provisions that explain the 
effects of ROS and other damage mechanisms (Longo, et. al., 2005). It has 
also been proposed that this theory could be expanded to incorporate 
elements of altruism (Longo, et. al., 2005), this suggests that an organism 
can pass advantages onto its kin or group members by remaining within 
the group. This in turn  be selected for and would improve the survival of 
such genetic traits that promote longevity (Longo, et. al., 2005). 
 
This theory also incorporates many of the ideas found in the 
antagonistic pleiotropy theory of the origin of ageing; which postulates 
that some genes are inherited because they are beneficial to younger 
organisms, despite having deleterious effects in old age. In other words 
genes are selected for by their benefits in reaching and utilising the 
fertile period, which outweigh any later costs when an organism is no 
longer able to reproduce. This idea was first suggested by George Williams 
(Williams, 1957) and was based on an original idea presented by Peter 
Medawar (Medawar, 1952). In more recent times this view on the origin of 
ageing has been challenged due to a lack of clear cut examples (Kirkwood, 
2005). Indeed one of the strongest classical examples of this was p53, 
however its position as a clear cut example has recently been challenged 
(Blagosklonny, 2010b). However, a new example in the form of 
mammalian target of rapamycin (mTOR) has emerged (Blagosklonny, 
2010b). It has also been demonstrated that calorie restriction (CR) can be 
antagonistically pleiotropic, although in the opposite direction (harmful in 
early life, but beneficial in ageing) (Blagosklonny, 2010a). This indicates 
that many of the genes regulated by CR may be involved in the principal 
behind antagonistic pleiotropy. This theory does not however address the 
promotion of mutations which have no obvious fertility/early growth 
benefits but do present improvements in longevity (Longo, et. al., 2005). 
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Examples of this are the deletion of a guanine nucleotide-binding protein 
known as RAS2 in yeast or the insulin like growth factor 1 known as daf-2 
mutants in Caenorhabditis elegans (C. elegans) (Kenyon, 2011; Longo and 
Finch, 2003). 
 
1.3.1.2 Endocrine based theory 
 
The endocrine theory, or hormone theory of ageing, suggests that 
the most important factors involved in ageing are the changes induced by 
the endocrine system. This theory is supported by the influence of insulin 
and insulin-like growth factor (IGF) on longevity (Tatar, et. al., 2003; van 
Heemst, 2010). This has been elegantly demonstrated in C. elegans by 
investigating longevity mutations and tracing the causal genetic mutation 
back to the IGF signalling cascade (IIS) (Honjoh, et. al., 2009; Kenyon, et. 
al., 1993). This effect, mediated through FOXO, has also been 
demonstrated in Drosophila models (Tatar, et. al., 2001). Growth 
hormone (GH) has also been implicated via its receptor, growth hormone 
receptor (GHR); this integral component of the endocrine system has been 
demonstrated to be involved in longevity in a knock out mouse model 
(Arum, et. al., 2009). The highly entwined nature of the IIS and GH 
pathways in higher mammals has made it extremely difficult to examine 
the roles of these molecules independently; however deletion of insulin 
receptor, specifically in the fat tissue of mice, increases life expectancy 
(Bluher, et. al., 2003). GHR knockout mouse models have also 
demonstrated the same effects mediated through reduced GH/IGF-1 
signalling (Chandrashekar, et. al., 1999; Flurkey, et. al., 2001). It is 
obvious from these reports that the hormonal system, particularly relating 
to metabolism, has a large impact on lifespan. This theory has also 
attributed control of circadian rhythms to the hormone system; however 
it is still disputable whether hormones drive or are driven by circadian 
rhythms. 
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1.3.1.3 Immunological theory 
 
Some have postulated that the immune system is programmed 
reduce over time, thus increasing susceptibility to infection resulting in 
ageing and death. Given a high level of ROS involvement in the activity of 
the immune system it is possible to tie some of these effects into the 
damage and error theories, particularly the free radicals theory (see 
below, 1.3.2.4 Free Radicals Theory). However, it is well documented 
that immune function peaks at adolescence and then declines with age; 
resulting in reduced ability to fight disease, causing cellular stress 
(Cornelius, 1972).  
 
The immunological theory of ageing was first proposed by Roy 
Walford, who suggested that ageing is related to faulty immune function 
(Walford, 1964). This is tentatively supported by clinical observations that 
some immune function traits are associated with early mortality, 
regardless of the ultimate cause of death (Wayne, et. al., 1990; Wikby, 
et. al., 1998). Further evidence for this theory can be gleaned from C. 
elegans mutants with a daf-2 mutation which results in an extended 
lifespan; these mutants are also highly resistant to bacterial pathogens 
(Garsin, et. al., 2003). However, it should be noted that the involvement 
of daf-2 implicates the IGF pathways, which ties this theory with the 
endocrine theory (see above, 1.3.1.2 Endocrine based theory). Another 
major driver of this theory is T cell replicative senescence (Effros, 2004). 
Basically, the diversity of antigen recognition in the T cell population is 
driven by proliferation, with each T cell forming a unique combination of 
DNA encoding a T cell receptor. This combination is unique to each T cell 
and its progeny. Replicative senescence of T cells results in reduction and 
or loss of these unique receptors, thus reducing the available repertoire. 
Reduction in immunoregulatory molecules (cytokines and chemokines) 
from ageing natural killer (NK) cells further debilitates the immune 
system and its function. This is combined with a direct decline in the 
cytotoxicity of the same NK cells which results in impaired NK cell 
function (Hazeldine and Lord, 2013). This further ties this theory with the 
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„Hayflick limit‟ (Hayflick and Moorhead, 1961) or programmed longevity 
(see above, 1.3.1.1 Programmed longevity theory). 
 
Additionally, the involvement of the immune system in diseases 
associated with ageing for example Alzheimer‟s disease (AD) provides 
further evidence that the immune system may be involved in ageing 
(Rozemuller, et. al., 2005). The immunological theory, similarly to other 
theories, is ultimately a question of which comes first. It is obvious that 
reduced numbers of immunological cells are involved in establishing the 
phenotype of ageing. However, the question remains whether this 
reduction is a cause or a consequence of normal biological ageing? 
 
1.3.2 The damage or error theories 
 
The damage or error theories of ageing are based on the belief that 
ageing is a result of damage, both acute and chronic, or errors in repair 
mechanisms which accumulate over time. This ultimately results in an 
accumulation of biological problems as age increases, until these 
unresolved issues overwhelm the cell/organism and result in its death. In 
this context the senescence and apoptotic pathways are believed to 
protect against this by eliminating or halting cells that are too badly 
damaged, or full of errors, to be of further use to the organism. In actual 
fact, these cells may become a liability with errors that lead towards 
tumourigenesis. 
 
1.3.2.1 The wear and tear theory 
 
Exactly as it reads, this theory is based on the principal that all 
physical components of the body accumulate damage or „wear‟, with 
specific traumatic events inducing more severe damage in a short space of 
time, simply put as „tear‟. This theory was first postulated by Dr August 
Weissman in 1882 and stipulates that overuse and abuse lead to damage 
which ultimately overcomes repair mechanisms and causes us to age. This 
theory covers many of the modern insults to our bodies, including over 
consumption of sugar, alcohol, fats and caffeine; as well as our use of 
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nicotine, over exposure to UV light and other physical, emotional and 
environmental stress which have become an everyday part of our 
lifestyles (Salvi, et. al., 2006). 
 
Whilst appealing to the general public because it fits with the 
visual observations of ageing, this theory is no longer a prominent one. In 
fact this theory has been superseded by more modern and explanative 
theories, which describe the same phenomenon in more depth and with 
an appropriate mechanism. Both the free radicals theory (see below, 
1.3.2.4 Free radicals theory) and the disposable soma theory (see below, 
1.3.2.5 Disposable soma theory) can be viewed as examples of this. 
 
1.3.2.2 Rate of living theory 
 
The rate of living theory of ageing suggests that the basal 
metabolism rate, particularly the use of oxygen in metabolism, is directly 
related to its lifespan. This is based on studies in C. elegans which 
demonstrated that increased metabolism resulted in shortened lifespan 
(Brys, et. al., 2007). A modified version of the original theory (Pearl, 
1928) has been proposed which incorporates the antagonism seen 
between growth and stress in normal ageing, demonstrated by TOR and 
FOXO signalling pathways (Rollo, 2010). More recently, this has been 
developed to address a range of age related non-communicable diseases 
which appear to have common underlying cellular and molecular 
components, despite disparate overt pathologies. 
 
Despite some considering this theory as an independent entity, 
many consider this theory as synonymous with the free radicals theory 
(see below, 1.3.2.4 Free radicals theory), including Brys et al, the authors 
that originally demonstrated the links between metabolism and lifespan 
(Brys, et. al., 2007). In fact, others have postulated that this idea forms 
the basis of an oxidative-stress theory of ageing which incorporates the 
concepts of increased ageing resulting from oxidative damage, 
metabolism and stress (Hulbert, et. al., 2007). This in turn links to the 
lysosomal-mitochondria axis theory of ageing which postulates that the 
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damage from free radicals, and thus from mitochondria, progressively 
accumulates particularly in post-mitotic tissues resulting in ageing (Brunk 
and Terman, 2002; Terman, et. al., 2006; Terman, et. al., 2009). There is 
some evidence, from studies on Saccharomyces, that a substantial, almost 
catastrophic, drop in Nicotinamide adenine dinucleotide phosphate 
(NADPH) levels early in life initiates the ageing processes; furthermore it 
is suggested that activities which raise NADPH levels delay these 
processes, for example CR (Brandes, et. al., 2013). 
 
Notably, modulation of the Nicotinamide adenine dinucleotide 
(NADH) precursor Nicotinamide (NAM) in vivo, leads to an increase in 
healthspan and lifespan in mice (Schmeisser, et. al., 2013). There have 
been a few reports which indicate that ROS production increases with age 
in various mammalian tissues; for example the brain, liver and heart of 
rats (Sohal, et. al., 1990; Sohal and Brunk, 1992) and the brain, kidney 
and heart of mice (Sohal, et. al., 1994). Furthermore it has been 
demonstrated that redox couple ratios (e.g. NADH/NAD+ and 
NADHP/NADP+) become more oxidising with age (Noy, et. al., 1985). 
Interestingly, it has been demonstrated recently that phosphate 
homeostasis plays a role in healthspan (Stenvinkel and Larsson, 2013). 
This role appears to be substantial and is supported by numerous systems 
within the organism to maintain this homeostasis, e.g. FGF-23, FGF-7 and 
MEPE; as well as protective mechanisms to prevent phosphate toxicity, 
including parathyroid hormone (White, et. al., 2006). Phosphate is a 
critical post-translational modification for many proteins which can 
effectively activate many enzymatic functions and an imbalance in levels 
can lead to a severe disruption of cellular function. Hyperphosphatemia is 
most commonly associated with chronic kidney disease, where it is 
considered a cardiovascular risk factor due to vascular calcification 
(Hruska, et. al., 2008).  
 
1.3.2.3 Cross-linking theory 
 
First suggested by Johan Bjorksten in 1942, the cross-linking theory 
suggests that glycation interactions between proteins and lipids in the 
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presence of excess glucose, particularly proteins like collagen, disrupts 
the normal function of these proteins resulting in accelerated ageing 
(Bjorksten, 1968). The accelerated ageing seen in diabetics appears to 
support this particular theory. Further evidence has been presented that 
chemical crosslinking agents can be used to alter proteins from young 
human brains to make them resemble those found in age advanced 
samples (Bjorksten and Tenhu, 1990).  
 
The evidence for this theory is rather limited and it may be 
considered more of a niche theory. This theory still fits comfortably into 
the premise that ageing is a result of a general accumulation of damage 
throughout the lifespan and that crosslinking is one form of that damage.   
 
1.3.2.4 Free radicals theory 
 
The free radicals theory is built on the observations of Gerschman 
et al. who demonstrated the toxic effects of ROS (Gerschman, et. al., 
1954). The theory is based on the principal that free ROS, produced as a 
result of normal metabolism, cause damage to macromolecules, 
organelles, cell membranes and DNA/RNA; it postulates that the process 
of ageing is a direct result of the cumulative damage that ROS inflict over 
time (Balaban, et. al., 2005; Harman, 1956). There is a robust and 
substantial literature supporting this effect (Beckman and Ames, 1998). 
Furthermore, ROS signalling has emerged as a key moderator of both 
cellular senescence and whole organism ageing (Afanas'ev, 2010). 
However, there is some evidence that low-levels of ROS may have a 
positive influence on lifespan, derived from observations on C. elegans 
involving the consumption of a known chemical ROS generator, juglone (5-
Hydroxy-1,4-naphthalenedione) (Heidler, et. al., 2009). The addition of 2-
Deoxyglucose, which effectively blocks glycolysis and glucose metabolism 
(Sols and Crane, 1954), increases mitochondrial respiration and ultimately 
results in an increase in ROS and extends lifespan. The addition of an 
antioxidant along with the 2-Deoxyglucose removes this life extending 
phenomenon (Schulz, et. al., 2007). It should be noted that an alternative 
hypothesis, involving acetate toxicity and pH resulting in ageing as 
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opposed to oxidation, at least in yeast (Burtner, et. al., 2009). Overall, 
the influence of ROS on ageing is no longer disputed, however whether 
the damage caused by high levels of them is a result or a process of 
ageing is still debated (Salmon, et. al., 2010). 
 
1.3.2.5 Disposable soma theory 
 
The disposable soma theory takes Weissman‟s stipulation that 
mechanical and/or chemical damage could be repaired to a high degree of 
fidelity (Weissman, 1889) and balances it with energy requirements. 
Basically, the repair of such damage requires energy and this demand for 
energy must be balanced with other organismal requirements; ultimately 
this leads to compromises between repair mechanisms and lifespan, 
growth or reproductive ability (Kirkwood, 2005). This is supported by 
observations indicating decreased fertility/growth is found in many long-
lived mutant organisms (Longo and Finch, 2003). This has led to the idea 
that damage repair is balanced with other needs, therefore the need for 
extensive repairs may lead to a lack of fidelity due to insufficient energy 
availability. Seemingly at odds with this theory is the discovery that CR 
increases lifespan in a broad range of organisms (Mitteldorf, 2001). 
However, it is also notable that CR restricts growth and reduces energy 
investment in reproductive capability; this may ultimately lead to an 
increase in the level of energy available for repair and maintenance 
mechanisms (Mitteldorf, 2001; Shanley and Kirkwood, 2000). CR also 
facilitates a more efficient state of energy production and hence lowers 
the rate of ROS production during metabolism, thus mitigating ROS 
damage over time. 
 
1.3.2.6 Error catastrophe theory 
 
This theory was proposed and developed by Leslie Orgel (Orgel, 
1963; Orgel, 1970; Orgel, 1973) and covers the DNA damage that occurs in 
every organism due to replication and environmental insult (Saul and 
Ames, 1986). Despite extremely accurate and effective repair and 
protection mechanisms some damage occurs that is not repaired or 
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replaced. These mutations accumulate at an increasing rate with age 
resulting in loss of function and cell death. This forms the basis of this 
particular theory where these errors accumulate over time resulting in the 
characteristics and pathologies we associate with ageing. Furthermore, 
the accumulation of these errors would further restrict the repair of 
future errors resulting in an exponential increase in error occurrence and 
accumulation. This theory has been analysed and supported by 
mathematical models which suggest that the accumulation of errors below 
a specific threshold would be dealt with by the systems in place; however 
upon reaching and broaching the threshold errors would begin to 
accumulate ultimately resulting in an error catastrophe (Goel and Ycas, 
1976). 
 
1.3.3 Post mitotic cells and ageing 
 
Post mitotic cells, by their very definition, manifest ageing 
differently than mitotic cells. They already exhibit some of the conditions 
considered to be senescent. In fact, many consider the process of ageing to 
be mainly focussed on the post-mitotic tissues, particularly the cardiac and 
neural tissues. In these cells, which don‟t actively divide and thus are 
incapable of replacing or diluting damaged tissues, there is believed to be 
an accumulation of detritus (damaged biological structures) (Terman, et. 
al., 2006). Furthermore, post mitotic tissues like neurons and cardiac 
myocytes have higher energy requirements (Grote, 1989); this in turn leads 
to greater levels of oxygen metabolism and ROS production. The idea that 
metabolism is at the centre of ageing is supported by data which suggests 
that mitochondrial function declines with age (Byrne, et. al., 1991). This is 
consistent with the mitochondrial environment being more prone to 
mutation due to the high local levels of ROS, less efficient DNA repair and 
having a high turnover (Byrne, et. al., 1991). When ROS accumulation was 
investigated, it was demonstrated that this increase was not associated 
with disruption of oxygen metabolism in the mitochondria using a mutant 
mouse model (Trifunovic, et. al., 2004). In fact these mutant mice 
demonstrated an increased ageing phenomenon without any associated 
increase in ROS production or oxidative stress, potentially indicating that 
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disruption of metabolism is enough to induce an increased ageing 
phenotype (Trifunovic, et. al., 2005). This further supports the idea that it 
is accumulation of damaged structures which results in ageing; this could 
be a result of ROS or translation/transcription issues which would include 
DNA damage. 
 
Another important component of this system is phosphate 
equilibrium. Phosphate is a critical component of the cellular balance, 
required for functions ranging from intracellular/extracellular signalling, 
lipid biosynthesis and the formation and maintenance of DNA both directly 
and indirectly (Bergwitz, et. al., 2013). In mammals levels of phosphate in 
the blood and retention/excretion of phosphate is tightly regulated by 
Fibroblast growth factor 23 (FGF23), parathyroid hormone and 1,25-
dihydroxy vitamin D (1,25(OH)2D) (Bergwitz and Juppner, 2011; Bringhurst 
and Leder, 2006). Disruption of these mechanisms has been demonstrated 
to result in severe human disease (Bringhurst and Leder, 2006). Knockout 
Fgf23 mice have drastic growth retardation and abnormal bone formation 
in addition to a greatly reduced lifespan (Shimada, et. al., 2004). The 
toxicity of high phosphate levels (hyperphosphatemia) has been 
demonstrated by knockout mouse models for klotho, these mice have a 
shortened lifespan and show signs of premature ageing (Ohnishi and 
Razzaque, 2010). Furthermore, when this knockout was combined with a 
sodium-phosphate cotransporter knockout the premature ageing effects 
were ameliorated; feeding these mice a phosphate rich diet again reduced 
lifespan and induced a similar premature ageing phenotype (Ohnishi and 
Razzaque, 2010). Hyperphosphatemia is most commonly seen in patients 
with chronic kidney disease (CKD), where serum phosphate levels can be 
predictive of outcome (Razzaque, 2009). Similarly, hypophosphatemia has 
severe consequences, most commonly seen as a result of cancer or 
malnutrition this too can have lifespan reducing consequences (Bergwitz 
and Juppner, 2009).  
 
Phosphate is so critical to cellular functions that it is stored, as poly 
P chains, in both bacterial and mammalian cells (Docampo, et. al., 2005). 
In mammals the concentration of poly P can reach 1.5M under normal 
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physiological conditions (Kumble and Kornberg, 1995). These intracellular 
stores of phosphate appear to stimulate the activity of mTOR, which is a 
critical component of the regulation system for cell growth and 
proliferation (Schmelzle and Hall, 2000). The importance of phosphate 
balance in the control of redox has been established through the 
NADH/NADPH mechanism which is essential not only as a signalling 
mechanism, but also as a form of resistance to oxidative stress. This is 
evidenced by the lifespan promoting effects of glucose-6-phosphate 
dehydrogenase (G6PD) a critical enzyme in NADPH biosynthesis (Legan, et. 
al., 2008). The combination of these factors indicates that phosphate levels 
and regulation are critical for both energy production and usage, which is 
evident in the consequences of its disruption. Furthermore, this suggests 
that phosphate regulation may also contribute significantly to not only the 
generation of ROS but also to ageing related damage accumulation more 
directly. 
 
Despite apparent evidence that ROS itself is not responsible for 
ageing, human studies have demonstrated a significant increase in ROS 
production from 40 years old upwards; thus demonstrating an association 
between increased ROS and age. It has been suggested that this increase 
may result from an up-regulated inflammatory response related to age. 
Increases in ROS are associated with inflammation and the destruction of 
healthy tissue (Winrow, et. al., 1993); this is also part of a positive 
feedback loop where inflammation promotes ROS production which further 
increases inflammation associated gene transcription (Conner and Grisham, 
1996). Although, there is some debate as to which comes first as ROS 
damage has been shown to initiate the inflammatory response which leads 
to ageing (Chung, et. al., 2001). Alternatively, ageing may be associated 
with an age-related reduction in antioxidant defensive mechanisms, which 
gives some credence to the programmed theories of ageing. 
 
1.3.4 Combined theories 
 
Although no official combined theories have been presented, it is 
rapidly becoming the consensus that most if not all of these theories have 
P a g e  | 1-49 
Ageing in the Mammalian Brain 
merit and that the true process of ageing is likely to be an amalgamation 
of these ideas. Some researchers have attempted to unify these theories 
under other auspices, for example a reduction in bioenergetics as we age, 
driven by the mitochondria, has been suggested as the central tenet for 
biological ageing (Trubitsyn, 2012). However, this particular theory states 
that the reduction in bioenergetics is programmed but does not address 
the possibility that this programmed reduction is a result of ageing or 
progressive damage.  
The most successful combined theory to date is the MTR theory 
(mitochondrion, telomere nucleo-protein complexes and the control of 
ribosome biosynthesis) (Shiels and Davies, 2004), which effectively 
integrates energy production/usage with damage detection and responses. 
This covers three critical areas of ageing the ability to detect and respond 
to oxidative damage, the production of energy (and thus ROS) and the 
measurement of energy usage. The Sirtuin family of proteins are critical 
regulators of all three components of the MTR making them ideal markers. 
The demonstrable roles for the various Sirtuins in CR and enhancement of 
lifespan and healthspan add further credence to this theory. Furthermore, 
the AGEMAP study demonstrated that a geneset based around the NADH 
dehydrogenase system, which is related to mitochondrial and Sirtuin 
function, is differentially expressed in accordance with age this supports 
the mitochondrial arm of the MTR theory. Providing support for the 
ribosomal arm of the MTR theory is the discovery that gene sets related to 
the function of the ribosome also demonstrate age-related changes in the 
mouse model (Zahn, et. al., 2007). Many of the genes found in the ageing 
databases also have functions related to the MTR trinity either directly or 
indirectly. 
 
The association of specific genes and pathways with longevity or 
lifespan across multiple species strongly indicates that there is a genetic 
(or programmed) component. Likewise, the evidence for the influence of 
diet, toxins and oxidative stress in terms of longevity is similarly 
irrefutable. This leads to the optimal conclusion that ageing is 
programmed but heavily influenced by our environment and the 
damage/stress we undergo; as well as by internal mechanisms including 
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the action of the endocrine and immunological systems. This combined 
approach also helps to explain the discrepancies in both types of theory. 
In fact, the main dispute between these theories is whether programmed 
deterioration leads to increased susceptibility to damage (or wear and 
tear) or whether this damage leads to the activation/silencing of genes 
resulting in the consequences of ageing; i.e. which comes first. 
 
1.4  Diseases of ageing 
 
There are many diseases associated with ageing, some obvious and 
well known and others which are not generally considered as being so closely 
linked with ageing. However, when analysing the effects of cellular 
senescence and the molecules involved in it, it becomes obvious that 
diseases like cancer are closely linked to the ageing process. Some of the 
most well known and high incidence diseases related to advanced ageing 
now have well documented connections with the processes and molecules 
involved in the ageing process. The connections of these diseases with 
ageing is strengthened by the influence each has on the prevalence of 
others, most are considered co-morbidities with at least one or two other 
diseases of ageing. In fact, most of these ageing associated diseases share a 
low grade pro-inflammatory status (Olivieri, et. al., 2013). Furthermore, age 
associated diseases may also be related to early life environmental 
influences, in particular extreme CR (Tarry-Adkins and Ozanne, 2014). The 
main diseases of ageing are outlined in Table 1.1 below. 
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Table 1.1 Age related diseases. The major age related diseases are described and their links to ageing presented here. 
 
Disease Description and aetiology 
Arthritis There are over 100 variations of this inflammatory joint disorder, although these tend to fall into three 
categories: auto-immune, infection and degenerative. It is the latter of these that is related directly to 
advanced ageing, however auto-immune forms have late onset and are also considered related to age. Common 
symptoms for all forms of arthritis include pain, swelling and stiffness of the affected joints. There are several 
forms of arthritis, most of which increase with age indicating that this is a prominent disease of ageing and 
consequently is a major issue for the provision of healthcare in an ageing society. 
Osteoarthritis: Obesity and age are the most common risk factors (Arden and Nevitt, 2006); may be a disease of 
“wear and tear”. There are differences in occurrence between sexes and races (Arden and Nevitt, 2006); 
Localised premature ageing induced by oxidative stress and resulting in cellular senescence and/or apoptosis is 
possibly at the core of the aetiology (Loeser, 2009). 
Rheumatoid arthritis (RA): an auto-immune disorder which is reported to be far more common in women than 
men and demonstrates earlier onset in females. An early study suggested that its occurrence is equal in men 
and women, but men were far more likely to enter remission while women are more likely to develop chronic 
ongoing disease (Otten and Boerma, 1959). Other studies in the same time period reported ratios of nearly 2 to 
3 times as many females to men (Rotes-Querol and Roig-Escofet, 1968) (Jacoby, et. al., 1973) The occurrence 
and symptoms areincreased due to immunosenescence (Goronzy, et. al., 2013; Weyand, et. al., 2013). In 
particular, senescence in T-cells has been linked to chronic tissue inflammation similar to that seen in RA 
P a g e  | 1-52 
Ageing in the Mammalian Brain 
(Weyand, et. al., 2013). Additionally, increased levels of CD56+ monocytes have been demonstrated to increase 
with age; as well as being significantly elevated in RA, this was particularly evident in individuals under 40 
years old (Krasselt, et. al., 2013). Furthermore, patients with RA have been demonstrated to have defects in 
DNA repair (Hohensinner, et. al., 2012), including telomerase and the kinase Ataxia telangiectasia mutated 
(ATM) which is involved in repair of double stranded DNA breaks; these are also associated with premature 
ageing (Hohensinner, et. al., 2012).  
Gout induced arthritis: formation of urate crystals which cause inflammation in the joints, particularly in the 
western nations. This form of arthritis is related to age (Hootman and Helmick, 2006), lifestyle and metabolic 
syndrome (also age-related) which individually or in combination promote hyperuricemia. The involvement of 
glutamate transporters in the aetiology of this disorder (Vitart, et. al., 2008) heavily implicates the metabolic 
system as a causative element; in turn this directly relates this disorder to age. The metabolic system has been 
shown to deteriorate with advancing age, particularly when put under great stress due to lifestyle choices, in 
this case high lifetime fructose intake may cause aberrant expression of the glutamate receptors, particularly 
for a specific genotypic variant (VanItallie, 2010). 
Cardiovascular 
Disease (CVD) 
Increased risk of CVD associated with increased age. Not only is CVD directly related to ageing (Finegold, et. 
al., 2012) its incidence is also influenced by age related risk factors including metabolic syndrome (MetS) 
(Mazza and Morley, 2007), type II diabetes mellitus (T2D) (Snell-Bergeon, et. al., 2013) and hypertension 
(Castelli, 1996). Furthermore key BoA and senescence markers are directly related to increased risk of CVD, for 
example the CDKN2A/2B locus (Congrains, et. al., 2011; Landman, et. al., 2012). It is also interesting to note 
that CVD is a common manifestation of the premature ageing phenotype seen in progeroid syndromes, for 
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example Werner syndrome (WS) (Ishida, et. al., 2013).  
Cancer Cancer is now widely accepted as a disease of ageing and the processes of tumourigenesis are very closely 
related to cellular senescence, the process behind ageing. This has been clearly demonstrated by a mouse 
model that is remarkably free of tumours but demonstrates extreme signs of advanced ageing (Tyner, et. al., 
2002). Furthermore, the involvement of critical cellular senescence markers in tumourigenesis provides further 
proof of the links between senescence and tumourigenesis. For example, p53 (Zuckerman, et. al., 2009) is 
heavily involved in tumourigenesis and senescence, as is p16INK4a (Fung, et. al., 2013), Rb (Sperka, et. al., 2012) 
and p21 (Warfel and El-Deiry, 2012). 
Cataracts Symptoms include difficulty with accurate vision (recognition of faces or text), problems distinguishing colours 
and contrasts and an inability to cope with glare (Allen and Vasavada, 2006). Although cataracts can arise from 
genetic abnormalities (Chang, et. al., 2013; Malt, et. al., 2013) or heat/electrical damage (Reddy, 1999), age is 
considered the most common cause of this disease (Courtney, 1992). Advancing age results in a reduction in 
repair and protective mechanisms which defend against environmental insults to which the eye is exposed, for 
example UV radiation (Sliney, 2001). Cataracts can also be induced by other forms of radiation including 
microwave and ionising (Lipman, et. al., 1988), again incidence of these is enhanced by slower repair and 
protection mechanisms characteristic of advancing age. 
Diabetes 
Mellitus type II 
(T2D) 
T2D is associated with ageing and poor diet, characterised by insulin resistance. Symptoms often develop 
gradually, in fact some cases do not demonstrate any symptoms in the early stages. Classic symptoms include 
frequent urination (polyuria), excessive thirst (polydipsia), weight loss and hunger (polyphagia), although these 
are often far subtler and develop more slowly than type 1 diabetes. T2D is the most prominent form accounting 
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for approximately 90% of cases and the world has experienced a massive surge in the diagnosis of T2D in the 
past three decades (Smyth and Heron, 2006). Increases the risks for several other age-related diseases including 
CVD. MetS is closely related to T2D with both being considered a risk factor for each other (Mazza and Morley, 
2007).  
T2D is also directly linked with the key ageing/senescence biomarkers encoded by the CDKN2A and cyclin 
dependent kinase inhibitor 2B (CDKN2B) loci (Landman, et. al., 2012). Mouse models have also revealed that 
animals subjected to hyperglycaemia exhibit early senescence in endothelial cells, this was accompanied by a 
reduction in expression of all seven Sirtuins; diabetic mice exhibited similar changes with increased senescence 
in renal glomerulus and retinal blood vessels with a reduction in Sirt1 levels (Mortuza, et. al., 2013). 
Hypertension Hypertension is a risk factor for many diseases and disorders, particularly for other diseases of ageing including 
CVD (Castelli, 1996) and MetS (Mazza and Morley, 2007). This increase in blood pressure is linked to the reduced 
elasticity in blood vessels that comes with advancing age (Rammos, et. al., 2014; Sherratt, 2014). Unlike other 
diseases of ageing, hypertension appears to induce cellular senescence via the expression of p16INK4a rather 
than be caused or worsened by it (Westhoff, et. al., 2008). This indicates that hypertension may accelerate 
ageing and would explain its role in the promotion of so many other age related disorders. Furthermore, 
genetic variations (Single nucleotide polymorphisms) at the CDKN2A/CDKN2B locus are linked to the incidence 
of cerebrovascular disease (stroke) (Wahlstrand, et. al., 2009). 
Metabolic 
syndrome 
(MetS) 
Metabolic syndrome (MetS) consists of five chronic risk factors: central (visceral) obesity, hypertension, 
aberrant glucose metabolism (insulin resistance), proinflammatory state, abnormal lipid balance and 
prothrombotic state (Alberti, et. al., 2006). Originally it also included sleep apnoea as well (Morley and 
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Sinclair, 2009). The incidence of MetS rises rapidly with age with more than 40% of individuals over 60 years old 
exhibiting the symptoms (Mazza and Morley, 2007). Many factors influence the occurrence of MetS, however 
the most prominent risk factor appears to be abdominal obesity (Setayeshgar, et. al., 2012). All of the other 
risk factors increase with age (Garner and Rubio-Ruiz, 2012). Age decreases the influence of central obesity as 
a risk factor for developing MetS (Okazawa, et. al., 2013). MetS is a critical risk factor for several age related 
diseases including CVD (Aoqui, et. al., 2014) and diabetes (Mazza and Morley, 2007). In fact some people 
believe that MetS is the precursor to CVD and non-alcoholic fatty liver disease (Monteiro, et. al., 2014). 
Osteoporosis A progressive bone disorder characterised by reductions in bone mass/density, which ultimately leads to an 
increased risk of fracture. In general these fractures occur in locations that contain higher levels of cancellous 
or trabecular bone (also known as spongy bone), these are subject to higher turnover when bone remodelling is 
imbalanced as it is in osteoporosis. These sites depend upon the trabecular bone for strength, they develop 
microfractures which severly weaken the bones (Abed and Moreau, 2009; Chen and Kubo, 2014). These areas 
include the vertebrae (Old and Calvert, 2004), ribs (Prior, et. al., 2014), hips (Mpalaris, et. al., 2015) and 
wrists (Cummings, et. al., 1985). It is generally diagnosed by measuring bone mineral density. The incidence 
and severity of this disorder increases with age, one proposed form (primary type 2) is suggested to occur in 
the over 75 population and is referred to as senile osteoporosis (Riggs, et. al., 1982). The other proposed form 
is commonly known as postmenopausal osteoporosis or primary type 1; this has been linked to the reduction of 
hormones that occurs with menopause in women (Riggs, et. al., 1982). However, the two forms hypothesis 
(Riggs, et. al., 1982) has now been challenged with the general consensus being that osteoporosis is a continual 
process with several pathogenetic mechanisms that cause deterioration of the bones (Raisz, 2005). In women 
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osteoporosis can be linked to oestrogen deficiency and in men it can be caused by a reduction in testosterone. 
Secondary osteoporosis can occur at any age and equally afflicts men and women; however this form is linked 
to pre-existing medical issues or prolonged use of glucocorticoids. A genetic element is also present with an 
inheritable increased risk (Raisz, 2005). Particularly, polymorphisms in oestrogen receptor alpha have been 
linked to risk of developing osteoporosis (Lee, et. al., 2003). Like many other age related diseases, 
osteoporosis has well established links with metabolic dysfunction (Hu and Liu, 2014). The problems of bone 
fragility in age related osteoporosis are compounded by other age related problems including movement 
disorders (e.g. Parkinson‟s disease [PD]), eyesight problems, sarcopenia (loss of skeletal muscle) and dementia 
which may result in a greater propensity to fall. 
Progeroid 
syndromes 
Progeroid syndromes are a rare class of genetic disorders which present with the symptoms of ageing, i.e. they 
are diseases of accelerated ageing caused by a genetic defect. These defects are thus far believed to arise 
from mutations of single genes (Navarro, et. al., 2006), usually involved in DNA repair mechanisms (Mohaghegh 
and Hickson, 2001) or nuclear stability/chromatin structures (McClintock, et. al., 2007). This class of disease 
includes the familial forms of AD and PD, WS, Bloom syndrome (BS), Cockayne syndrome (CS), and Hutchinson-
Gilford progeria syndrome (HGPS). All of these disorders have the commonality of resulting in a reduced 
lifespan (Navarro, et. al., 2006); in some cases this is extreme for example HGPS ordinarily results from novel 
mutations as individuals rarely reach reproductive age. Furthermore, some of the ageing mechanisms seen in 
other age-related diseases mimic those seen in progerias, for example the laminopathy seen in HGPS is 
reminiscent of CKD (Shanahan, 2013). 
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1.5  The Mammalian Brain 
 
1.5.1  The Brain and its Functions 
 
The human brain has a similar structure to that of other mammals, 
although not the largest brain found in mammals in absolute terms it is the 
largest relative to the size of the body. In fact in terms of relative size the 
human brain is almost three times the size of our closest relative, the 
chimpanzee. The larger brain capacity appears to be mostly focussed in the 
cerebral cortex and particularly the frontal lobes, which are responsible for 
working memory (short term memory), problem solving and conscious 
thought. However, this does not account for the relative difference in size 
compared with the great apes, as research has demonstrated that they 
have a similarly large frontal cortex (Semendeferi, et. al., 2002).  
 
Evolution has provided the brain with highly effective and 
substantive protection in the form of the thick skull bones, suspension in 
cerebrospinal fluid and a blood-brain barrier; but despite this the brain is 
still susceptible to disease and damage. The anatomy of the human brain is 
extremely complex and research into the intricacies of its function and 
structure is still continuing. However, a great deal is known and the 
anatomy of the cerebrum of the brain has been segregated into six main 
areas, or lobes (Ribas, 2010; Strominger, et. al., 2012) (four of which are 
shown in Figure 1.1) with each lobe having specific functions associated 
with it. The frontal lobe (shown in red - Figure 1.1) is primarily associated 
with cognitive abilities and conscious thought, which includes short term 
memory, planning, motivation, attention and ultimately action selection 
(Coutlee and Huettel, 2011). The temporal lobe (shown in yellow – Figure 
1.1) is believed to play an important role in the organisation of sensory 
input, language comprehension, memories (particularly visual) and 
emotion. The parietal lobe (shown in green – Figure 1.1) is mostly 
associated with information processing, spatial orientation, speech, 
recognition and perception of stimuli. The occipital lobe (shown in blue – 
Figure 1.1) is associated with the sense of sight (Goodale and Milner, 1992), 
this is also demonstrated by disruptions in visual acuity associated with 
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damage to the occipital lobe (Zihl, et. al., 1983). The limbic lobe is found 
on the interior of the brain and has borders with the frontal, parietal and 
temporal lobes, it is responsible for emotion and longer term memory 
functions. The insular lobe is also found on the interior of the brain 
between the frontal and temporal lobes and is believed to house the 
centres for pain and some other sensory systems. 
 
Although each of these lobes has individual processes attributed to it 
the brain functions as one, making decisions, actions, thoughts and 
memories by interaction between lobes, for example an internal thought 
train is believed to result from cooperation between the frontal and 
parietal lobes (Smallwood, et. al., 2012) and memory in social cognition 
involves interactions between the hippocampus, temporal and parietal 
lobes (Spreng and Mar, 2010). This interactivity could also be attributed to 
the arbitrary method of defining the four major lobes by the bones of the 
skull which they underlie. Despite this major connectivity and crosstalk the 
metabolic state, and ageing processes, proceed at different rates and in 
different manners between regions of the brain. This is most apparent 
when looking at functional areas of the brain. 
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 Figure 1.1 The General Anatomy of the Human Brain. Diagram of 
the human brain, with four of the six lobes of the brain highlighted: 
the frontal lobe (red), parietal lobe (green), temporal lobe (yellow) 
and occipital lobe (blue). 
 
The brain and spinal cord are separated into three distinct 
categorical areas (Figure 1.2); the first is the forebrain which encompasses 
the cerebrum and internal structures including thalamus and hypothalamus. 
The forebrain is responsible for most of the functions of the brain, 
particularly conscious thought, memory, data collation and interpretation 
etc. The midbrain connects the forebrain and hindbrain; together with the 
hindbrain it forms the brainstem. This region of the brain is involved in 
auditory and visual responses and motor functions. The hindbrain extends 
from the spinal cord and includes the pons, cerebellum and medulla 
oblongata resulting in control of balance, equilibrium, movement 
coordination and autonomic functions (i.e. breathing, circulation and 
digestion). 
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Figure 1.2 Major Structural Features of the Human Brain. A cross-
sectional diagrammatic representation of the human brain divided on 
the sagital plane. The forebrain, midbrain and hindbrain areas are 
shown as well as several key components including the cerebellum and 
cerebral cortex. 
 
1.5.1.1 The Cerebellum 
 
The cerebellum (or little brain) so called for its similarity in 
appearance to the cerebral cortex, however the structure and function of 
this brain region is vastly different. It is located posterior in the cranium, 
beneath the cerebral cortex (Figure 1.2) and is a major component of the 
hindbrain. Its structure is similar to the bellows of an accordion, being a 
thin layer comprising a highly organised and structured arrangement of 
neurons, particularly Purkinje cells and granule cells, which is tightly 
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folded on itself. The cerebellum also contains stellate, basket and golgi 
neurons as well as mossy, climbing and parallel fibres (Ghez and Fahn, 
1985).  
 
The primary function of the cerebellum is believed to be the 
coordination of motor function; particularly it contributes to coordination, 
timing and accuracy by integrating signals from various parts of the CNS 
and PNS including the spinal cord and sensory systems (Fine, et. al., 
2002). In fact damage in this area of the brain results in problems with 
fine motor control, motor learning and balance (Fine, et. al., 2002). 
However some evidence suggests it may be involved in personality, mood 
or psychosis. This is supported by links with the associative and paralimbic 
cortices (Schmahmann and Pandya, 1997) and also the prefrontal cortex 
(Ramnani, 2006); it appears that the non-motor functions of this area are 
similar to the motor functions in that it monitors signals for errors in 
thought (Schmahmann and Sherman, 1998). The “dysmetria of thought” 
postulated by Schmahmann (Schmahmann, 1998) and/or 
structural/functional disruption are believed to be involved in 
schizophrenia (Andreasen, et. al., 1999; Reyes and Gordon, 1981; Tran, 
et. al., 1998), depression (Pillay, et. al., 1997; Videbech, et. al., 2001) 
and bipolar disorder (Brambilla, et. al., 2001; Kruger, et. al., 2003). One 
study investigating damage within the cerebellum revealed associations 
with a variety of behavioural and personality problems (Wolf, et. al., 
2009). 
 
1.5.1.2 The cerebral cortex 
 
The cerebral cortex is the major component of the human brain 
(~40% of total mass) and constitutes the largest component of the 
forebrain; it forms the outermost layer of the cerebrum (Figure 1.2). It 
forms two cortices along the sagittal plane divided by the medial 
longitudinal fissure, dividing the two cerebral hemispheres. It is believed 
to be responsible for conscious thought, memory, perception, language 
skills, processing of sensory inputs and realisation of motor functions. It is 
divided into the neocortex, which is the major component of the cerebral 
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cortex in humans (~90%), and the allocortex (Strominger, et. al., 2012). 
The neocortex in mammals comprises six individual cell layers labelled in 
roman numerals (I to VI) with the outermost layer being I (Lui, et. al., 
2011). This area is believed to be responsible for sensory perception, 
motor initiation, spatial awareness/reasoning, language skills and 
consciousness (Strominger, et. al., 2012). The size, shape and general 
structure of the neocortex varies dramatically even within mammalian 
species with rodents demonstrating a small unfolded region and humans 
showing a much larger and highly folded neocortex (Herculano-Houzel, 
2009). The neocortex mainly contains two types of neurons, pyramidal 
neurons (excitatory) and interneurons (inhibitory), in a 4:1 ratio 
respectively. In contrast to the neocortex the allocortex has 3-4 layers 
rather than 6. The hippocampus and olfactory system are the major 
components of this region (Strominger, et. al., 2012). 
 
The cerebral cortex region of the brain contains mostly grey 
matter; this is due to the high density of neuronal cell bodies, glial cells, 
capillaries and unmyelinated axons. This is in contrast to the white matter 
which is primarily composed of myelinated axons and few cell bodies. The 
primary excitatory neurotransmitter in the cerebral cortex is glutamate 
(Strominger, et. al., 2012). 
 
1.5.1.3 The basal ganglia 
 
Found within the corpus callosum, the basal ganglia are nuclear 
complexes in the cerebrum and midbrain which consists of five discreet 
areas, all with unique structures and functions: the substantia nigra (SN), 
the ventral tegmental area (VTA), the striatum, the globus pallidus (GP) 
and the subthalmic nucleus (STN) (Strominger, et. al., 2012). It has 
connections throughout the cerebral cortex which appear to be organised 
into discreet loops indicating a level of two-way communication that was 
unanticipated until recently (Middleton and Strick, 2000). These areas are 
collectively involved in somatomotor and motivation behaviours as well as 
adaptive behaviours, e.g. attention, learning, planning and memory 
(Reiner, et. al., 1998). The basal ganglia can be further categorised into 3 
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distinct functional categories: a) the input nuclei which receive 
information from other areas of the brain and include the caudate 
nucleus, the putamen and the nucleus accumbens which are collectively 
known as the striatum; b) the intrinsic nuclei which form the 
intercommunication/processing link between the input nuclei and the 
output nuclei, consisting of the GP (lateral segment), the STN, the 
substantia nigra pars Compacta (SNC) and the VTA; c) the output nuclei 
which transmit inhibitory signals to other areas of the brain, these consist 
of the GP (medial segment), the substantia nigra pars reticulata (SNR) and 
the ventral pallidum (Strominger, et. al., 2012). The major inputs are 
from the cerebral cortex and the thalamus using glutamate as a 
neurotransmitter (Strominger, et. al., 2012). 
 
The SN can be sub-divided into two regions the SNC and SNR. These 
areas use different neurotransmitters, dopamine (DA) for SNC and -
amino-butyric acid (GABA) for SNR, and have different connectivity 
(Strominger, et. al., 2012). The SN has a population of actively dividing 
progenitor cells which give rise to glial cells (Lie, et. al., 2002). 
Interestingly, given the correct stimulation these cells appear to have the 
potential to differentiate into neurons (Lie, et. al., 2002). The VTA is 
located medial to the SNC, uses the same neurotransmitter and appears to 
have a similar role (Strominger, et. al., 2012). 
 
The striatum, also referred to as the striate nucleus or the 
neostriatum, is the largest component of the basal ganglia consisting of 
the caudate nucleus and the putamen, collectively known as the dorsal 
striatum and also the nucleus accumbens (or ventral striatum) 
(Strominger, et. al., 2012). It is located on the interior of the forebrain 
laterally to the thalamus. It has two major neuron populations: projection 
neurons and interneurons, projection neurons communicate out with the 
striatum, whereas the axons of interneurons remain within the striatum. 
The majority of neurons found in the striatum are medium spiny neurons 
(>90%) which use the neurotransmitter GABA (Kita and Kitai, 1988; Parent 
and Hazrati, 1995), but also carry DA receptors (Strominger, et. al., 
2012). It is the major receiving area (Parent, 1990) of the basal ganglia 
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with incoming connections from the three other areas of the basal 
ganglia. It receives dopaminergic connections from the SNC, and smaller 
connections from the GP and the STN. It also sends projections back out 
into the SNR and STN. These connections are mainly glutamatergic and 
come from many areas throughout the cerebral cortex (McGeorge and 
Faull, 1989).   
 
The GP is also known as the pallidum or paleostriatum. This area 
consists of the Dorsal pallidum, containing medial (internal segment) and 
lateral (external segment) components, as well as the ventral pallidum 
(Strominger, et. al., 2012). It maintains close ties with the SN and 
striatum (Smith and Villalba, 2008). It is part of the mechanism for 
regulating voluntary movements, evidenced by movement disorders which 
result from damage within this area, for example dystonia (Shakkottai, 
2014); however deliberate creation of microlesions using implanted 
electrodes has been used to treat involuntary muscle movements, 
including dystonia and PD (Gross, et. al., 1999; Singh, et. al., 2012; Tisch, 
et. al., 2007). Being largely inhibitory the main function of the GP is to 
provide regulation and fine control over the excitatory movement signals 
generated in the cerebellum. Other inputs come from the striatum and 
the collated data are transmitted to the thalamus (Strominger, et. al., 
2012). 
 
The STN forms the major component of the subthalamus, located 
ventrally to the thalamus. It is primarily populated by long spiny dendrites 
which use glutamate as their neurotransmitter (Rafols and Fox, 1976); in 
humans there is a small percentage of interneurons which use GABA as a 
neurotransmitter. It receives excitatory signals from the somatosensory 
areas and the prefrontal and motor cortices of the cerebral cortex; it also 
receives inhibitory signals from the GP (Canteras, et. al., 1990) and 
neuromodulatory inputs from the SNC via DA signalling (Cragg, et. al., 
2004). The STN has been implicated in obsessive compulsive disorder 
(OCD) and severe impulsive behaviour, it has also been suggested that 
stimulation of this region may be utilised as an alternative treatment for 
these problems (Mallet, et. al., 2008). 
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1.5.1.4 Brainstem 
 
The brainstem encompasses the midbrain to the medulla oblongata, 
including the pons (Figure 1.2). This area, with 10 of the 12 pairs of major 
cranial nerves, provides the main sensory and motor functions for the 
head and neck. Additionally, because of the inclusion of the medulla 
oblongata it is also responsible for many autonomic functions particularly 
respiratory and cardiac systems. It also regulates the sleep cycle and is a 
critical control point in the maintenance of consciousness. 
 
The brainstem plays a major role in relaying information in both 
direction between the body and brain. It also plays a major role 
integrating and transmitting information for the autonomic functions, 
maintaining proper control of consciousness, awareness, pain sensitivity, 
respiratory and cardiovascular control. These integral roles underlie the 
potential disruption to bodily function due to damage within this region. 
 
1.5.1.5 The differences between rat and human brains 
 
There are several model species that can be used to study the 
mammalian brain, each with its own advantages/disadvantages (Clancy, 
et. al., 2007). Studies have demonstrated that the early development of 
the brain is remarkably conserved in mammals (Finlay, et. al., 2001). 
Furthermore, by using overlapping techniques, i.e. neuroinformatics, 
Carnegie stages and neuroanatomical comparisons an accurate mapping of 
development between several mammalian species has been established 
(Clancy, et. al., 2007). The rat has emerged as a preferred species in 
many research laboratories for a few good reasons: 1) large litter sizes, 2) 
generally disease resistant, 3) easy to care for, 4) short gestation period 
(~22.5 days), and 5) well established neuroanatomy, neurophysiology and 
behavioural patterns (Clancy, et. al., 2007). These reasons alone are 
enough to convince many researchers to utilise this as a model organism, 
further work which has mapped the development of rat brains onto the 
timescale for human brains (Bayer, et. al., 1993) has added further to the 
appeal of this model organism.  
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There are some obvious and distinct differences in the appearance 
of rat brains when compared with human brains. Firstly, overall size the 
human brain is much larger, however all mammals have the same basic 
brain structures; therefore the only real differences between the brains of 
mammals are found in the size and proportion of each region. The 
proportional size of each region varies according to the mammal in 
question with larger olfactory areas found in rats than those seen in 
humans. Similarly, humans have a much larger cerebral cortex relatively 
speaking. Another major difference is found in the connection between 
the brain and the spinal cord due to the angular difference between 
standing upright and running on all fours. Overall the structure and 
function of the brain is very similar throughout mammals. Even in the 
motor cortex, which was thought to be much simpler in rats than the 
human equivalent, it has been demonstrated that the rat brain region is 
almost as complex both structurally and functionally (Smith and Alloway, 
2013). This makes the rat an ideal model to study brain function. 
 
1.5.2 Energy usage in the brain 
 
The Brain is the most resource intensive part of the human body, 
utilising up to 20% of the body‟s resting energy production to maintain 
proper function (Rolfe and Brown, 1997), with action potentials (47%) and 
postsynaptic effects of glutamate (34%) accounting for the majority of 
energy usage (Attwell and Laughlin, 2001). Furthermore, the brain 
effectively singles out glucose as its source of energy sequestering around 
65% of circulating glucose (Reinmuth, et. al., 1965), while the rest of the 
body uses a combination of glucose, fats and proteins. The energy demand 
from the brain can drop up to 40% during deep sleep (Boyle, et. al., 1994). 
However, energy requirement can dramatically increase during times of 
stress (Hitze, et. al., 2010), even mild stress can increase the brain‟s 
requirements by 12% (Madsen, et. al., 1995). The critical nature of the 
brain and its high energy demands are highlighted by its ability to switch 
energy sources during fasting and exercise, including the use of unusual 
energy sources, for example ketone bodies and lactate (Quistorff, et. al., 
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2008; van Hall, et. al., 2009), to ensure sufficient energy is made available 
to maintain brain function. This relative increase in energy demand for 
higher brain functions is believed to have been balanced by evolution in the 
form of a smaller gastro-intestinal tract, another high level metabolic 
tissue, which therefore requires a high quality diet to maintain (Foley and 
Lee, 1991). It is believed that higher brain function and the enhanced 
abilities it imparts were sufficient to provide the organism with access to a 
higher quality diet allowing it to maintain brain function at the expense of 
dietary processing capability. Ketone bodies have been shown to replace 
glucose as the brain‟s energy source during times of starvation (Davis and 
Tate, 2001; Owen, et. al., 1967).  
 
Of the 20% of total body energy and oxygen used by the brain 95% is 
consumed within the grey matter, indicating the extremely high energy 
demands of active neurons (Miller, et. al., 1980). The mechanism by which 
the brain sequesters additional energy resources has been dubbed “brain 
pull” (Peters and Langemann, 2009). Two mechanisms have been suggested 
by which this energy pull occurs; the first involves the sympatho-nervous 
system (SNS) and the hypothalamus-pituitary-adrenal axis suppressing de 
novo insulin secretion. This action termed cerebral insulin suppression (CIS) 
results in insulin dependent uptake of glucose in the body periphery via 
GLUT4 glucose transporter being effectively suspended, thus increasing the 
available glucose in the blood which can cross the blood-brain barrier via 
the insulin independent GLUT1 glucose transporter. CIS has been shown to 
become active in a broad range of situations from circumstantial e.g. CR 
(Peters, et. al., 2011), sleep deprivation (Spiegel, et. al., 1999) and 
hypoxia (Chen, et. al., 2007) to damage and disease states e.g. burns 
(Allison, et. al., 1968), haemorrhage (Cerchio, et. al., 1971; Kruyt, et. al., 
2011), stroke (Harada, et. al., 2009; McPherson, et. al., 2009) and heart 
attacks (Taylor, et. al., 1969). The second mechanism is known as cerebral 
lactate demand (CLD), where lactate is used to satisfy increased energy 
demands during times of stress (Kubera, et. al., 2012). SNS activation has 
been shown to increase lactate production in muscles (Meyer, et. al., 
2005), some studies have demonstrated a 17% reduction in glucose uptake 
in the brain as a result of increased lactate levels (Smith, et. al., 2003). In 
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fact the availability of energy for use in the brain has been linked to brain 
size and thus intelligence (Aiello, 1995). In order to ensure swift and 
adequate supply of energy to the brain a suitably strong supply chain is 
required. Thus supply to the brain accounts for a large proportion of blood 
flow and oxygen usage as well. This places additional pressure on the 
mitochondria to produce larger levels of energy, as a result disruption or 
dysfunction in these organelles results in the manifestation of diseases and 
disorders, for example HD (Yano, et. al., 2014), migraine attacks (Colombo, 
et. al., 2014) and psychiatric disorders (Streck, et. al., 2014). 
Mitochondrial dysfunction in combination with ROS damage (oxidative 
stress) has been postulated to play a major role in Amyotrophic lateral 
sclerosis (ALS), shown in mouse models (Pollari, et. al., 2014).  
 
1.6  Ageing in the brain 
 
The brain, as with all organs in the body demonstrates signs of ageing, 
specifically reduced functional capacity associated with old age. This can be 
seen at the physiological and psychological level with obvious outward 
symptoms. The situation at the biological and chemical level is far more 
complicated, and unique. The brain still possesses some ability to repair and 
replace damaged cells. There are two areas of constitutive neurogenesis, the 
olfactory bulb and the hippocampal dentate gyrus (Emsley, et. al., 2005). 
Additionally, there are several areas that have been demonstrated to be 
capable of neurogenesis, although in most cases this has not been 
demonstrated under normal conditions in vivo or in humans. These areas 
include the subventricular zone (SVZ) (Gritti, et. al., 1996; Lois and Alvarez-
Buylla, 1993), striatum (Palmer, et. al., 1995; Reynolds and Weiss, 1992), 
cortex (Reynolds and Hardy, 1997), retina (Turner and Cepko, 1987), septum 
(Palmer, et. al., 1995) and tectum (Galileo, et. al., 1990).  
 
Changes in brain biology and chemistry have been associated with the 
ageing process; although research on the ageing process in healthy brains is 
limited, there has been a plethora of research into neurodegenerative 
disorders and their effect on brain morphology. In many cases these 
neurodegenerative diseases are seen as a form of accelerated ageing, with 
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one particular area or cell type demonstrating more senescence or atrophy 
than others. Some magnetic resonance imaging based studies have 
demonstrated an overall reduction in long range connections, particularly 
the fronto-parietal and fronto-occipital links and higher connectivity in short 
range links, for example within the frontal, parietal and occipital lobes 
(Sala-Llonch, et. al., 2014). Furthermore, there appears to be a general 
increase in the activity seen in the prefrontal cortex (Turner and Spreng, 
2011), which may result from a progressive inefficiency seen in neural 
circuits with age placing an increased load on the frontal lobe (Park and 
Reuter-Lorenz, 2009). Socio-economic status has also been shown to be 
related to both BoA (Shiels, et. al., 2011) and cerebellar volume (Cavanagh, 
et. al., 2013). Additionally, other age related disease markers, particularly 
for CVD, have also been shown to relate to. Age related changes in 
connectivity between regions are seen throughout the brain with some areas 
increasing and others decreasing (Ferreira and Busatto, 2013). Whilst some 
neurochemical changes occur within the brain during ageing (Strong, 1998), 
the most significant changes appear to be related to neuronal and axonal 
loss. In fact, many of the neurochemical changes seen may be a direct result 
of these losses. 
 
General studies have demonstrated that there are age related 
reductions in regional cerebral volumes (Raz, et. al., 2005). However, these 
reductions do not appear to be uniform and can vary greatly from area to 
area, with some areas shrinking by up to 1% per year while others remain 
constant for most of the person‟s lifespan only to shrink rapidly in the latter 
stages of the life-span (Raz and Rodrigue, 2006). For example, studies have 
demonstrated that the frontal lobes of the cerebral cortex reach maturity 
around 20 years of age in humans (Giedd, et. al., 1999) and in healthy, older 
individuals appear to shrink on average 0.5% per year (Coffey, et. al., 1992; 
Fjell, et. al., 2009). This age related volume loss appears to be highly 
variable and has been demonstrated in the cerebral cortex (Bigler and Raz, 
1996; Platt and Haug, 1989) and cerebellum (Ellis, 1920; Sullivan, et. al., 
2000). Despite no apparent overall shrinkage in the brainstem (Bigler and 
Raz, 1996), the midbrain region also appears to show age-related volume 
loss (Doraiswamy, et. al., 1992; Luft, et. al., 1999; Weis, et. al., 1993). 
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However, it has more recently demonstrated that the age related shrinkage 
in the cerebellum is also highly variable according to the region examined 
(Luft, et. al., 1999). Jernigan et. al. demonstrated that there are marked 
differences in the rate of loss, or shrinkage, in subcortical structures as well; 
in particular the greatest losses were seen in the hippocampus followed by 
the caudate nucleus and nucleus accumbens, whereas no losses were 
observed in the amygdale, thalamus and lenticular nucleus (Jernigan, et. 
al., 2001). The lack of change in the thalamus has been disputed with some 
researchers demonstrating an age-related reduction in size (Raz, et. al., 
2001; Raz, et. al., 1997). Others have suggested that there is no reduction in 
the hippocampus with age (Sullivan, et. al., 1995); or there is no differential 
loss in the amygdale and hippocampus relative to other grey matter (Good, 
et. al., 2001). However, it has been speculated that these differences in 
opinion and results may be a result of different age ranges being sampled, 
with those studies utilising the oldest age ranges demonstrating differences 
(Walhovd, et. al., 2005). There are some questions about whether these 
changes are normal ageing or indicative of early neurodegenerative diseases 
as many of the same losses or age associated issues are seen exaggerated in 
the likes of AD. However, demonstrations of similar changes in individuals 
with very low probability of having or developing AD have strongly suggested 
that neurodegenerative diseases are an accelerated ageing phenomenon and 
that these changes are normal (Fjell, et. al., 2013; Fjell, et. al., 2012). It 
has also been suggested that areas with high neuroplasticity are more prone 
to ageing phenotypes, for example dendritic spines involved in long term 
memory (Benavides-Piccione, et. al., 2012; Sanders, et. al., 2012). It has 
been speculated that increased requirements for plasticity in specific regions 
increases susceptibility to pathologies associated with ageing (Walhovd, et. 
al., 2014). Unlike other areas of the body neurogenesis in adults is highly 
restricted (Rakic, 2004), thus it is unlikely that changes in neurogenesis are 
responsible for age-related phenomenon, particularly volume loss (Walhovd, 
et. al., 2014). This age related shrinkage in the grey matter is most 
frequently related to neuronal loss (Anderton, 2002; Kolb and Whishaw, 
1998) 
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The reduction, or lack thereof, in white matter is similarly debated 
with some researchers reporting an overall loss in volume with age 
(Guttmann, et. al., 1998; Jernigan, et. al., 2001); whilst others report no 
significant changes (Blatter, et. al., 1995; Good, et. al., 2001). In white 
matter this decrease in volume is believed to be a result of loss of axons and 
progressive demyelination (Sasson, et. al., 2011; Schmierer, et. al., 2007; 
Schmierer, et. al., 2008; Song, et. al., 2002). However, it has been reported 
that some of the volume reduction may result from cell loss, particularly in 
the SN (Hirai, 1968; Vaillancourt, et. al., 2010). Interestingly, this cell loss 
has been reported to be greatest in the dorsal SN with normal ageing but is 
reversed with the ventral SN showing greater cell loss in PD (Fearnley and 
Lees, 1991). It has been noted, however, that deterioration of brain tissue in 
the temporal lobe is associated with ageing (Sasson, et. al., 2013). This lobe 
has several major white matter projections, involved in many brain functions 
including working memory (Sepulcre, et. al., 2009), attention (Nestor, et. 
al., 2007), learning (Spiers, et. al., 2001), language (Catani, et. al., 2003), 
visual memory (Shinoura, et. al., 2007), memory formation and retrieval 
(Levine, et. al., 1998). Given that all of these functions can be impaired as a 
result of ageing it could be suggested that degradation of this white matter 
is a major component of the ageing pathology. 
 
Although researchers originally believed that ageing resulted in 
reductions in both blood flow and metabolism, there is currently a great 
debate over whether or not brain metabolism is significantly altered during 
ageing. There have been several small scale studies directed at this 
phenomenon, reviewed by Cunnane et. al. (Cunnane, et. al., 2010); which 
have proven to be inconclusive with around half showing some degradation 
in metabolism, particularly glucose usage, whilst the other half 
demonstrated no differences. However two such studies which showed 
decreases in brain metabolism with age reverted to no change when 
adjusted for ageing related brain atrophy (Cunnane, et. al., 2010); thus 
indicating that any such change may simply be a result of general brain 
shrinkage and loss of cells as opposed to any significant reduction in 
metabolism in the remaining cells. 
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Interestingly, despite their permanent quiescent state neurons still 
express a number of cell cycle regulators which are essential for normal cell 
cycle progression, albeit at levels which vary from neural progenitors or 
tumourigenic cells (both of which are mitotic cells) (Yoshikawa, 2000). For 
example CDK2 is reduced while CDK4 is increased during neural 
differentiation (Kranenburg, et. al., 1995); furthermore levels of Rb protein 
are also increased (Gill, et. al., 1998). The differential expression of these 
cell cycle regulators appears to balance the post mitotic state of terminally 
differentiated neurons, with their disruption leading to problems; for 
example overexpression of cyclin D1 induces apoptosis (Freeman, et. al., 
1994; Kranenburg, et. al., 1996). 
 
It is obvious from the differences presented here, the differences in 
function of various areas, the differential reduction in size with age, 
neurogenesis limited to specific areas and different levels of energy usage in 
each area, that each region of the brain ages at a unique rate. This rate will 
be a factor which combines energy usage and function. Due to these obvious 
differences it seems prudent to examine each region of the brain 
independently to determine the specific effects of ageing within each area. 
This is particularly evident when discussing previous studies which appear to 
present conflicting findings, particularly when the brain is examined in its 
entirety. All of the regions used in this study demonstrate changes with 
ageing, albeit with different rates and manifestations. 
 
1.6.1 Neurodegenerative disorders 
 
The cellular processes linked to ageing can have a particularly 
detrimental effect in non-replacing tissues, e.g. brain, skeletal and cardiac 
muscle, therefore it is unsurprising that ageing is the main risk factor in 
neurodegenerative disease (Gonzales Mc Neal, et. al., 2001; Lin and Beal, 
2006). Furthermore, it has been demonstrated that the mitochondria play a 
key role in both ageing and neurodegeneration (Beal, 2005); with oxidative 
stress playing a major role in both (Mariani, et. al., 2005). These 
neurodegenerative diseases include well known disorders such as AD, 
Cerebrovascular disease, PD, ALS and Huntington‟s disease (HD). All of 
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these have been correlated with a progressive loss of specific neurotrophic 
factors as a result of cell death in specific subsets of neurons (Gorman, et. 
al., 1996); these neurotrophic factors are normally involved in cell 
proliferation, differentiation, migration, survival, neurite outgrowth and 
synapse formation (Skaper, 2012). The best known of these include brain 
derived growth factor, neurotrophin-3 and nerve growth factor, which have 
been studied both in vivo and in vitro (Skaper, 2012). The age related loss 
and/or deterioration of specific neurons has also been linked to the 
aetiology of neurodegenerative disorders, for example PD and the 
dopaminergic neurons of the SNC (Agid and Blin, 1987); more recently it 
has become apparent that dopamine signalling throughout the Basal ganglia 
may play a role in the development and manifestation of this disorder 
(Benazzouz, et. al., 2014; Smith and Villalba, 2008). 
 
1.7  Models of ageing in the brain 
 
1.7.1 SAMP and SAMR mice 
 
Originally, there were nine strains of senescence accelerated mouse 
prone (SAMP) models, and three of senescence accelerated mouse resistant 
(SAMR) (Takeda, et. al., 1981). This has since been expanded to fourteen 
SAMP and four SAMR strains, all based on a AKR/J strain background 
(Takeda, 1999). The SAMP models present with various diseases and 
disorders that are associated with ageing including osteoporosis, 
degenerative joint disease, amyloidosis and deficits in learning and memory 
(Takeda, 1999; Takeda, et. al., 1991). The SAMP and SAMR strains have 
similar growth rates and are sexually mature at the same age points but the 
SAMP mice demonstrate accelerated ageing phenotypes to varying degrees 
(Hosokawa, et. al., 1984) and the animals have a shorter lifespan (Takeda, 
et. al., 1991; Takeda, et. al., 1981). These models have been extensively 
studied and characterised, and are now used as a model to study specific 
diseases associated with ageing. These mouse models have been analysed 
at the genetic level (Higuchi, 1997; Tanisawa, et. al., 2013; Xia, et. al., 
1999). Furthermore they have been used in studies to demonstrate the 
effects of age related changes in the brain (Shimada and Hasegawa-Ishii, 
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2012), for example the influence of ROS on proteins and lipids (Butterfield, 
et. al., 1998). The individual differences between the strains have also 
been used to elucidate novel information about the aetiology of neuronal 
age related disorders including using SAMP8 mice for the study of dementia 
(Okuma and Nomura, 1998) and glucose hypometabolism (Ohta, et. al., 
1996). Furthermore a comparison between two models which both 
demonstrate age related deterioration in memory and learning, SAMP8 and 
SAMP10, as they present with low and high levels of amyloidosis 
(respectively) demonstrates significant morphological differences 
(Kawamata, et. al., 1997), they also demonstrate behavioural differences 
and abnormalities in circadian rhythms (Miyamoto, 1997). SAMP6 mice have 
been used for studying age related increases in S100 which has been 
linked to AD (Griffin, et. al., 1998).  
 
Although these mouse strains have proved to be useful tools for the 
investigation of age-related diseases, they are not without their problems. 
Many researchers question the validity of the model and its application to 
humans. Furthermore the SAMP mice are also somewhat immune 
compromised, requiring a low calorie diet and/or pathogen free 
environment to extend lifespan and allow research with these strains. 
Investigations into the relationship between this immune impairment and 
age-related neurological deterioration suggest that the two phenomena are 
independent, at least in the case of amyloidosis (Hosono, et. al., 1997). 
These reports are however at odds with the general consensus that 
immunosenescence is related to ageing and age-related deterioration 
(Panda, et. al., 2009); although the extent of the immune-compromisation 
seen in these mice has never been compared to the profile seen in natural 
immunosenescence. 
 
1.7.2 AS and AS/AGU rats 
 
The AS/AGU (Albino Swiss/Anatomy Glasgow University) rat strain 
arose from a spontaneous recessive mutation (Campbell, et. al., 1996) 
which introduced a stop codon into the gene encoding Protein kinase C 
gamma (PKC) (Craig, et. al., 2001), a member of the PKC family (Saito and 
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Shirai, 2002). PKC was originally believed to be solely neuronal in its 
distribution and activity, however it has now been demonstrated to be 
expressed in the heart (Rouet-Benzineb, et. al., 1996) as well as in 
pulmonary fibroblasts (Ludwicka-Bradley, et. al., 2000) and pulmonary 
epithelial cells (Lin, et. al., 2000). In this model the stop mutant appears 
to have a largely neuronal impact, with no obvious cardiac or pulmonary 
effects. The stop mutant leads to a disruption in the release of 
neurotransmitters (Dopamine [DA] and Serotonin [5-hydroxytryptamine, 5-
HT]) within the Basal Ganglia of these rats. Despite presenting with normal 
cerebral morphology the AS/AGU rat demonstrates reduced whole tissue 
levels of DA (20-30%) at 6 months old (Campbell, et. al., 1996) and 
extracellular DA levels are reduced by 80-90% in the dorsal caudate 
putamen by 3 months old (Campbell, et. al., 1998), both compared with 
similar age AS rats. Similarly 5-HT levels are significantly lower in the 
dorsal caudate putamen at 3 months old (Al-Fayez, et. al., 2005). They also 
suffer from a loss of tyrosine hydroxylase in the SNC at 12 months old 
(Clarke and Payne, 1994). This disruption in neurotransmitter levels results 
in a progressive gait disturbance which increases with age. Although, 
rodent models with disrupted motor function is not novel, the SAMP1 mouse 
presents with motor dysfunction (Aoyama, et. al., 2013), the AS/AGU rat is 
unique in that the motor impairment seen is a result of DA disruption. 
Furthermore, it has been demonstrated that glucose usage in the brains of 
AS/AGU rats, particularly in the basal ganglia, is significantly different from 
the AS strain (Lam, et. al., 1998). However, the other areas of the brain 
investigated in this study demonstrated no significant alterations in glucose 
utilisation. Despite these major differences there are no gross 
morphological manifestations as a result of the stop mutant. The PD 
phenotype of this mutant rat, in the same manner as PD itself, can be 
reduced by the administration of L-Dopa (Campbell, et. al., 1998). It is also 
worth noting that these AS/AGU rats have a much lower final body weight 
than comparably aged AS rats and a greatly reduced lifespan. Manifestation 
of symptoms is evident from a very early age including a staggering gait, a 
tendency to fall, difficulty initiating movement and whole body tremor 
(Clarke and Payne, 1994). The disruption of motor function, loss of DA in 
the SN of the Basal Ganglia, the characteristics of PD and a greatly 
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shortened lifespan leads to the possibility that this novel rat strain may 
represent a model of accelerated ageing when compared with its 
progenitor background, the AS rat. The early onset of symptoms and 
disruption of DA signalling suggests that the PD like phenotype is also early 
onset, this further implies that any differences later in life within this 
model is unlikely to be attributable to these early events and is more likely 
to be associated with ageing in general. The differences between the basal 
ganglia of these two rat strains make it a prime target for this study to 
investigate the differences in ageing. 
 
This is not the first model to incorporate the knockout of PKC, 
another mouse model has also been studied and it presented with very mild 
differences, although several were noted 1) they exhibited alterations to 
the long term potentiation (LTP) in the hippocampus; 2) demonstrate mild 
disruption in spatial/contextual learning; 3) reduced effect of ethanol on 
type A GABA receptors; 4) reduced activation of opioid receptors (Saito and 
Shirai, 2002). Furthermore, this mouse model also demonstrated mild 
motor impairment, however this was attributed to innervations of the 
Purkinje cell climbing fibres, in this model Purkinje neurons posses multiple 
climbing fibres rather than one to one connections due to these not being 
eliminated early in the post-natal period (Chen, et. al., 1995a), and not DA 
disruption. Additionally, AS/AGU rats do not demonstrate the LTP seen in 
the PKC KO mice (Shahraki and Stone, 2002). PKC also appears to play a 
critical role in the cerebellum as it is highly expressed in Purkinje cells, 
during development it plays a role in the elimination of unnecessary 
climbing fibres (Kano, et. al., 1995). The role of PKC in the cerebellum 
indicates that this region may also present differences in the AS/AGU rat; 
therefore this region was investigated in this study. 
 
1.7.3 Sex and ageing in animal models 
 
Traditionally male rats have been used for most studies conducted in 
rats, although this has recently changed with the NIH (National Institute of 
Health) in the USA announcing that all projects which they fund must use 
both male and female rats. This predominant use of males is due to several 
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reasons mostly focussed around the differences between the sexes. This is 
almost solely attributable to the sex hormones and their variance during 
the menstrual cycle, which adds another level of variability to experiments. 
This variability is evident throughout the body including the immune system 
(Northern, et. al., 1994; Oertelt-Prigione, 2011), introducing the possibility 
of far reaching changes exerted in a relatively short time span; in general, 
rats have a 4-5 day menstrual cycle which changes with age (Meites, et. al., 
1980). Other differences have also been cited, specifically it has been 
demonstrated that there are significant differences in memory and learning 
between the sexes (Belviranli, et. al., 2012), further differences have been 
shown when diet is altered (Rajab, et. al., 2014). 
On a more study specific note, estrogen has been clearly 
demonstrated to influence methylation patterns (Vrtacnik, et. al., 
2014{Thakur, 1981 #6368)} and thus has the potential to affect global 
methylation levels. The expression and function of the sirtuins has also 
been shown to be effected by estrogen levels (Buler, et. al., 2014). 
Furthermore, the Ras-p16-Rb pathway has been shown to be inhibited via 
an oestrogen receptor mediated mechanism (Zhu, et. al., 2011). For these 
reasons alone the use of female rats is not suitable, in addition to this there 
have been no studies conducted in the AS/AGU rat model using female rats 
it is therefore plausible, although unlikely, that there are significant 
differences in the effects of the PKC mutation that are not evident in 
males. In this case dopamine levels, release and metabolism would have to 
be remeasured, as would glucose levels in various areas of the brain in 
order to construct a solid foundation for the measurements in female rats 
within the current study. It is therefore reasonable to conclude that only 
male rats would be suitable for use in this particular study. 
In addition to this, males and females age differentially (Maklakov, 
2013, Bioessays) possibly due to sex hormone (oestrogen and testosterone) 
regulation of various components of the ageing machinery. For example, 
Sirt5 is up-regulated in an oestrogen related receptor  dependent manner 
with over expression of peroxisome proliferator-activated receptor g 
coactivator 1- (Buler, et. al., 2014). The regulation of mitochondrial 
biogenesis by oestrogen, via the oestrogen related receptor  (Ranhotra, 
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2014) further serves to confirm that ageing pathways are heavily influenced 
by the sex hormones, particularly oestrogen. 
These major differences precludes the possibility of using a 
combination of the sexes for direct comparison and would require separate 
experiments for each sex to determine the differences in each sex, 
requiring a dramatic increase in animal numbers used in these experiments 
and a further level of complexity for incomparable results. 
 
1.8 Aims 
 
Previous studies have demonstrated that ageing does indeed occur in 
the mammalian brain; however these studies investigated individual areas or 
time points in various models. Therefore, to investigate ageing in the 
mammalian brain this study investigated two temporally distinct age points, 
2 months and 12 months, to allow intra-strain and inter-strain differences to 
be demonstrated. Furthermore, studies involving expression of biomarkers in 
four regions of the brain were carries out to address the contemporary 
theories that ageing manifest variably dependent on location. These four 
locations were selected because they have demonstrable histopathological 
differences between AS and AS/AGU rats or with age. 
 
Specifically, it aimed to: 
1. Determine if an enhanced ageing phenotype was present in the AS/AGU 
strain when compared to the parent strain, by measuring differential 
expression of a validated BoA (CDKN2A) at two age points (2 months and 
12 months) and in four areas of the brain (cerebral cortex, brainstem, 
cerebellum and basal ganglia). 
2. Determine if the accelerated ageing phenotype was related to metabolic 
disruption and/or increased DNA damage accumulation by measuring 
expression of MTR related metabolic stress/DNA damage markers 
(Sirtuins) at two age points (2 months and 12 months) and in four areas of 
the brain (cerebral cortex, brainstem, cerebellum and basal ganglia). 
3. To decouple AS/AGU pathology from specific age related processes in the 
rat brain. 
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2. General materials and methods 
 
The general materials and methods used throughout this thesis are 
presented here. Any additional steps or reagents specific to a series of 
experiments will be outlined and detailed in the materials and methods 
section of the appropriate chapter. 
 
2.1 Chemicals 
 
All chemical reagents used throughout this thesis, unless otherwise 
stated, were purchased from Sigma-Aldrich (Dorset, UK), Fisher Scientific 
(Leicester, UK), Promega (Madison, WI, USA) and Life Technologies Ltd 
(Paisley, UK). 
 
2.1.1 DEPC (Diethylpyrocarbonate) treated water 
 
1l of DEPC treated water was prepared by mixing 0.1% v/v DEPC 
(Sigma-Aldrich, Dorset, UK) with de-ionised water (10ml DEPC and 990ml 
water), incubated for 2 hours at 37oC then autoclaved at 121oC for 15 
minutes. Once cooled this was used or stored in a sealed container at room 
temperature (Rt, ~25oC). 
 
2.1.2 0.1M Sodium citrate in 10% v/v ethanol 
 
1l of this solution was prepared by making a 10% v/v mixture of 
ethanol in DEPC treated water (100ml absolute ethanol and 900ml of DEPC 
treated water). To this 29.41g of Monosodium citrate was added to 950ml 
of the 10% v/v ethanol mixture and mixed well. 
 
2.1.3 10x Tris buffered saline (TBS) 
 
1l solution of 10x TBS was prepared by adding 60g of Tris 
(tris(hydroxymethyl)aminomethane) and 87.6g of Sodium chloride (NaCl) to 
800ml of DEPC treated water, stir to dissolve. Using a fully calibrated pH 
meter concentrated Hydrochloric acid (HCl) was used to buffer the pH to 
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7.5, a less concentrated (1M) solution of HCl acid may be used when pH 
approaches the target pH. Use DEPC treated water to top up buffered 
solution to 1l. 
 
2.1.4  1x TBS (1l) 
 
Dilute 10x TBS stock solution in DEPC treated water: 100ml stock 
solution in 900ml of DEPC treated water. 
 
2.1.5  400mM Potassium ferricyanide (K3[Fe(CN)6]) 
 
5ml of a 400mM Potassium ferricyanide solution was prepared by the 
addition of 0.658g of Potassium ferricyanide to 5ml of de-ionised water 
(dH2O) and mixed well. 
 
2.1.6  400mM Potassium ferrocyanide (K4[Fe(CN)6]) 
 
5ml of a 400mM Potassium ferrocyanide solution was prepared by the 
addition of 0.845g of Potassium ferricyanide to 5ml of dH2O and mixed 
well. 
 
2.1.7  200mM Magnesium chloride (MgCl2) 
 
4ml of a 200mM Magnesium chloride solution was prepared by the 
addition of 0.163g of Magnesium chloride to 4ml of dH2O and mixed well. 
 
2.1.8  1.5M Sodium chloride (NaCl) 
 
40ml of a 1.5M Sodium chloride solution was prepared by the 
addition of 3.506g of Sodium chloride to 40ml of dH2O and mixed well. 
 
2.1.9  800mM Citric acid (C6H8O7) 
 
A 800mM solution of Citric acid was prepared by adding 4.61g of 
Citric acid to 30ml of dH2O and mixing well. 
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2.1.10  800mM Sodium phosphate dibasic(Na2PO3) 
 
A 800mM solution of Sodium phosphate was prepared by adding 
3.408g of Sodium phosphate (dibasic) to 30ml of dH2O and mixing well. 
 
2.1.11 800mM Sodium citrate (Trisodium citrate; Na3C6H5O7) 
 
A 800mM solution of Sodium citrate was prepared by adding 7.058g 
of Trisodium citrate (dihydrate) to 30ml of dH2O and mixing well. 
 
2.1.12 Nuclear fast red solution 
 
Nuclear fast red counter stain solutions was prepared by adding 25g 
of Aluminium potassium sulphate dodecahydrate (Sigma Aldrich, Dorset, 
UK) to 500ml of dH2O and mixing to dissolve. To this solution 0.5g of 
Nuclear Fast Red was added and the solution was heated to dissolve. Final 
solution was filtered using filter paper [3mm] (Whatman) before use. 
 
2.2 Animal tissues 
 
All animal tissues were obtained using humane methods in accordance 
with University of Glasgow and national regulations, all experiment 
methodologies were approved by the Ethical Review Process Application 
Panel, University of Glasgow. All animal husbandry and sacrifices were 
carried out by a professional home office licence holder within the 
guidelines and regulations set out by the University of Glasgow. 
 
2.2.1 Preparation of brain tissue samples 
 
Brains were cut in half mid-sagittally, one-half in preparation for 
Immunohistochemical  analysis and the other half for gene expression and 
DNA methylation. Brains were rapidly removed from AS and AS/AGU rats 
aged 2 and 12 months (6 per group) after death by Carbon dioxide (CO2) 
inhalation. All tissue samples were rapidly frozen in isopentane using liquid 
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nitrogen. The tissue was mounted onto a carefully labelled cryomold 
(25mmx20mmx5mm), using a solvent resistant marker, and frozen by 
insertion of the cryomold into the cooled isopentane. The cryomolds were 
then stored at -700C. 
 
2.2.2 Section preparation and mounting 
 
To obtain slides of brain sections, tissue was taken immediately after 
removal from the animal and mounted on a cryomold in preparation for 
sectioning. To mount the tissue a small amount of 22-oxacalcitriol (OCT) 
compound (BDH Laboratory Supplies, Merck Ltd, Leicester, UK) was placed 
onto the base of a cryomold. The tissue was oriented with the side of 
interest towards the bottom of a cryomold and gently placed on top of the 
OCT compound. The cryomold was then quick frozen by immersion in 
isopentane cooled with liquid Nitrogen until the OCT compound was fully 
frozen. 10μm sections were then cut on a cryostat (BRIGHT 5030). Sections 
were then mounted onto slides by placing a fresh super frost plus slide 
(Thermo Scientific, Wilmington, USA) under each section. Slides were fixed 
in 95% alcohol before storing at 4oC. Prior to use, slides were removed from 
4oC and warmed to Rt before immersion in 95% ethanol for 10 minutes, air 
dried for 30 minutes followed by three 5 minute washes in Phosphate 
buffered saline (PBS; Gibco, Life Technologies, Paisley, UK).  
 
2.3 Methodology 
 
2.3.1 RNA Isolation from Tissue Samples 
 
All equipment and reagents used in the isolation of Ribonucleic acid 
(RNA) from tissue samples were RNase-free, nuclease free reagents and 
consumables were used and all equipment was cleaned using RNase Away 
reagent (Fisher Scientific, Leicester, UK). Filtered pipette tips were used 
throughout to reduce the risk of contamination.  
 
Tissue samples were homogenised in 1ml of TRIzol reagent (Ambion, 
Life Technologies, Paisley, UK) for every 50-100mg of tissue used in a tissue 
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homogeniser, frozen samples were homogenised immediately upon removal 
from -80oC storage. This step ensured that the RNase neutralising reagent 
(TRIzol) was thoroughly distributed and could eliminate RNase activity 
completely. Samples were then transferred into centrifuge tubes and 
incubated for 5 minutes at Rt. 200l of Chloroform (Sigma-Aldrich, Dorset, 
UK) was added for every 1ml of TRIzol and vortexed for 15 seconds. This 
mixture was incubated at Rt for 2 to 3 minutes and then centrifuged at 
12,500g for 15 minutes at 4oC. The colourless upper phase (aqueous phase) 
was carefully removed to a fresh microcentrifuge tube. An equal volume of 
a 1:1:1 ration mixture of phenol:chloroform:isoamyl alcohol (Ambion, Life 
Technologies, Paisley, UK) at pH 6.6 was then added to the samples and 
vortexed for 15 seconds. Samples were then centrifuged at 12,500g for 10 
minutes at 4oC. Once again the upper aqueous phase was carefully 
transferred to a fresh microcentrifuge tube. To precipitate the purified 
RNA, an equal volume of ice cold isopropanol (Sigma-Aldrich, Dorset, UK) 
was added and mixed well this was incubated for 1 hour at -20oC. 
GlycoBlue, catalogue number AM9516, (Ambion, Life Technologies, Paisley, 
UK) can be added at this point to improve visualisation of the RNA pellet in 
smaller sample volumes. Samples were again centrifuged at 12,500g for 30 
minutes at 4oC and the supernatant was carefully removed and discarded, 
removing as much as possible without disturbing the RNA pellet. 1ml of ice 
cold 95% v/v ethanol in DEPC treated water was then added to the pellet, 
vortexed briefly and then centrifuged at 12,500g for 20 minutes at 4oC. 
Once again the supernatant was carefully removed and discarded, taking 
care not to disturb the pellet. This ethanol wash was repeated once more 
and the pellets were air dried for 5 to 7 minutes. Pellets were resuspended 
in 30l of RNase free or DEPC treated water and placed on ice. After at 
least 15 minutes a 1.6l aliquot was removed for quantitation using a 
NanoDrop 1000 (Nanodrop, Thermo Scientific, Wilmington, USA) measuring 
absorbance at 260nm and 280nm. A high quality sample should have an 
absorbance ratio, A260/A280, close to 2 (ideally between 1.9 and 2). 
Samples below 1.9 were subjected to further purification using Lithium 
chloride precipitation or phenol-chloroform extraction, as a low reading 
suggests high levels of proteins which may inhibit reverse transcription 
and/or Polymerase Chain Reaction (PCR) procedures. Samples were stored 
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at -80oC until use. Samples were DNase treated using Turbo DNase I, 
according to manufacturer‟s instructions (Promega, Southampton, UK). 
 
2.3.2 Generation of complementary DNA (cDNA) using reverse 
transcription (RT) 
 
Reverse transcription (RT) was completed, using the Transcriptor 
Reverse Transcriptase kit (Roche Products Ltd, Welwyn Garden City, UK), 
by mixing 500ng of purified RNA with 2l of random primers (Invitrogen, 
Life Technologies, Paisley, UK) with dH2O to a final volume of 13l for each 
sample tested. These were then incubated at 65oC for 10 minutes and 
cooled on ice. To each sample 4l of 5x Transcriptor RT reaction buffer 
(Roche Products Ltd, Welwyn Garden City, UK), 0.5l of RNase®OUT (20U) 
(Roche Products Ltd, Welwyn Garden City, UK), 2l 10mM deoxynucleotide 
triphosphates (dNTPs) (Roche Products Ltd, Welwyn Garden City, UK) was 
added for a final reaction volume of 20l. RT reaction was then completed 
using a PCR machine with the following thermal profile: 
   10 minutes at 25oC 
   30 minutes at 55oC 
   5 minutes at 85oC 
   2 minutes at 4oC 
cDNA samples were then stored at -20oC until use, a negative control 
which contained all components except RNA was completed for every set of 
cDNA reactions. 
 
2.3.3 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
 
Quantitative Real-time PCR was completed using TaqMan® pre-
designed assays and probes (Applied Biosystems Inc., Paisley, UK) consisting 
of specific primer-probe set with a conjugated quencher (MGB) and 
reporter tags (FAM). This kit is based on fluorescence detection and 
measurement of amplified PCR product. The specific TaqMan® assays 
(Applied Biosystems Inc., Paisley, UK) used are referenced in each chapter 
and in Appendix 1. The control/reference gene used for all qRT-PCR 
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reactions was Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Taqman® assay: Rn01775763_g1, Applied Biosystems Inc., Paisley, UK). 
qRT-PCR was performed in 96 well plates with a final reaction volume of 
10l using an ABI Fast 7500 Real Time PCR machine (Applied Biosystems 
Inc., Paisley, UK). Each sample was run in triplicate and a standard 
deviation between cycle threshold (Ct) values of less than 0.25 was 
considered as acceptable for further analyses. Each qRT-PCR reaction 
consisted of 1l of cDNA, 0.5l of specific primer/probe set, 5l of Master 
Mix (Applied Bioscience Inc., Paisley, UK) and 3.5l of nuclease free water. 
The thermal cycle profile applied for each gene amplification was:  
50oC for 2 minutes 
95oC for 10 minutes 
    then 40 cycles of: 95oC for 15 seconds 
60oC for 1 minute 
 
Relative gene expression was analysed using comparative threshold 
(Ct) method (2-Ct method) (Livak and Schmittgen, 2001) using GAPDH as 
the endogenous reference gene. The amplification of these genes has been 
previously validated in the host lab, and the efficiencies of amplification 
for genes of interest and the endogenous control were approximately 
equal. Controls included in each batch of samples were a no template (the 
no RNA control from cDNA generation) and an amplification control (no 
cDNA added). 
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3. Differential age related expression of p16INK4a (CDKN2A) in the rat brain. 
 
3.1 Introduction 
 
3.1.1 Cell Cycle 
 
The cell cycle is vital to all living organisms and follows the same 
sequence regardless of phylum or species. This cycle is highly conserved 
between species and employs many similar proteins to regulate it. The 
complete cell cycle consists of four phases: gap 1 (G1), synthesis (S), gap 2 
(G2) and Mitotic (Mi) (Figure 3.1) (King, et. al., 1994). These phases are 
essential for the methodical reproduction of the cell and its division into 
two identical daughter cells. The first phase, G1 or 1st growth phase (gap 
1), involves the duplication of all cellular contents with the exception of 
the chromosomes (Deoxyribonucleic acid, DNA) (Donjerkovic and Scott, 
2000). The second phase, S or synthesis phase, is when the chromosomes 
are replicated; this is one of the most conserved phases with higher 
organisms demonstrating a high level of homology with the budding yeast, 
Saccharomyces cerevisiae (Huberman, 1996). The next phase is G2, or 2nd 
growth phase (gap 2), where the cell checks for errors in the replication of 
chromosomal DNA and makes any necessary repairs before proceeding to 
the final phase (Cuddihy and O'Connell, 2003). The last phase is the Mi, or 
mitotic phase, where karyokinesis, or nuclear division occurs followed by 
cytokinesis where cell organelles, cytoplasm and membrane divide to form 
two new daughter cells each with its own nucleus (Koshland, 1994). Due to 
the nature of the cell cycle, controlling not only growth but cell division as 
well, it is central to the life and death of a cell. Furthermore, its control 
over growth and reproduction make it a central tenet of cellular 
senescence; therefore, all molecules involved in the control and regulation 
of the cell cycle are prime candidate markers for cellular senescence.  
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Figure 3.1 The cell cycle 
Diagram of the general cell cycle found in all eukaryotic cells. 
 
 
3.1.2 Cell Cycle Regulation 
 
The framework of proteins required for the cell cycle is present in all 
cells, even though not all cells undergo complete cycles. Each type of cell 
has a tightly regulated cell cycle which is either a) cycling at a rate specific 
to that cell or cell type or b) blocked within a specific phase of the cell 
cycle. For example, post-mitotic cells are generally halted in the first 
growth phase, G1, and are deemed to be in G0 (gap 0, resting). These cells 
are senescent; therefore they normally do not undergo the processes 
required for duplication, growth or mitotic division, and they essentially 
remain frozen in time. However, there is a mechanism to switch G0 cells 
back into G1 phase if necessary (Heckmann, et. al., 2012). The switch to 
G0 phase also occurs in cells that have undergone DNA damage and would 
therefore produce non-viable or dangerous offspring. The checkpoints 
present at each stage of the cell cycle are present to identify these cells 
and halt their progress, thus preventing mitosis. This mechanism prevents 
the replication of damaged cells, and thus cancer, making the proteins 
involved in these checkpoints key players in tumourigenesis. These 
regulatory molecules are subdivided into two key classes, cyclins and CDKs; 
between them they balance the progression of a cell through the cell cycle 
(Arellano and Moreno, 1997; John, et. al., 2001; MacLachlan, et. al., 1995; 
Suryadinata, et. al., 2010). CDK inhibitors also play critical roles, for 
example p16INK4a which is found in the CDKN2A locus and is upregulated 
during cellular senescence (Martin, et. al., 2013). Also known as Multiple 
G1
SG2
Mi
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tumour suppressor 1, p16INK4a is a tumour suppressor with a vital role in 
regulating the cell cycle. It acts through the Rb pathway and inhibits the 
action of the CDKs; in particular it targets CDK4 and CDK6 to induce 
cellular senescence (Rayess, et. al., 2012). Damage or modification of the 
CDKN2A/p16INK4a gene increases the risk of developing cancer (Liggett and 
Sidransky, 1998; Rocco and Sidransky, 2001); this has been demonstrated in 
several types of cancer including pancreatic (Caldas, et. al., 1994; 
Morrison, 2012), mesothelioma (Sekido, 2013), oesophageal (Igaki, et. al., 
1994), squamous cell carcinoma (Hillbertz, et. al., 2012), colorectal (Bihl, 
et. al., 2012) and head and neck cancers (Loyo, et. al., 2013).  
 
3.1.3 CDKN2A 
 
The CDKN2A locus has three potential products, which vary in the 
first exon and produce the p16INK4a, p12 and p14ARF protein products. It is 
located on the short arm of chromosome 9, region 2, band 1 (9p21). This 
locus, and in particular the p16INK4a product, is a well known susceptibility 
gene for melanoma estimated to account for up to 50% of familial 
melanoma cases (Marzuka-Alcala, et. al., 2013). This link has been 
confirmed by studies demonstrating close links between variants in the 
CDKN2A locus and this familial melanoma risk (Maccioni, et. al., 2013). The 
p14ARF product has also been linked to cancer, for example non-small-cell 
lung carcinoma (NSCLC) where specific knockout mice have demonstrated 
increases in tumour size, malignancy and morbidity (Busch, et. al., 2013). 
In another study these mice also demonstrated higher levels of morbidity 
associated with haemangiomas and haemangiosarcomas in the liver (Busch, 
et. al., 2012). The third transcript isoform from the CDKN2A locus, p12, 
overexpression of which leads to senescence (cell cycle arrest at the G1 
phase) in human pancreatic cells, also has links with cancer in the pancreas 
(Poi, et. al., 2013). Although heavily implicated in many cancers, the 
disease-mediating effects of the CDKN2A locus are far broader, being 
involved in type 2 diabetes (Landman, et. al., 2012), and COPD (Acquaah-
Mensah, et. al., 2012) while p16INK4a has also been clearly linked as a risk 
factor for Primary Open-Angle Glaucoma (Ng, et. al., 2013b). Interestingly, 
this locus has been shown to be heavily regulated by a variety of epigenetic 
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mechanisms including long non-coding RNAs (ANRIL) (Congrains, et. al., 
2013), promoter methylation (Popov and Gil, 2010) and histone 
modifications (Huang, et. al., 2010). Epigenetic regulation of this locus has 
been implicated in the control of proliferation found in Schwann cells after 
nerve injury or neurofibroma challenge (Gomez-Sanchez, et. al., 2013) as 
well as development of CVD (Congrains, et. al., 2011; Pilbrow, et. al., 
2012) and tumourigenesis (Ushijima, et. al., 2006). 
 
3.1.4 p16INK4a expression, cellular senescence and ageing 
 
Expression has been clearly demonstrated to increase with age, 
reducing the ability of stem cells to reproduce (Perez-Campo, et. al., 2013; 
Yu and Kang, 2013). This has led to p16INK4a being regarded as a tissue BoA 
(Koppelstaetter, et. al., 2008). This reduction in the ability of stem cells to 
reproduce is generally considered a defence against cancer; however it also 
increases the risks associated with cellular senescence. Forkhead box A1 
has been shown to activate the transcription of p16INK4a by multiple 
pathways through a direct transcriptional activator role, a potential distal 
loop-back site (~150bp away) and by opposing polycomb function (Li, et. 
al., 2013b). The senescence-promoting effects of p16INK4a can be reversed 
by the recruitment of polycomb repressive complexes (PRCs) to the 
CDKN2A locus by homeobox proteins, in particular HLX1 and HOXA9, which 
have been linked to leukaemia (Martin, et. al., 2013). Jun dimerisation 
protein 2 has been demonstrated to promote the dissociation of PRCs from 
the CDKN2A locus, and thus promote cellular senescence through its 
histone modification properties (Huang, et. al., 2010). Silencing of Yes-
associated protein, a transcription coactivator, leads to reduced cell 
proliferation and premature senescence which is dependent on the 
Rb/p16INK4a/p53 axis, further demonstrating the key role of p16INK4a in 
cellular senescence.  
 
It has also been demonstrated that suppression of p16INK4a expression 
is a key target for some viruses, particularly the Epstein-Barr Virus which 
produces the EBNA3C protein to specifically reduce p16INK4a levels and 
overcome the cellular senescence it induces (Skalska, et. al., 2013). The 
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same virus also produces another protein, EBNA3A, which specifically 
targets p14ARF (Maruo, et. al., 2011). Knockout mice experiments have also 
demonstrated that over-expression of p16INK4a in renal allografts may be 
responsible for some negative outcomes, including tubular atrophy and 
interstitial fibrosis (Braun, et. al., 2012). Significantly, given the ties of 
p16INK4a with cellular senescence, it is associated with many diseases 
associated with ageing including cancer, CVD, T2D, RA (Murakami, et. al., 
2012; Nonomura, et. al., 2006), cataracts (Baker, et. al., 2013; Cheong, et. 
al., 2006) and osteoporosis (Kua, et. al., 2012). 
 
3.1.5 p16INK4a expression in the brain 
 
Although there have been few studies of the expression of p16INK4a in 
the brain, it has been demonstrated that it is up-regulated in the ageing 
brains of mice (Abdouh, et. al., 2012). Furthermore, it has been 
demonstrated that -irradiation of rat cerebromicrovascular cells (CMVECs) 
promotes cellular senescence by up-regulating p16INK4a (Ungvari, et. al., 
2013). The CDKN2A locus was also found to demonstrate abnormal gene 
expression in the brains of SAMP8 mice (Cheng, et. al., 2013). Additional 
evidence for its role in the nervous system is available from the PNS, where 
p16INK4a expression is linked to regeneration in Schwann cells (Gomez-
Sanchez, et. al., 2013). Regarding tumours, diffuse intrinsic pontine 
gliomas (DIPGs) can present with a loss of p16INK4a/p14ARF in a small number 
of cases; however, it would appear that rather than a direct involvement, 
regulation of CDK4 and CDK6 is necessary for this particular type of cancer 
to progress in the brain (Barton, et. al., 2013). This strongly implies that 
the CDKN2A locus, and thus p16INK4a, plays a major role in the regulation of 
senescence in the brain as loss of function can result in tumourigenesis. 
 
Despite the paucity of direct evidence addressing the role of p16INK4a 
in the function and physiology of the brain, there is a considerable amount 
of indirect evidence given the roles of two key interactions with p53 and 
Rb. Rb has been demonstrated to force S-phase in neurons, with 
concomitant neuronal degeneration as a result of cell death (Oshikawa, et. 
al., 2013). The role of p53 in neurodegenerative diseases and ageing in the 
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brain has been investigated in terms of its pro-oxidant activity (Chatoo, et. 
al., 2011). p53 has also been shown to promote inflammation after brain 
trauma or disease stimuli; this neuroinflammation is linked to stroke and 
neurodegenerative diseases and is mediated through microRNAs, 
particularly mir-155 and its capacity to down regulate the anti-
inflammatory c-Maf (Su, et. al., 2013). After brain trauma, p53 promotes 
apoptosis resulting in neuronal loss and subsequently can cause further 
impairments (Rachmany, et. al., 2013). In fact a similar role, promoting 
apoptosis, is believed to be critical in the progression of two of the most 
prevalent neurodegenerative diseases: PD and AD (Checler and da Costa, 
2013; de la Monte, et. al., 1998). These links between key p16INK4a 
interactive proteins, neurodegenerative disease, brain trauma and cancer 
in the brain suggest that p16INK4a may play a major role in normal brain 
physiology. 
 
The close ties between CDKN2A/p16INK4a expression, cellular 
senescence and bio-ageing make it a key player in any study involving 
ageing or senescence. The work in this chapter sought to: 
 
 confirm that CDKN2A was differentially expressed between 
two age points (2 months and 12 months) in four different 
regions of the brain (cerebral cortex, brainstem, cerebellum 
and basal ganglia) and in two related rat strains (AS and 
AS/AGU). 
 Determine if CDKN2A was differentially expressed between 
two rat strains (AS and AS/AGU) at two time points (2 months 
and 12 months) and in four different brain regions (cerebral 
cortex, brainstem, cerebellum and basal ganglia). 
 
3.2 Materials and methods 
 
3.2.1 Animals used 
 
The animals used for these experiments were raised and sacrificed in 
accordance with all regulations, both national and local, and all animal 
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husbandry/operations were performed by a qualified Home Office licence 
holder. Both strains of rat were fed a standard diet, with drinking water 
provided as required. Animals were reared and housed in the Joint 
Research Facility, University of Glasgow under standardised conditions – 
light/dark cycle 12/12 hours, temperature 22oC +/- 2oC, humidity 50% +/- 
5% in plastic-metal cages. 
 
A total of twenty four rats, six for each of the four experimental 
groups were used. The experimental groups used were AS rats at 2 months 
old, AS rats at 12 months old, AS/AGU rats at 2 months old and AS/AGU rats 
at 12 months old. 
  
Sacrificed animals had their brains excised and rapidly frozen using 
liquid Nitrogen; these were then stored at -80oC until required.  
 
3.2.2 qRT-PCR for P16INK4a mRNA 
RNA was isolated from tissue samples as described in the general 
method (Chapter 2: General Materials and Methods, section 2.3.1). cDNA 
was generated as described previously (Chapter 2: General Materials and 
Methods, section 2.3.2). 
 
qRT-PCR was then conducted in accordance with the general method 
set out in Chapter 2: General Materials and Methods, section 2.3.3. The 
following amendments to the protocol were used: 
 
Taqman assay primers used - Rn00580664_m1 (Applied Biosystems 
Inc., Paisley, UK). 
 
The sequence of these primers is provided in Appendix 1a. 
The sequence of the housekeeping/reference gene used (GAPDH) is 
provided in Appendix 1c. 
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3.2.3 Immunohistochemistry Staining for p16INK4a protein 
 
Following fixation of the frozen tissue sections with 95% v/v ethanol 
for 10 minutes and air drying, slides were allowed to warm up to Rt and 
then rehydrated with 1xPBS (Gibco, Life Technologies, Paisley, UK) for 5 
minutes. Sections were treated with 3% v/v Hydrogen peroxide (Sigma-
Aldrich, Dorset, UK) for 10 minutes to remove any endogenous peroxidase 
activity. Sections were then washed for 5 minutes in water and surrounded 
with a hydrophobic barrier pen, for example a DAKO Delimiting pen 
(S200230-2; DAKO, Ely, UK). Non-specific antibody binding was prevented 
by incubation in a blocking solution, 20% v/v normal goat serum (PCN5000; 
Invitrogen, Life Technologies, Paisley, UK) in TBS for 1 hour at 37oC.  After 
the blocking step, sections were incubated with a primary antibody raised 
against CDKN2A/p16INK4a (M-156, cat no: sc-1207; Santa Cruz Biotechnology 
Inc., Heidelberg, Germany) at a dilution of 1:100 in DAKO antibody diluent 
(S0809; DAKO, Ely, UK) at 4oC overnight. Following incubation with primary 
antibody, sections were washed twice for 5 minutes in TBS. The secondary 
antibody, Horse radish peroxidase (HRP)-conjugated goat anti-rabbit 
(P0448; DAKO, Ely, UK), was diluted 1:200 in 20% v/v goat serum in TBS. 
Sections were incubated with secondary antibody for 30 minutes at 37oC 
and then washed twice for 5 minutes in TBS. Slides were then developed 
for chromogenic reactivity using 3,3‟-Diaminobenzidine (DAB) as a substrate 
for HRP (SK- 4100; Vector Laboratories, Peterborough, UK). DAB solution 
was prepared by adding and mixing 5 ml of distilled water, 2 drops buffer 
stock solution (Vector Laboratories, Peterborough, UK), 4 drops of DAB and 
2 drops of hydrogen peroxide as supplied with the kit. Sections were 
incubated with DAB substrate at Rt until a brown colour developed (~4 
minutes). The chromogenic reaction was stopped by dipping slides in 
water. The slides were then washed for 5 minutes in water, followed by 
counterstaining with Harris Haematoxylin (Sigma-Aldrich, Dorset, UK) for 40 
seconds, washed in running water and subsequently incubated with blueing 
agent (Scott‟s tap water substitute: 2g Sodium bicarbonate, 20g Magnesium 
sulphate in 1000ml distilled water; VWR International, Lutterworth, UK). 
Sections were again washed thoroughly using running water, before they 
were dehydrated in serial 1 minute Rt incubations of 70% ethanol, 90% 
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ethanol and absolute (100%) ethanol; followed by 2x1 minute incubations 
with Xylene (Fisher Scientific, Leicester, UK). After the final Xylene step, 
the sections were mounted with DPX histology mounting medium (Sigma-
Aldrich, Dorset, UK). The negative control used only antibody diluent at the 
primary antibody step, and all subsequent steps including secondary 
antibody treatment were conducted as above. 
 
3.2.4 Statistics 
 
All datasets were tested for normality using the Kilmagorov-Smirnoff 
test, all datasets presented herein passed this normality test and were 
deemed of normal distribution for all further analyses. 
 
The unpaired t test (2-tailed) was used to demonstrate differences 
between the means of experimental groups and between brain regions; p 
values are presented to 3 decimal places. A 95% CI (p<0.05) was used 
throughout to determine significance, however significance at the 99% CI 
(p<0.01) and 99.9% CI levels (p<0.001) are also denoted where appropriate. 
 
3.3 Results 
 
3.3.1 CDKN2A expression in rat brains at 2 months 
 
Expression levels for CDKN2A were determined using qPCR for 4 
different brain regions (cerebellum, brainstem, cerebral cortex and basal 
ganglia) in each of the rat strains at 2 months old. The results for each 
experimental group (AS rats at 2 months old and AS/AGU rats at 2 months 
old) are presented in Figure 3.2. 
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Figure 3.2 Expression of CDKN2A mRNA in brain regions of AS and AS/AGU 
rats at 2 months.  
Box and whisker plot demonstrating the distribution of results and mean 
CDKN2A expression levels. Results from both AS and AS/AGU rat brains in 
four regions (cerebellum, brainstem, cerebral cortex and basal ganglia) at 2 
months of age are presented. The mean expression data were compared 
using the unpaired t test. Results significant at the 95% CI level (p<0.05) 
are marked with *.  
 
 
 
The results demonstrated differential expression in AS versus 
AS/AGU rats in all 4 regions at 2 months old, however only the differences 
seen in the cerebellum (p=0.01) and basal ganglia (p=0.032) were 
significant; those in the brainstem (p=0.17) and cerebral cortex (p=0.171) 
were not.  
 
Though expression of CDKN2A was significantly higher in the 
cerebellum of AS/AGU rats when compared with AS rats; this pattern is 
reversed in the basal ganglia with AS/AGU rats demonstrating significantly 
lower levels of CDKN2A expression. 
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3.3.2 CDKN2A/p16INK4a expression in rat brains at 12 months 
 
Expression of CDKN2A was measured in both AS and AS/AGU rats 
aged 12 months old. The results are presented in a box and whisker plot 
below (Figure 3.3). 
 
Figure 3.3 Expression of CDKN2A in brain regions of AS and AS/AGU rats 
aged 12 months old.  
Box and whisker plot demonstrating the distribution and mean CDKN2A 
expression levels. Results from both AS and AS/AGU rat brains in four 
regions (cerebellum, brainstem, cerebral cortex and basal ganglia) are 
presented. Results significant at the 95% CI level (p<0.05) are marked with 
*. Results significant at the 99% CI level (p<0.01) are marked with **. 
 
 
 
Significant differences were observed between AS and AS/AGU rats 
in all four brain regions: cerebellum (p=0.032), brainstem (p=0.006), 
cerebral cortex (p=0.006) and basal ganglia (p=0.002). Levels of p16INK4a 
were significantly higher in AS/AGU rats in all regions of the brain tested. 
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3.3.3 CDKN2A expression in AS rat brains at 2 months and 12 months 
 
A comparison of CDKN2A expression in regions of the AS rat brain at 
2 months and 12 months was conducted. The results are presented as a box 
and whisker plot in figure 3.4. 
 
Figure 3.4 Comparison of expression of CDKN2A in brain regions of AS rats 
at 2 and 12 months.  
Box and whisker plot demonstrating the distribution and mean levels. 
Expression levels from AS rat brains in four regions (cerebellum, brainstem, 
cerebral cortex and basal ganglia) at both 2 months and 12 months old are 
presented. Results significant at the 95% CI level (p<0.05) are marked with 
*. Results significant at the 99% CI level (p<0.01) are marked with **. 
 
 
 
In general the AS rat brain shows declines in CDKN2A levels, with the 
notable exception of the cerebellum and no significant change in cerebral 
cortex. In the instance of the brainstem (p=0.03) and basal ganglia 
(p=0.009) these reductions were significant, whereas in the cerebral cortex 
there was no significant change in either direction (p=0.359). The increase 
seen in the cerebellum was also significant (p=0.014). 
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Comparison of different brain regions in the AS rat at 2 months old 
using an unpaired t test revealed significant differences in CDKN2A 
expression levels. Levels in the cerebellum were significantly lower to 
those found in the brainstem (p=0.022) and in the basal ganglia (p=0.006), 
while levels in the brainstem were significantly higher to those found in the 
cerebral cortex (p=0.038) and levels in the cerebral cortex were lower than 
those found in the basal ganglia (p=0.014). 
 
Expression levels of CDKN2A in brain regions of 12 month old AS rats 
also demonstrated significant differences, although these were restricted 
to the cerebellum. The cerebellum differed from all other measured 
regions of the brain: brainstem (p=0.041), cerebral cortex (p=0.024) and 
basal ganglia (p=0.032).    
 
3.3.4 CDKN2A expression in AS/AGU rat brains at 2 months and 12 
months 
 
A Comparison of the CDKN2A expression levels in AS/AGU rat brains 
at 2 months old and 12 months old was conducted (Figure 3.5). 
Furthermore, levels in different brain regions were compared at each age 
to determine any variation between areas in mean expression levels. 
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Figure 3.5 Comparison of expression of CDKN2A in brain regions of AS/AGU 
rats at 2 and 12 months.  
Box and whisker plot demonstrating the distribution and mean levels. 
Results from AS/AGU rat brains in four regions (cerebellum, brainstem, 
cerebral cortex and basal ganglia) at both 2 months and 12 months old are 
presented. Results significant at the 95% CI level (p<0.05) are marked with 
*. Results significant at the 99% CI level (p<0.01) are marked with **. 
 
 
In general, CDKN2A levels are higher in the 12 month old rats when 
compared with 2 month old rats in all four brain regions. However, only the 
differences seen in the brainstem (p=0.046) and the basal ganglia (p=0.006) 
were significant. 
 
The only differences in CDKN2A levels in 2 month old AS/AGU rats 
were observed between the cerebellum and the basal ganglia (p=0.05). 
There were no significant differences in levels between any of the four 
brain regions examined in 12 month old AS/AGU rats. 
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3.3.5 Immunohistochemical analysis of CDKN2A expression in rat brains 
 
Following initial examination of CDKN2A transcript levels, an 
evaluation of the expression of the cognate protein, p16INK4a was 
undertaken. Immunohistochemical analysis of para-sagittal rat brain 
sections was then carried out to determine differences in overall 
expression of p16INK4a protein levels (Figure 3.6) using a clinically validated 
histoscoring technique. 
 
Figure 3.6 Total histoscores from immunohistochemical staining of rat 
brain sections. 
Histoscores were generated by double blind scoring of 
immunohistochemical staining for p16INK4a in brain sections from both 
strains of rat, at 2 time points (2 months and 12 months old). Highly 
significant differences (p<0.001) are marked with ***. 
 
0
100
200
300
    AS           AS/AGU                            AS            AS/AGU
      2 months                                        12 months
***
T
o
ta
l 
h
is
to
s
c
o
re
 C
D
K
N
2
A
 
 
Analysis of the total histoscores revealed highly significant 
differences between the brains AS and AS/AGU rats, at 2 months old 
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(p<0.001). Although the AS rats demonstrated a larger spread of p16INK4a 
protein expression, these differences were no longer significantly different 
to those seen in AS/AGU rats at 12 months of age. Overall expression levels 
were significantly different between 2 months and 12 months in both AS 
(p<0.001) and AS/AGU (p<0.001) rat strains. 
  
An example of typical staining is presented in Figure 3.7, the 
negative controls demonstrate little or no perceptible background staining, 
confirming the specificity of the secondary antibody and showing no cross 
reaction with epitopes in rat brain sections. The results show expression of 
p16INK4a in both AS and AS/AGU rat brains at both time points: 2 months and 
12 months. In the case of both strains of rat, AS and AS/AGU levels of 
specific reaction appears to increase at 12 months, which is consistent with 
the histoscore results. 
P a g e  | 3-104 
Ageing in the Mammalian Brain 
Figure 3.7 Immunohistochemical staining for p16INK4a in para-sagittal brain sections from AS and AS/AGU rats at 2 months and 12 
months old.  
Immunohistochemical staining using a CDKN2A/p16INK4a specific antibody (Rabbit anti-mouse monoclonal Antibody) at 100x 
magnification; A: negative control (AS at 12 months old). B: 2 month old AS. C: 12 month old AS. D: negative control (AS/AGU at 2 
months old). E: 2 month old AS/AGU. F: 12 month old AS/AGU. Blue staining represents the haematoxylin staining nuclear staining 
brown/blue staining represents specific HRP staining for p16INK4a. 
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3.4 Discussion 
 
The results presented in this chapter indicate distinct differences in 
the expression of CDKN2A/p16INK4a in both rat strains in association with each 
age point. Both strains demonstrate an increase in expression of this BoA 
with increasing age, at both the transcriptional and translational levels, in 
keeping with its status as a validated BoA, fitting the Baker and Sprott 
criteria (Baker and Sprott, 1988; Koppelstaetter, et. al., 2008). These two 
strains do, however, differ in the level and magnitude of these differences 
and the changes that occur within the 10 month period surveyed.  
 
These findings are consistent with the current literature which 
suggests that p16INK4a expression in the brain increases with age in mouse 
models (Abdouh, et. al., 2012). However, they appear at odds with another 
similar study conducted in mice which compared expression of genes in two 
related strains of mice, the accelerated ageing model SAMP8 and its 
background strain SAMR1. In this comparative model, expression of CDKN2A 
was recorded as being reduced in the accelerated ageing model, SAMP8, 
compared with the control SAMR1 mice (Cheng, et. al., 2013). Although, this 
disparity may be explained by a lack of specific information on each of the 
products of the CDKN2A locus, little is known of the expression of p14ARF or 
p12 in the brain, it may be that overall expression of the entire locus may be 
lowered while an individual product may increase. Moreover, these data are 
incongruent with a range of other rodent studies showing increased CDKN2A 
expression/p16ink4a expression with age (Krishnamurthy, et. al., 2004). 
Notably, data in the present AS and AS/AGU studies, looked specifically at 
CDKN2A/p16INK4a, not the entire CDKN2A locus transcript or protein set. 
 
Furthermore, it should be noted that in the Cheng et.al. study, these 
differences were seen in the hippocampal regions, whereas they showed no 
significant differences in the other region they measured, the cerebral 
cortex. This is consistent with the earlier 2 month time point in the rat 
study; however a significant difference was noted between the strains at the 
12 month time point. It may also be the case that the AS/AGU accelerated 
ageing phenotype is mediated through the actions of p16INK4a and its related 
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pathways, while the SAMP8 phenotype may be a result of another pathway 
which does not require elevation of p16INK4a. This would include alternative 
pathways and downstream activation, or over-expression of signalling 
components, of the p16INK4a pathway.  
 
It must also be noted that the AS/AGU rat is considered a model for 
disruption of the dopaminergic system (Payne, et. al., 2000) and dopamine 
disruption is linked to major depression (Kapur and Mann, 1992). Similarly, 
increased expression of p16INK4a is linked to depression (Teyssier, et. al., 
2012). Taken together this indicates that the level of p16INK4a may be 
“naturally” higher in AS/AGU rats compared with AS rats. In fact, expression 
appears to be higher in the AS/AGU rats in most cases. This is supported by 
overall histoscores of complete brain sections and the results from 12 month 
old AS/AGU rats which demonstrate significantly higher levels of p16INK4a in 
all brain regions compared with AS rats of a similar age. However, there are 
some areas where levels are significantly lower, for example the basal 
ganglia at 2 months of age demonstrate significantly lower levels of p16INK4a 
expression than equivalent AS rats. Furthermore, the age-related increase 
seen in expression levels suggests that, while dopamine disruption may lead 
to a low to moderate increase in overall levels, it is not wholly responsible 
for the levels or expression pattern of p16INK4a seen in AS/AGU rats. To 
investigate the effects of dopamine disruption on expression of p16INK4a, 
further experimentation would be required utilising a similar experimental 
design as used here, but with concurrent measurement of dopamine levels 
and/or function.  
 
Similarly, the Parkinson‟s disease like phenotype of the AS/AGU rat 
(Payne, et. al., 2000), with highly disrupted dopamine levels leads to the 
possibility that abnormalities in comparative expression levels in AS and 
AS/AGU rats, i.e. the distribution of p16INK4a expression, may be a part of the 
locomotor disease phenotype. This hypothesis is supported by the role of p53 
in Parkinson‟s disease (Checler and da Costa, 2013; Levine, et. al., 2012; 
Venderova and Park, 2012). However, in order to test this hypothesis, 
further work would be required; for example, dopamine levels would be 
measured in conjunction with p16INK4a expression; p53 could also be 
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measured and compared as well as monitoring the physical manifestations of 
the disease. All of these measurements and comparisons should also be 
measured in the AS rat to provide a suitable control. 
 
Interestingly, these two strains also exhibit different distributions of 
p16INK4a, particularly in the AS strain where expression varies depending on 
brain region, especially in the 2 month old rats. This variation in expression 
is more muted in the 12 month rats, whilst the expression pattern found in 
the AS/AGU rats at 2 months is similar to that of 12 month old AS rats, in 
keeping with an accelerated ageing phenotype and a commensurate increase 
in the rate of molecular damage. At 12 months old the AS/AGU rats have 
almost ubiquitous expression of p16INK4a. This would indicate that the 
AS/AGU rats have reached “old-age” where expression becomes ubiquitous 
and the cells are truly senescent and possibly beginning to degrade and 
apoptose. The only other study of this type measured the CDKN2A locus as a 
whole in the brains of normal and accelerated ageing phenotype mice 
(Cheng, et. al., 2013), as part of a much larger gene expression study, and 
did not focus on the expression of specific products. Cheng and co-workers 
demonstrated no difference in gene expression from the CDKN2A locus in the 
only directly comparable region (the Cerebral cortex); however, as 
mentioned previously, this encompasses three distinct products which may 
have variable expression in this brain region and makes direct comparisons 
difficult. 
 
Levels of p16INK4a have been clearly established as an age-related 
marker that increases expression with age (Koppelstaetter, et. al., 2008; 
Krishnamurthy, et. al., 2004; McGlynn, et. al., 2009). Particularly, this 
biomarker is proposed to result in increased cellular senescence, a 
mechanism that has been suggested as a defence against cancer. As 
expected, expression of p16INK4a increases with age in the brains of both 
strains. The most profound increases occur in the non-mutant AS rat, this 
may indicate a more natural, or slower, ageing process, as opposed to the 
accelerated phenotype proposed to exist in the AS/AGU rat. The higher 
expression levels found at 2 months old in the AS/AGU strain, compared with 
2 month old AS rats, further supports a more rapid onset of ageing or cellular 
P a g e  | 3-108 
Ageing in the Mammalian Brain 
senescence in the brains of these rats. The data presented here supports the 
premise that AS/AGU rats demonstrate accelerated ageing compared to 
other strains; for example, biomarkers show that 12 month old AS rats 
appear to be of a similar age to 2 month old AS/AGU rats. However, 
variations in expression patterns suggest that this is either not an exact 
comparison or that further abnormalities in the ageing process of the 
AS/AGU rats are present.  
 
Overall, both AS and AS/AGU rats follow a similar pattern of 
increasing p16INK4a levels consistent with its status as a BoA. The levels in 
AS/AGU rats are notably higher at the 12 month time point. This is 
consistent with their shortened lifespan and their neurodegeneration. 
However, these notable differences in expression may be involved in the 
Parkinson‟s-like phenotype displayed by these rats due to disruption of the 
dopaminergic system. The increase in CDKN2A levels seen in the basal 
ganglia of AS/AGU rats when comparing 2 month old and 12 month old rats 
may be dismissed as a change induced by DA disruption. However, when this 
is taken in context with the rest of the brain, particularly the brainstem 
which shows no overt differences in any PKC model it is more likely that 
these are a result of accelerated ageing and not the PKC mutation. It is also 
worthy to note that differences are seen between the levels in each brain 
section, this is more overt in the AS rat strain which is a more accurate 
model of normal ageing. Measurement of DA alongside CDKN2A levels may be 
able to separate this more conclusively. Similarly, these differences may be 
attributable to differences in the ageing process within these rats, and 
further experimentation would be required to elucidate the true reasons for 
these differences in p16INK4a expression. 
 
3.5 Overall Conclusions 
 
The results presented here are consistent with levels of CDKN2A 
increasing in association with advancing age, this is confirmed in both 
models. Furthermore, higher levels are seen in the AS/AGU rats indicating 
that these rats may represent an accelerated ageing phenotype. These 
results also confirm that differential expression is seen in different areas of 
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the brain, this is evident at two temporally distinct age points and in two 
species. This is unsurprising given the different functions performed by the 
different areas of the brain. This is consistent with other findings that 
different tissues age at different rates, however this does uniquely 
demonstrate intra-tissue differences in ageing. Furthermore, it has been 
shown that these differences vary between two closely related strains. 
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4. Expression of Sirtuins 5, 6 and 7 in the brains of AS and 
AS/AGU rat strains at two time points. 
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4. Expression of Sirtuins 5, 6 and 7 in the brains of AS and AS/AGU rat strains 
at two time points. 
 
4.1 Introduction 
 
4.1.1 The Sirtuin protein family 
 
The Sirtuins are a family of highly conserved proteins, found in a 
diverse range of organisms ranging from bacteria to humans. First 
identified in the budding yeast Saccharomyces cerevisiae, the Silent 
information regulator 2 (Sir2) gene (Rine, et. al., 1979) has served as the 
basis for detection of orthologs in all other species. SIR2 was the first 
discovery of 4 other similar protein products, which constitute the Sir 
family, in Saccharomyces cerevisiae (Ivy, et. al., 1985; Ivy, et. al., 1986; 
Shore, et. al., 1984). Although originally identified as modulators of mating 
type in a role unique to yeast, identification of orthologs in other species 
rapidly identified new functions. For example, Sir2 was soon identified as 
suppressing recombination in ribosomal RNA tandem repeats (Gottlieb and 
Esposito, 1989). Further research has revealed that the Sir family of 
proteins are involved in lifespan determination and health not only in 
yeast, but also nematodes and flies (Dali-Youcef, et. al., 2007). In fact this 
function appears to be mediated via CR, at least in lower organisms 
(Hamilton, et. al., 2005; Hansen, et. al., 2007; Kaeberlein, et. al., 1999; 
Rogina and Helfand, 2004; Sinclair and Guarente, 1997). This has been 
challenged recently by Burnett et. al., who suggest that, after controlling 
for genetic background, there is no apparent effect of CR in Sir2 transgenic 
studies with nematodes and flies (Burnett, et. al., 2011). Despite this, 
studies in primates suggest similar roles for the Sirtuins and CR in higher 
organisms (Ramsey, et. al., 2000). Human research also appears to suggest 
a role for the Sirtuins in improved lifespan, with allelic variants being 
linked to elongated lifespan (Bellizzi, et. al., 2005; Kuningas, et. al., 2007; 
Rose, et. al., 2003). Sirtuins are also key players in the MTR theory of 
ageing (Shiels and Davies, 2004), by relating all three components of the 
theory together via their roles in modulating metabolism and ribosome 
biogenesis, as well as influencing DNA damage repair mechanisms. 
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In humans, seven members of the Sirtuin (Sirt) family have been 
identified, numbered 1 to 7 (Frye, 2000; Michishita, et. al., 2005). All are 
orthologs of the original Sir2 gene (Rine, et. al., 1979), each with unique 
interactions, targets and localisations (Table 4.1). Cellular energy 
production is at the centre of most Sirtuin function, mediated through 
Nicotinamide Adenine Dinucleotide (NAD+)-dependent deacetylation 
reactions, as each contains a NAD+ binding site and a catalytic domain 
(Haigis and Sinclair, 2010). The reliance of the deacetylase function on the 
presence of NAD+ clearly links these proteins and their functions with 
cellular metabolism. Their function can be inhibited by a number of small 
molecules, particularly the NAD+ intermediate product NAM, which may 
also be able to reverse the reaction (McGuinness, et. al., 2011). These 
proteins are heavily implicated in ageing of mammals as well as lower 
organisms and appear to provide a key link between the regulation of 
metabolism and ageing (Haigis and Guarente, 2006; Westphal, et. al., 
2007). Their key roles in metabolism and ageing are reinforced by their 
deep involvement in diseases of ageing (Donmez and Guarente, 2010; Haigis 
and Sinclair, 2010; Srivastava and Haigis, 2011). Such as cancer 
(Schumacker, 2010), T2D (Avogaro, et. al., 2009), atherosclerosis (Ota, et. 
al., 2010) and major neurodegenerative diseases such as AD (Albani, et. 
al., 2010) and PD (Esteves, et. al., 2010).   
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Table 4.1 Sirtuins in humans, distribution and known interactions/functions (Donmez and Outeiro, 2013; Haigis and Guarente, 
2006; Haigis and Sinclair, 2010; Li and Kazgan, 2011; McGuinness, et. al., 2011; Sebastian, et. al., 2012a; Westphal, et. al., 2007) 
Sirtuin Localisation Known interactions Enzyme Activity Biological Function 
Sirt1 
Nucleus (but has been 
found in cytosol) 
FOXO, PGC-1SREBP-1c, 
PPARUCP2, LXR, NF-B, p53, 
MyoD, Ku70, LXR, p300, Tat, 
PCAF, ER, AR, SMAD7, p73, 
Sox9, HES1, Hey2, NcoR/SMRT, 
E2F1 
NAD+ deacetylase 
Cell survival/metabolism, lipogenesis, 
cholesterol metabolism, insulin secretion, 
inflammation, neurodegeneration 
Sirt2 
Cytoplasm (but known 
to interact with some 
nuclear proteins) 
-Tubulin, H4, NF-B, FOXO NAD
+ deacetylase 
Cell cycle control, tumourigenesis, inhibits 
adipocyte differentiation, promotes 
gluconeogenesis, tubulin deacetylation 
Sirt3 
Mitochondria (but can 
localise to nucleus if 
Sirt5 is 
overexpressed) 
AceCs2, HMGCS2, SDHA, 
ornithine carbamoylase, GDH 
complex 1 
NAD+ deacetylase 
Thermogenesis/metabolism, fatty acid 
catabolism, promotes ketone body synthesis, 
upregulates electron transfer chain, 
upregulates urea cycle, ATP production 
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Sirt4 Mitochondria GDH, IDE, ANT 
ADP-ribosyl 
transferase 
Insulin secretion/ metabolism, fatty acid 
oxidation (opposes Sirt3) 
Sirt5 
Cytoplasmic/ 
Mitochondria 
CPS1 
NAD+ deacetylase, 
demalonylase, 
desuccinylase 
Ammonia detoxification, Urea cycle 
Sirt6 Nucleus 
DNA polymerase Sirt1, 
FOXO3a, NRF-1, NF-B, Hif1, 
helicase 
ADP-ribosyl 
transferase, NAD+ 
deacetylase 
DNA repair/metabolism, telomeres and 
telomeric function, lipid metabolism, lipid 
storage, glucose uptake and metabolism 
Sirt7 Nucleus 
RNA Polymerase type 1, E1A, 
SMAD6, UBF 
NAD+ deacetylase rDNA, RNA polymerase I transcription 
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4.1.2 Sirtuins in the brain 
 
The brain is the most energy hungry component of the body, in this 
regard the presence of Sirtuins is vital to its survival as they modulate not 
only metabolism but also mitigate the damage that can result from 
increased metabolic pressure i.e. oxidative stress. Sirt1 has been 
investigated in the mammalian brain and has been linked to many 
functions, particularly in the hypothalamus (Guarente, 2013). It has also 
been demonstrated to fluctuate in accordance with dietary change. In 
connection with this, it has been shown to localise specifically to pro-
opiomelanocortin (POMC) neurons which are vital for the maintenance of 
glucose levels and normal body weight (Ramadori, et. al., 2008). Its effects 
in POMC are mediated via the interaction between leptin and 
phosphoinositide 3-kinase (PI3K) (Ramadori, et. al., 2010). Sirt1 has also 
been shown to be active in steroidogenic factor 1 neurons, where it heavily 
influences obesity due to diet (Ramadori, et. al., 2011). Sirt1 has 
previously been shown to influence the circadian rhythm or clock via BMAL1 
(Nakahata, et. al., 2008) and Per2 (Asher, et. al., 2008), which have been 
demonstrated to be linked to health and ageing (Pittendrigh and Minis, 
1972). It has recently been demonstrated that this influence over the 
circadian clock occurs via the amplification of BMAL1 (Chang and Guarente, 
2013). Furthermore, Sirt1 over-expression has been shown to be beneficial 
in models of neurodegenerative diseases, for example AD (Donmez, 2012; 
Donmez, et. al., 2010; Min, et. al., 2010), HD (Jeong, et. al., 2012; Jiang, 
et. al., 2012) and PD (Donmez, et. al., 2012). Interestingly, poor short and 
long term memory functions are found in Sirt1 knockout models (Michan, 
et. al., 2010). The effect of Sirt1 in PD has been disputed, since no 
protection was observed in Sirt1 transgenic mice in a 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced PD model (Kakefuda, et. al., 
2009). Despite this, most studies demonstrate protective effects in PD and 
this is currently the prevailing hypothesis. This may indicate that MPTP-
induced PD is not a truly representative of the mechanisms behind 
spontaneous PD aetiology and pathology. 
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Sirt2 has been demonstrated to both promote (Ji, et. al., 2011) and 
retard (Li, et. al., 2007) oligodendrocyte differentiation, as well as 
promoting Schwann cell myelin formation (Beirowski, et. al., 2011). Sirt2 
has also been shown to be detrimental in neurodegenerative disease 
(Donmez and Outeiro, 2013), particularly in HD using knock down models 
(Luthi-Carter, et. al., 2010) and PD (Outeiro, et. al., 2007). 
 
Very little information is available on the localisation, influence and 
function of other Sirtuin family members in the brain. However, Sirt3 has 
been demonstrated to be important in neuron viability in cell models (Kim, 
et. al., 2011b) and has been suggested to have a neuroprotective effect 
(Kincaid and Bossy-Wetzel, 2013). Whereas Sirt4 is highly expressed in post 
natal astrocytes and during embryogenesis in radial glia, a general decrease 
in expression is seen during development (Komlos, et. al., 2013). There is 
no direct evidence for the role of Sirt5 in neural development or neural 
ageing; however its role in mitochondria and metabolism suggests that 
expression of this Sirtuin will be linked to neural ageing. Furthermore, the 
involvement of the other mitochondrial Sirtuins (Sirt3 and Sirt4) in neural 
ageing and development as well as the fact that Sirt5 can modulate the 
localisation of Sirt3 provides further support for a role for Sirt5. Sirt6 
appears to act in a different manner in the brain compared with the rest of 
the body; full body knock outs die due to hypoglycaemia whereas neuron 
specific deletion does not have the same effect (Schwer, et. al., 2010). 
Sirt6 knockouts also appear to demonstrate symptoms of extreme ageing 
(Mostoslavsky, et. al., 2006). 
 
Sirt7 plays a key role in ribosome biogenesis and protein synthesis via 
multiple pathways (Tsai, et. al., 2013b), this indicates that this Sirtuin 
would be critical for the measurement of ribosomal biogenesis and thus the 
„R‟ of the MTR trinity. Sirt6 binds to histones at the telomeric structures 
and influences telomere function (Michishita, et. al., 2009). Additionally, 
null mouse models for Sirt6 experience severe metabolic disruption leading 
to death after only 1 month post-natal (Mostoslavsky, et. al., 2006). Sirt6 
also regulates ribosome metabolism via its influence on the activity of myc 
(Sebastian, et. al., 2012b). This indicates that Sirt6 exerts an influence 
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over all components of the MTR trinity which may explain the severity of 
outcome when it is knocked out. While Sirt5‟s role in the mitochondria, 
regulation of the urea cycle, may not immediately appear to be directly 
related to metabolism it is however critical for the elimination of ROS 
promoting ammonia and this reducing oxidative stress. More importantly, 
however, are its novel demalonylation and desuccinylation enzyme 
functions (Du, et. al., 2011). Both of the substrates for these enzyme 
activities are intermediates for the tricarboxylic acid (TCA) cycle in 
mitochondria (Peng, et. al., 2011; Zhang, et. al., 2010) which is at the core 
of energy production. This indicates that Sirt5 probably exerts an influence 
over the TCA cycle by injecting intermediates into the cycle thus increasing 
capacity and activity. More recently, Sirt5 has been shown to demonstrate 
lysine-glutarylation activity as well, however this appears to be directed at 
carbamoyl phosphate synthase 1 (CPS1) (Tan, et. al., 2014). Therefore 
these enzymatic activities are at the core of the „M‟ component of the MTR 
trinity. 
 
The key roles for Sirtuins in ageing and stress response make them 
prime candidates for involvement in any disease of ageing. Furthermore the 
recent elucidation of the roles of Sirt1 and Sirt2 in the aetiology of several 
neurological disorders suggests that the action and expression of this family 
of proteins is going to be critical to our understanding, and ultimately 
treatment, of these disorders. The biology of ageing suggests roles for 
metabolism (Sirt5), DNA damage (Sirt6) and reduction of tandem repeats in 
ribosomal DNA (rDNA) (Sirt7). Therefore Sirtuins 5, 6 and 7 were selected 
for their roles in these areas to determine the potential differences in the 
ageing process between the two rat strains, AS and AS/AGU rats; as well as 
providing a vehicle to investigate the implications of these differences in 
the context of neurological disorders, for example PD. 
 
 
 
 
 
 
P a g e  | 4-118 
Ageing in the Mammalian Brain 
4.2 Materials and Methods 
 
4.2.1 Animals used 
 
The animals used for these experiments were raised and sacrificed in 
accordance with all regulations, both national and local, and all animal 
husbandry/operations were performed by a qualified Home Office licence 
holder. Both strains of rat were fed a standard diet, with drinking water 
provided as required. Animals were reared and housed in the Joint 
Research Facility, University of Glasgow under standardised conditions – 
light/dark cycle 12/12 hours, temperature 22oC +/- 2oC, humidity 50% +/- 
5% in plastic-metal cages. 
 
A total of twenty four rats, six for each of the four experimental 
groups were used. The experimental groups used were AS rats at 2 months 
old, AS rats at 12 months old, AS/AGU rats at 2 months old and AS/AGU rats 
at 12 months old. 
  
Sacrificed animals had their brains excised and rapidly frozen in 
Isopentane using liquid Nitrogen; these were then placed in a cryomold, 
clearly labelled and stored in Isopentane at -80oC until required. 
 
4.2.2 qRT-PCR for Sirtuin mRNA 
 
Material for qRT-PCR was obtained from frozen samples as described 
in Chapter 2: General Materials and Methods, section 2.3.1. cDNA was 
generated as described previously (Chapter 2: General Materials and 
Methods, section 2.3.2). Then qRT-PCR was conducted in accordance with 
the general method set out in Chapter 2: General Materials and Methods, 
section 2.3.3. The following amendments to the protocol were used: 
 
Taqman assay primers used: 
Sirt5: Rn01450559_ml (Applied Biosystems, Paisley, UK) 
Sirt6: Rn01408249_ml (Applied Biosystems, Paisley, UK) 
Sirt7: Rn01471420_ml (Applied Biosystems, Paisley, UK) 
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Control GAPDH: Rn01775763_g1 (Applied Biosystems, Paisley, UK) 
 
Sequence of primers is given in Appendix 1b. Sequence for the 
housekeeping/reference gene used is provided in Appendix 1c. 
 
4.2.3 Statistics 
 
All datasets were tested for normality using the Kilmagorov-Smirnoff 
test, all datasets presented herein passed this normality test and were 
deemed of normal distribution for all further analyses. 
 
The unpaired t test (2-tailed) was used to demonstrate differences 
between the means of experimental groups and between brain regions; p 
values are presented to 3 decimal places. A 95% CI (p<0.05) was used 
throughout to determine significance, however significance at the 99% CI 
(p<0.01) and 99.9% CI levels (p<0.001) are also denoted where appropriate. 
 
4.3 Results 
 
4.3.1 Sirtuin 5 expression in rat brains 
 
The levels of Sirtuin 5 were measured in the brains of both AS and 
AS/AGU rats, and compared at 2 months old and 12 months old. 
 
4.3.1.1 Comparison of expression levels of Sirtuin 5 at 2 months old in 
both AS and AS/AGU rats 
 
Levels of Sirt5 expression in the brains of AS and AS/AGU rats were 
determined and compared in 2 month old rats (Figure 4.1). Levels in the 
cerebellum (p=0.005) and basal ganglia (p=0.016) were significantly higher 
in the AS rats than in the AS/AGU; although levels found in the brainstem 
(p=0.061) were also higher, these were not significant at the 95% CI level. 
Interestingly, the levels of Sirt5 found in the cerebral cortex were also 
significantly different (p<0.001), however higher levels were seen in the 
AS/AGU rats. Furthermore, cerebral cortex demonstrated higher levels in 
P a g e  | 4-120 
Ageing in the Mammalian Brain 
general when compared to other areas of the brain in AS/AGU rats, whilst 
the cerebral cortex demonstrated the lowest levels of expression seen in 
AS rats. 
 
Figure 4.1 Comparison of expression levels of Sirt5 in 2 month old 
rats of AS and AS/AGU backgrounds.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from both AS and AS/AGU rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at 2 months of 
age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with *, significance at 99% CI level (p<0.01) is denoted with ** and 
highly significant results (p<0.001, 99.9% CI level) are denoted with ***. 
 
 
 
4.3.1.2 Comparison of expression levels of Sirtuin 5 at 12 months old 
in both AS and AS/AGU rats 
 
Sirt5 Expression levels were determined in four regions of brains 
from both AS and AS/AGU rats at 12 months old (Figure 4.2). AS/AGU rats 
demonstrated significantly higher expression of Sirt5 in both the 
brainstem (p=0.011) and the basal ganglia (p=0.027). Levels found in the 
cerebral cortex (p=0.048) were significantly lower in the AS/AGU rats; 
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levels in the cerebellum also appeared to be lower in these rats but the 
difference was not significant (p=0.106). 
 
Figure 4.2 Comparison of expression levels of Sirt5 in 12 month old rats 
of AS and AS/AGU backgrounds.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from both AS and AS/AGU rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at 12 months 
of age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with *. 
 
 
 
4.3.1.3 Comparison of expression levels of Sirtuin 5 at 2 months old 
and 12 months old in AS rat brain regions 
 
A comparison of the expression levels found in AS rat brain regions 
at 2 months and 12 months was carried out; the results are presented in 
Figure 4.3. Levels in the cerebral cortex (p=0.044) were significantly 
higher in the older AS rats when compared to the 2 month old rat brains, 
whereas levels in the older rats were found to be significantly lower in the 
Basal ganglia (p=0.005). Levels in the brainstem appeared to be lower in 
the older rats , however this was not significant (p=0.108), and levels in 
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the cerebellum did not demonstrate any real differences in expression 
levels between 2 month old and 12 month old rats (p=0.258). 
 
Figure 4.3 Comparison of expression levels of Sirt5 in 2 month old and 12 
month old rats from the AS background.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Levels from AS rat brains in four regions (cerebellum, brainstem, 
cerebral cortex and basal ganglia) at both 2 months old and 12 months old 
are presented. Results significant at the 95% CI level (p<0.05) are marked 
with * and significance at the 99% CI level (p<0.01) is denoted with **. 
 
 
 
4.3.1.4 Comparison of expression levels of Sirtuin 5 at 2 months old 
and 12 months old in AS/AGU rat brain regions 
 
The expression levels of Sirt5 found in AS/AGU rat brain regions at 
2 months and 12 months were compared (Figure 4.4). Levels in the 
cerebral cortex (p=0.004) were significantly lower in the older AS/AGU rat 
brains when compared to the 2 month old rat brains. Levels in the older 
rats were found to be significantly higher in the brainstem (p<0.001). 
Levels in the basal ganglia appeared to be higher in older AS/AGU rats, 
however this was not significant (p=0.1), and levels in the cerebellum did 
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not demonstrate any difference in expression levels between 2 month old 
and 12 month old rats (p=0.795). 
 
Figure 4.4 Comparison of expression levels of Sirt5 in 2 month old and 12 
month old AS/AGU rats.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from AS/AGU rat brains in four regions (cerebellum, 
brainstem, cerebral cortex and basal ganglia) at 2 months old and 12 
months old are presented. Results significant at the 95% CI level (p<0.05) 
are marked with *, significance at the 99% CI level (p<0.01) is denoted 
with ** and highly significant results (p<0.001, 99.9% CI level) are denoted 
with ***. 
 
 
 
4.3.2 Sirtuin 6 expression in rat brains 
 
The levels of Sirtuin 6 were measured in the brains of both AS and 
AS/AGU rats, and compared at 2 months old and 12 months old. 
 
4.3.2.1 Comparison of expression levels of Sirtuin 6 at 2 months old in 
both AS and AS/AGU rats 
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The levels of Sirt6 expression measured in regions of brain from AS 
and AS/AGU rats were graphed and compared (Figure 4.5). Levels were 
found to be significantly elevated in the brainstem (p=0.029), cerebral 
cortex (p=0.003) and basal ganglia (p=0.003) of the 2 month old AS/AGU 
rats when compared with AS rats of an equivalent age. This pattern was 
reversed with significantly higher expression in the AS rats found in the 
cerebellum brain region (p=0.003). Furthermore, the highest levels seen 
in the AS rats were found in this region, whilst the lowest levels from 
AS/AGU rats were seen here. Expression levels seen in the other three 
regions were similar, dependant on the strain of rat. 
 
Figure 4.5 Comparison of expression levels of Sirt6 in 2 month old rats of 
AS and AS/AGU backgrounds.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from both AS and AS/AGU rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at 2 months of 
age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
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4.3.2.2 Comparison of expression levels of Sirtuin 6 at 12 months old 
in both AS and AS/AGU rats 
 
Sirt6 levels of expression measured in the brains of 12 month old AS 
and AS/AGU rats were compared and graphed (Figure 4.6). The results 
demonstrate significantly lower expression levels found in AS/AGU rats in 
the brainstem (p=0.013), cerebral cortex (p=0.016) and basal ganglia 
(p=0.001), whilst higher expression is seen in the cerebellum (p=0.011). 
The cerebellum contains the lowest levels of Sirt6 expression seen in the 
brain regions tested of the AS rat, while levels in other areas are broadly 
similar. Levels in the AS/AGU rat at 12 months old appear to be similar in 
all brain regions. 
 
Figure 4.6 Comparison of expression levels of Sirt6 in 12 month old rats 
of AS and AS/AGU backgrounds.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from both AS and AS/AGU rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at 12 months 
of age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with *. 
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4.3.2.3 Comparison of expression levels of Sirtuin 6 at 2 months old 
and 12 months old in AS rat brain regions 
 
A comparison of the expression levels of Sirt6 in AS rats at two time 
points, 2 months and 12 months, revealed that expression in the 
Cerebellum (p=0.002), Brainstem (p=0.011), Cerebral Cortex (p=0.015) 
and Basal Ganglia (p=0.001) was significantly different  (Figure 4.7).  
 
Figure 4.7 Comparison of expression levels of Sirt6 in 2 month old and 12 
month old AS rats.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Expression levels from AS rat brains in four regions (cerebellum, 
brainstem, cerebral cortex and basal ganglia) at 2 months and 12 months 
of age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
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4.3.2.4 Comparison of expression levels of Sirtuin 6 at 2 months old 
and 12 months old in AS/AGU rat brain regions 
 
Comparing the observed expression levels in AS/AGU rats at 2 
months and 12 months (Figure 4.8) revealed that levels were generally 
lower in older rats, with the exception of the cerebellum although this 
was not significant (p=0.248). The lower expression seen in the cerebral 
cortex (p=0.009) and basal ganglia (p=0.004) was significant, however the 
reduction in the brainstem (p=0.071) was not. 
 
Figure 4.8 Comparison of expression levels of Sirt6 in 2 month old and 12 
month old AS/AGU rats.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from AS/AGU rat brains in four regions (cerebellum, 
brainstem, cerebral cortex and basal ganglia) at 2 months old and 12 
months old are presented. Results significant at the 95% CI level (p<0.05) 
are marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
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4.3.3 Sirtuin 7 expression in rat brains 
 
The levels of Sirt7 were measured in the brains of both AS and 
AS/AGU rats, and compared at 2 months old and 12 months old. 
 
4.3.3.1 Comparison of expression levels of Sirtuin 7 at 2 months old in 
both AS and AS/AGU rats 
 
Measured expression levels of Sirt7 in both AS and AS/AGU rats at 2 
months of age were compared (Figure 4.9). Levels were found to be 
significantly higher in all brain regions of AS/AGU rats: cerebellum 
(p=0.004), brainstem (p=0.03), cerebral cortex (p=0.003) and basal 
ganglia (p=0.008). 
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Figure 4.9 Comparison of expression levels of Sirt7 in 2 month old rats of 
AS and AS/AGU backgrounds.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from both AS and AS/AGU rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at 2 months of 
age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
 
 
 
4.3.3.2 Comparison of expression levels of Sirtuin 7 at 12 months old 
in both AS and AS/AGU rats 
 
The measured expression levels of Sirt7 at 12 months were 
compared between the two rat strains AS and AS/AGU (Figure 4.10). In 
general, levels in the AS/AGU rats were lower than those observed in the 
AS rats. However, this reduction was only significant in two regions: 
cerebellum (p=0.039) and the brainstem (p=0.002), it was not significant 
in the cerebral cortex (p=0.537) or the basal ganglia (p=0.057). 
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Figure 4.10 Comparison of expression levels of Sirt7 in 12 month old rats 
of AS and AS/AGU backgrounds.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from both AS and AS/AGU rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at 12 months 
of age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
 
 
 
4.3.3.3 Comparison of expression levels of Sirtuin 7 at 2 months old 
and 12 months old in AS rat brain regions 
 
A comparison of the expression levels of Sirt7 in both 2 month old 
and 12 month old AS rats was completed and graphed (Figure 4.11). 
Although levels were generally higher in the older rats, this was only 
found to be significant in the brainstem (p=0.002), which also contained 
the highest levels overall in older rats (12 month old) but one of the 
lowest levels in younger rats (2 months old). The other areas, cerebellum 
(p=0.106), cerebral cortex (p=0.468) and basal ganglia (p=0.21) were 
found not to be significantly different, although the cerebellum displayed 
a trend of increasing expression with age. 
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Figure 4.11 Comparison of expression levels of Sirt7 in 2 month old and 12 
month old AS rats.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Expression levels from AS rat brains in four regions (cerebellum, 
brainstem, cerebral cortex and basal ganglia) at 2 months and 12 months 
of age are presented. Results significant at the 95% CI level (p<0.05) are 
marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
 
 
 
4.3.3.4 Comparison of expression levels of Sirtuin 7 at 2 months old 
and 12 months old in AS/AGU rat brain regions 
 
Expression of Sirt7 in 2 month old and 12 month old AS/AGU rats 
was compared (Figure 4.12). Levels were found to be significantly reduced 
in older rats in all areas of the brain: cerebellum (p=0.002), brainstem 
(p=0.041), cerebral cortex (p=0.004) and basal ganglia (p=0.001). Levels in 
the 12 month old rats were consistently low in all regions and relatively 
ubiquitous throughout. Expression in younger rats appears to be more 
widely varied in addition to being higher, with the highest levels in the 
cerebellum and basal ganglia. 
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Figure 4.12 Comparison of expression levels of Sirt7 in 2 month old and 12 
month old AS/AGU rats.  
Box and whisker plot demonstrating the distribution of results and mean 
levels. Results from AS/AGU rat brains in four regions (cerebellum, 
brainstem, cerebral cortex and basal ganglia) at 2 months old and 12 
months old are presented. Results significant at the 95% CI level (p<0.05) 
are marked with * and significance at the 99% CI level (p<0.01) is denoted 
with **. 
 
 
 
4.4 Discussion 
 
The results presented in this chapter demonstrate that the expression 
of all 3 Sirtuins measured here not only varies with age, but also shows 
highly distinctive differences between rat strains. These results are 
summarised in Table 4.2. 
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Table 4.2 Summary of Sirtuin Results 
Table 4.2 summarises the results presented in this chapter as simple increase 
(green) or decrease (red), when comparing the first factor with the second in 
each case, with the significance marked with ns showing no significance, * 
representing p<0.05, ** denoting p<0.01 and *** showing significance p<0.001. 
 AS 2 months 
vs 12 months 
AS/AGU 2 
months and 
12 months 
AS vs AS/AGU 
2 months 
AS vs AS/AGU 
12 months 
Sirt 5 
Cerebellum 
ns ns ** ns 
Sirt5 
Brainstem 
ns *** ns * 
Sirt5 
Cerebral 
cortex 
* ** *** * 
Sirt5 
Basal ganglia 
** ns * * 
Sirt 6 
Cerebellum 
** ns ** * 
Sirt6 
Brainstem 
* ns * * 
Sirt6 
Cerebral 
cortex 
* ** ** * 
Sirt6 
Basal ganglia 
** ** ** ** 
Sirt 7 
Cerebellum 
ns ** ** * 
Sirt7 
Brainstem 
** * * ** 
Sirt7 
Cerebral 
cortex 
ns ** ** ns 
Sirt7 
Basal ganglia 
ns ** ** ns 
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4.4.1 Sirt5 expression in the mammalian brain 
 
The expression of Sirt5 mRNA in the various brain regions 
demonstrates significant and distinct differences not only due to age, but 
also due to strain. At both age points the expression pattern of Sirt5 mRNA 
appears to be opposite in the two rat strains. For example, at 2 months of 
age expression is high in the cerebellum, brainstem and basal ganglia of the 
AS rats, whereas low expression is seen in the AS/AGU rat in these areas. 
Furthermore where expression is lowest in the AS rats, in the cerebral 
cortex; it is highest in the AS/AGU rats. This contrasting nature of 
expression between the strains is repeated in the 12 month old rats. 
However, the pattern was altered such that low expression was now seen in 
the brainstem and basal ganglia in the AS rats and high expression is seen in 
the AS/AGU strain. The cerebellum appears to be the only region that does 
not fluctuate, with high expression of Sirt5 in AS rats and low in AS/AGU 
rats at both ages. The cerebral cortex, at 12 months, demonstrates high 
levels of expression in the AS rats with low expression levels in the AS/AGU 
strain. Interestingly, the cerebellum shows no significant changes in 
expression levels between 2 month and 12 month old AS or AS/AGU rats; 
consistent with the maintenance of the pattern alluded to above. This also 
suggests that, although there is significantly different expression between 
strains in the cerebellum, Sirt5 levels do not fluctuate greatly in this brain 
region in response to age. This stable state for Sirt5 possibly reflects a 
constant demand for energy, furthermore the differences between the 
strains is most likely a factor of the PKC mutation in the AS/AGU rats.  
 
The brainstem demonstrates a significant increase in expression in the 
AS/AGU rats between the 2 month and 12 month time points, but no 
significant changes in the AS strain across the same time frame. The 
cerebral cortex shows changes in opposite directions with an increase in 
expression between 2 months and 12 months in the AS strain and a 
decrease in the AS/AGU rats. The switch in pattern for the basal ganglia 
appears to be as a result of a significant decrease in levels between 2 
months and 12 months in AS rats, with no significant change in AS/AGU 
rats. These notable differences are not unheard of when comparing 
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animals, one study investigating the effect of breed using a fatty breed and 
a lean breed of pig on the levels of Sirtuins in the brains demonstrated that 
expression of all Sirtuins varied significantly, some increased and some 
decreased. However, this study also demonstrated that the levels of all 
Sirtuins decreased with age in both breeds (Ren, et. al., 2013). This 
appears to be consistent with the AS strain, although a direct comparison is 
not possible without measuring total expression throughout the brain at 
both time points and determining whether it increases or decreases with 
age. However, this appears to be opposite to the situation found in the 
AS/AGU strain, although similarly to the AS strain total expression levels 
would be required to demonstrate this conclusively.  
 
Taking the AS strain alone, levels of Sirt5 appear to lower as the rats 
age, with the notable exception of a large increase in the cerebral cortex. 
By contrast the AS/AGU rats show a different pattern, with levels dropping 
in the cerebral cortex and rising in both the brainstem and basal ganglia. 
Interestingly, research into Neural stem cells (NSCs) and a v-myc 
transformed NSC line derived from mouse cerebral cortex demonstrated 
significantly lower levels of Sirt5 in the transformed cell line, linking lower 
expression with cancer (Wang, et. al., 2012a). This, taken with the lower 
levels in AS/AGU rats and higher levels in AS rats, may suggest a 
malfunction in Sirt5 regulation in AS/AGU rats. This malfunction however is 
likely to be a direct or indirect effect of the PKC mutation, suggesting that 
PKC is capable of influencing or altering the activities of Sirt5. However 
this would require further investigation, for example detection of 
succinylation/malonylation post-translational modifications of proteins. 
These experiments would have to be done in conjunction with Sirt5 levels 
to determine whether the PKC mediated effects, or lack thereof, are truly 
responsible for the modulation of Sirt5‟s behaviour. Sirt5 levels in the 
spinal cord have been linked to ALS (Korner, et. al., 2012). However, it 
must be noted that neither increased susceptibility to cancer nor the 
occurrence of ALS has been noted or demonstrated in the AS/AGU rat 
model. However, investigation of Sirt5 polymorphisms in humans has 
suggested that decreased expression may promote PD and HD through 
mitochondrial dysfunction (Glorioso, et. al., 2011). This is consistent with 
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very low levels of expression seen in the cerebral cortex of the AS/AGU rats 
at 12 months. The Parkinsonian phenotype associated with these rats 
(Payne, et. al., 2000) may also be a result of the lowered Sirt5 expression 
levels seen here. This argument is strengthened by the increase in levels 
seen in the relatively healthy AS strain across the same time frame. These 
reports and the results presented here appear to suggest that Sirt5 levels in 
the brain are highly localised and specific with deviation up or down 
resulting in increased risk of disease, which is dependent on localisation. 
This could be investigated using specific Sirt5 agonists and antagonists, for 
example suramin (Schuetz, et. al., 2007), to increase or decrease levels in 
specific areas of the brain. 
 
In order to investigate the effects of age properly with respect to Sirt5 
a third time point would be required, either in between for example 6 
months or outside the longer time point, for example 15 months. This 
would allow a more focussed comparison to determine the pattern of 
changes due to ageing in both strains. It would also allow a more accurate 
comparison between the levels of Sirt5 and the onset/severity of symptoms 
in the AS/AGU rat. The current dataset is difficult to interpret with respect 
to age alone as the patterns of expression are opposite at both time points 
and not consistent with a linear deployment due to age, rather these data 
points would appear to indicate that expression of Sirt5 may demonstrate a 
bell curve of expression with levels rising during the first few months after 
birth then dropping with increased age. This hypothesis is supported by the 
high early levels seen in pigs (at 1 month), which drops as they age (Ren, 
et. al., 2013), however this is at odds with the AS control rats which start 
low at 2 months and rise to 12 months and is more consistent with the 
pattern seen in the AS/AGU rats. Further evidence is provided by the lower 
levels of Sirt5 seen in transformed NSCs (Wang, et. al., 2012a) which, in 
general, have unhinged themselves from the ageing process, or found a way 
to counter it, suggesting that lower levels are seen in very young cells. It is 
important to note that although Sirt5 is related to age and in particular to 
longevity, it is a highly responsive mitochondrial protein which drives the 
stress/starvation response. Therefore some of the variation demonstrated 
here may be due to dietary issues including feeding times, variety of diet 
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and calorie intake. It is also interesting to note at this juncture that 
AS/AGU rats have a slower growth rate and a lower final body weight that 
the AS control rats; however, no metabolic or feeding studies have, as yet, 
been conducted with these animals. Additionally, the effects of other 
mitigating factors cannot be discounted and it may be that the levels of 
Sirt5 are highly influenced by the disruption of the dopaminergic system via 
the PKC mutation and therefore these strains may not truly be 
comparable; the third time point suggested earlier would also aid in 
determining whether this is a root cause of the variation or not. 
Alternatively localising the expression of Sirt5 and determining whether it 
is primarily mitochondrial or cytosolic (Park, et. al., 2013) may also allow 
determination of the cause of the variation. 
 
4.4.2 The expression pattern of Sirtuin 6 found in the rat brain 
 
Similar to Sirt5 expression, the pattern of distribution of Sirt6 mRNA 
levels appears to be opposite when comparing AS to AS/AGU rats, at both 
age points. Even though the levels switch between the age points, the 
opposing nature of expression is continued. At 2 months, AS rats 
demonstrate highest expression in the cerebellum, whereas AS/AGU rats 
demonstrate low expression in the same region. In the brainstem, cerebral 
cortex and basal ganglia, levels are low in AS rats and high in AS/AGU rats, 
all of these differences are significant at the 95% CI level. 
 
At 12 months the situation is almost completely reversed, with AS 
rats having low levels in the cerebellum, where levels are highest in the 
AS/AGU rat. High levels in the brainstem, cerebral cortex and basal ganglia 
in the AS rat are countered with low levels in the AS/AGU rats. Once again, 
all of these differences were significant. However, all of these changes 
were significant in the AS rats indicating that transcription of Sirt6 
fundamentally changes between the age points. Significant reductions were 
seen in the cerebral cortex and basal ganglia in AS/AGU rats, this indicates 
that the shift in expression patterns was driven by an increase in the 
cerebellum of AS/AGU rats, a reduction in the brainstem of AS rats and a 
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combination of reductions in the cerebral cortex and basal ganglia of the 
AS/AGU strain, with concurrent increases in the same regions in AS rats.   
 
In the case of Sirt6, it would appear that the AS/AGU rats reduce 
levels of mRNA as the animals age; this is consistent with previous reports 
that levels of Sirt6 reduce with age (Ren, et. al., 2013), However levels rise 
in three of the four areas in AS rats, possibly indicating that these animals 
are still maturing and have not reached the decline phase, this is consistent 
with increased expression of NADH hydrolysis gene sets with age in mice 
(Zahn, et. al., 2007). Expression of Sirt6 is predominantly localised to 
neurons and not glial cells and decreases in response to ischaemia (Lee, et. 
al., 2013). Increased levels are seen in transformed NSCs (Wang, et. al., 
2012a). Like Sirt5 levels, this would appear to suggest that neuronal cells in 
AS/AGU rats are highly disrupted, however it should be noted again that 
increased tumourigenesis has never been demonstrated in this model. 
Furthermore reduced levels in the brains of a diabetes mouse model were 
found to correlate with onset of T2D, and it was further proposed that this 
may also result in diabetes-induced neurodegeneration (Favero, et. al., 
2013). This report is consistent with the age-related status of T2D. Specific 
neuronal deletion of Sirt6 has been shown to promote obesity, as well as 
attenuate somatic growth, due to modulation of chromatin structures in 
neurons (Schwer, et. al., 2010). This may suggest a mode of neural 
degeneration in the AS/AGU model, where levels are low at an early age 
resulting in slow neural development. The expression of Sirt6 mRNA may be 
even more complicated by the discovery of splice variants, one of which 
was present in the brain of pigs (Jin, et. al., 2009); splice variants may 
represent different functions for this gene in vivo. 
 
Although there is little direct evidence for the influence of Sirt6 in 
neuroprotection, its interactions with Sirt1 heavily implicate it in the 
aetiology of several neurodegenerative disorders including AD, HD and PD. 
Sirt6 can mediate the function of peroxisome proliferator-activated 
receptor gamma (PPAR) coactivator 1 (PGC1) by deacetylating the 
general control non-repressed protein 5 which regulates 
PGC1(Beauharnois, et. al., 2013); these proteins have been implicated in 
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the development and progression of PD This role for Sirt6 in 
neurodegenerative disorders is reinforced by studies demonstrating lower 
levels of Sirt6 are present in mouse models of HD which can be 
counteracted by treatment with Rosiglitazone, a PPAR agonist (Jin, et. al., 
2013). Once again, the lower levels of Sirt6 present in AS/AGU rats is 
consistent with these reports and suggests that lower levels of this Sirtuin 
are related to neurodegenerative disorders, including the Parkinsonian 
phenotype of the AS/AGU rats. Furthermore, this indicates that Sirt6 may 
exhibit a neuroprotective function in the brain. These findings are 
consistent with the role of Sirt6 in resistance to DNA damage and stress, 
both key factors in age-related diseases (Beauharnois, et. al., 2013). 
 
The data presented in this thesis are also consistent with abnormal 
neurometabolism in the AS/AGU brain with age, as Sirt6 mediates glycolytic 
metabolism. Lower levels of Sirt6 may indicate aerobic glycolysis, while 
higher levels indicate aerobic metabolism via the TCA cycle. In 
mitochondria damage is likely occurring with age in both the AS/AGU and 
the AS animals, albeit at different rates. This damage could be measured 
by qPCR (Hunter, et. al., 2010; Santos, et. al., 2006). It has been shown 
that Sirt6 rapidly responds to changes in diet, primarily due to stabilisation 
of protein and not through increased transcription (Kanfi, et. al., 2008), 
however if this is continued long term it is reasonable to assume that a 
consistent change in diet would lead to altered transcription. Furthermore 
these data imply that SIRT6 is not upregulated in AS/AGU rats, perhaps 
because the pathology observed in these animals has a major mitochondrial 
component. Of note a dopaminergic specific phenotype could result from 
dopamine being trapped at synapses, unable to be exported in vesicles, 
with mitochondria concentrated well away from the nucleus and thus 
nuclear DNA. Therefore the ROS being generated by the mitochondria, 
being unable to be repackaged due to lack of vesicle transport, would 
primarily attack the mitochondrial DNA and ultimately destroy the 
mitochondria. This potential mechanism would explain both Sirt5 and Sirt6 
levels in the AS/AGU rats, it would also suggest that the levels of these 
Sirtuins is driven by PKC, determination of damage to nuclear and 
mitochondrial DNA would answer this question. 
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4.4.3 Pattern of expression for Sirtuin 7 in the mammalian brain  
 
Although the opposing pattern of expression seen in Sirt5 and Sirt6 is 
not apparent for Sirt7, the trend of levels moving in opposite directions 
with age is still present. Given that levels of Sirtuins generally decline with 
age, the rising levels seen in AS rats may represent a low level early in life 
which rises to a peak and then falls off with age. This may be due to a 
general increase in ribosome biogenesis throughout early life indicating 
healthy growth, followed by a decline in old age related to senescence and 
accumulated oxidative stress damage. This would be testable with older 
time points to determine if this is true. 
 
Levels of Sirt7 consistently decrease significantly with age in all 
areas of the brain in the AS/AGU strain, whereas general increases are seen 
in the AS rats during the same time span; however, this is only significant in 
the brainstem. This may indicate a general decline in ribosome biogenesis 
as these rats age, this would be consistent with an accelerated ageing 
phenomenon. Furthermore, this is also consistent with the MTR theory for 
ageing, where ribosome biogenesis would decline in older animals as they 
become more damaged by oxidative stress and increase the levels of 
cellular senescence. Levels in the AS/AGU strain are significantly higher in 
all areas at the 2 month age point; whereas they are lower at the 12 month 
age point – only significant in the cerebellum and brainstem. Again this fits 
with the theory that these rats demonstrate an accelerated ageing 
phenotype from an early age. This early increase in Sirt7 indicates a higher 
rate of ribosomal biogenesis and thus a higher rate of living. 
 
Decreasing levels in the AS/AGU rats in association with age is 
consistent with current understanding of the role of Sirt7 in ageing 
(Ghiraldini, et. al., 2013), furthermore it may be a factor in the shortened 
life expectancy of these rats, as this has been demonstrated in mice 
(Vakhrusheva, et. al., 2008b). While the data presented here for AS rats is 
not immediately consistent with these reports, and suggests an opposing 
rise in Sirt7 levels between 2 months and 12 months, it is consistent with 
P a g e  | 4-141 
Ageing in the Mammalian Brain 
the levels demonstrated for Sirt5 and Sirt6 which suggests that these 
Sirtuins are found at low levels very early on in life, increase and then 
begin their decline into old age. However, more age points would be 
required to confirm this hypothesis. Additionally testing using agonists and 
antagonists may be informative here, by using agonists to drive levels very 
early or very late in life it may be possible to extend the lifespan of these 
rats. Similarly the use of antagonists in the central point of the lifespan 
may have detrimental effects. 
 
The role of Sirt7 in ageing has been established in mouse models, 
where inactivation of the Sirt7 gene resulted in reduced lifespan 
(Vakhrusheva, et. al., 2008b) and Sirt7 levels were associated with ageing 
in normal BALB/c mice (Ghiraldini, et. al., 2013). Although there is little 
information on the expression or role of Sirt7 in the brain, the information 
that has been presented suggests that it will decrease with age (Ren, et. 
al., 2013). It will also be lower in tumour cells compared with normal 
(Wang, et. al., 2012a) and expression of Sirt7 has been inversely correlated 
with the tumourigenic potential of mouse derived cell lines (Vakhrusheva, 
et. al., 2008a). These reports are consistent with reducing levels of Sirt7 in 
the brain with age and the status of cancer as a disease of ageing. This 
apparent role for Sirt7 in tumourigenesis in the brain is however 
contradictory to the current understanding of the role of Sirt7 in 
tumourigenesis where lower levels have been linked to inhibition of tumour 
growth (Tsai, et. al., 2013a) and raised levels are associated with some 
cancers for example breast cancer (Ashraf, et. al., 2006) and 
hepatocellular carcinoma (Kim, et. al., 2012). Moreover, the deacetylation 
action of Sirt7 acting on Lysine 18 of Histone 3 (H3K18) has been shown to 
be critical for stabilising tumour cells (Barber, et. al., 2012). An interesting 
point with these reports is that they all concern mitotic cells and not post-
mitotic cells, therefore the situation in the brain may be unique. In fact 
the only data that has been reported for the brain suggests that lower 
levels are associated with tumourigenesis. The data presented here is 
consistent with the levels of other Sirtuins (5 and 6, also presented here) 
which suggest that levels in the AS/AGU rat, particularly at the advanced – 
12 month – age point, may promote the development of diseases associated 
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with ageing. Once again, however, there have been no investigations which 
have demonstrated this in the AS/AGU rat model. 
 
The role of modulating ribosomal RNA (rRNA) structures has been 
demonstrated in neurodegenerative disorders (Hwang, et. al., 2013). This 
involves the Upstream Binding Factor (UBF), which has been demonstrated 
to interact with Sirt7 (Grob, et. al., 2009). Furthermore, the interactions 
between Sirt7 and RNA Polymerase 1 (RNA pol 1) (Chen, et. al., 2013) 
clearly implicate it in the regulation of rRNA structures and production 
(Tsai, et. al., 2012). Regulation by the cell cycle machinery, the CDK1-
cyclin B pathway during normal mitotic cell division function (Grob, et. al., 
2009), combined with findings that loss of Sirt7 results in replicative 
senescence (Kiran, et. al., 2013), suggests that levels in the brain should be 
low or non-existent. However the findings here that Sirt7 is indeed 
expressed suggest that Sirt7 may either be constitutively active in post-
mitotic or senescent cells or may be further regulated by other mechanisms 
in areas with high levels of post-mitotic cells, e.g. the brain.  
 
4.4.4 Sirtuin expression in the mammalian brain 
 
An interesting disparity between the data presented here and the 
current literature exists; low levels of Sirt6 in the brains of AS/AGU rats 
may disrupt metabolism and has been shown to promote obesity in other 
models. However, the AS/AGU rats present with much lower body weight 
than the AS control group which may result from the higher levels of Sirt6 
seen at the earlier age point (2 months). The low levels of Sirt6 at the later 
age point and disrupted metabolism may in turn be a driver for Sirt5 level 
increases, as dietary input is processed differently due to altered Sirt6 
expression. This highlights the interplay between these proteins and 
suggests a larger network of interactions which lie behind the differences 
between these rat strains. Furthermore this is also indicative of the 
complexity of neurological disorder phenotypes; in particular in this case it 
suggests that at least these three Sirtuins, and more than likely others, are 
heavily involved in the parkinsonian phenotype found in the AS/AGU rats. 
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Experiments involving the measurement of Sirtuins with and without the 
administration of L-Dopa may be more informative in this regard. 
 
It must also be noted that dopamine involvement in appetite and CR 
has been previously demonstrated (Fernandes, et. al., 2013; Hansen, et. 
al., 2013; Manuel-Apolinar, et. al., 2013). Given the involvement of the 
Sirtuins in CR it is possible that the disruption in dopamine levels observed 
in AS/AGU rats (Campbell, et. al., 1996) may be responsible for higher than 
normal levels of Sirtuins, particularly in the brain. Furthermore, this 
disruption in levels becomes more evident with age, particularly after 6 
months (Campbell, et. al., 1997). This would ultimately lead to disruption 
of diet, resulting in differences in calorie intake. These changes might 
result in varied Sirtuin expression particularly at the 12 month age point, 
thus providing an explanation for the broad differences between the two 
related strains at the later time point and the opposing nature of 
expression seen. This phenomenon may also explain the high Sirtuin levels 
seen at early time points in the AS/AGU strain as calorie modulation in the 
mother‟s diet has been demonstrated to result in increased variation of 
dopamine receptor expression, with CR leading to increased numbers of 
receptors to promote weight gain post-natal (Manuel-Apolinar, et. al., 
2013). Given the disruption in dopamine signalling seen in AS/AGU rats and 
the observed slow weight gain it is possible that the increases in Sirt5 are a 
biological attempt to rebalance the metabolism of the AS/AGU rats. 
 
Interestingly, direct roles in the modulation of nutrient usage, 
storage or uptake have been demonstrated for both Sirt5 and Sirt6 
indicating the potential for variable levels of these Sirtuins to drive a 
change in diet or be induced by a change. Moreover, mice deficient in Sirt7 
have been shown to develop chronic hepatosteatosis, similar to fatty liver 
disease in humans (Shin, et. al., 2013). This introduces the possibility that 
much of the variation demonstrated here may be as a result of varied 
nutrient uptake and usage. In addition to this the role of Sirt1 in the 
regulation of diet via Ghrelin, which regulates weight gain (Karra, et. al., 
2013), is well established (Velasquez, et. al., 2011; Wang, et. al., 2012b), 
as is its role in the regulation of diet via the hypothalamus (Satoh, et. al., 
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2010) and the interaction between Sirt1 and Sirt6 provides further weight 
to the argument that diet plays a key role in the levels of Sirtuins seen in 
the brains of the AS/AGU rats. However, it is not possible from this data set 
to demonstrate whether this is the case, or whether these changes are a 
result of an already modified appetite, via dopamine modulation, or 
whether the changes are the result of normal ageing. The most likely 
answer is a mixture of both but without additional measurements and an 
additional time point it is impossible to state at this juncture.  
 
Interestingly, diet has been clearly linked to epigenetic status, in 
particular methylation (Lillycrop, et. al., 2008). The results presented here 
with the Sirtuins suggest that there may also be epigenetic disruption in 
association with the accelerated ageing phenotype.  In fact, there are 
studies which demonstrate that the maternal diet influences the epigenetic 
status of the offspring (Cooney, et. al., 2002). Furthermore, the disruption 
of DA may indicate that there is altered calorie intake in the maternal rats, 
potentially indicating a disruption in methylation patterns in newborn 
AS/AGU rats. In this regard, epigenetic status and/or changes may be the 
key to the accelerated ageing phenotype seen in the AS/AGU rats. 
Measurement of methylation levels would be critical to understanding 
whether this is true or not. 
 
Measuring dopamine levels or the level of dopamine receptor 
expression alongside levels of Sirtuins would provide more information on 
the influence of diet on the levels of Sirtuins in the brains of the AS/AGU 
rats and may provide a greater insight into the highly variable response 
seen here. Combining this with a third time point and monitoring of the 
physical abnormalities found in this strain (Campbell, et. al., 1996) at each 
time point would provide invaluable information into the interaction of the 
dopaminergic system and the Sirtuins in both the development of the 
Parkinsonian phenotype and ageing or cellular senescence. 
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5. Senescence associated -galactosidase (SA -gal) expression in the brains 
of AS and AS/AGU rat brains 
 
5.1 Introduction 
 
5.1.1 -galactosidase

Also known as beta-gal or -gal, the -galactosidases are a class of 
enzymes involved in the hydrolysis of the -glycosidic bond between a 
galactose (Gal) residue and another sugar residue (Figure 5.1). Targets of -
galactosidases include lactose, lactosylceramides, glycoproteins and 
gangliosides, although galactopyranosides have also been demonstrated to be 
useful substrates in the detection of -gal activity (Buller, et. al., 2003; 
Groth, et. al., 1998; Martin, et. al., 1996; Zhang, et. al., 1991) both in vitro 
and in vivo. In E. coli the -gal gene, lacZ, is part of the inducible lac system 
and becomes active when glucose levels are low but lactose is present. 
Deficiencies or disruptions in -gal function have been attributed to lysosomal 
storage diseases including galactosialidosis (Koike, et. al., 2008) and 
Morquio‟s syndrome (B variant) (Groebe, et. al., 1980; Ishii, et. al., 1995). 
 
Figure 5.1 Cleavage of the glycosidic bond by -gal. Schematic drawing 
indicating the reaction substrate, direction of reaction, additional 
components and reaction products. Magnesium (Mg) and Potassium (K) ions 
are required for maximum efficiency of the reaction although they are not 
essential. 
 
                        
-D-galactoside                                       -D-galactose         +    Alcohol 
 
-gal 
+ H2O + K
+ + Mg2+ 
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Structural studies in E. coli have determined that the enzyme forms a 
tetramer with 3 other identical copies of itself (Appel, et. al., 1965; Kalnins, 
et. al., 1983), a structure that is essential to normal function. Each individual 
enzyme consists of 5 domains with the third domain containing the enzymatic 
active site (Figure 5.2). The enzymatic hydrolysis reaction has an optimal pH 
of 7.2, and the presence of Potassium (K) and Magnesium (Mg) cations have 
also been demonstrated to enhance the reaction efficiency.  
 
Figure 5.2 The tetrameric structure of the E. coli LacZ protein. Image 
obtained from the Protein Data Bank in Europe (PDBe) (available at: 
http://www.ebi.ac.uk/pdbe-srv/view/entry/3muy/summary); PDB accession: 
3MUY. Structure published by Dugdale et. al. (Dugdale, et. al., 2010). Each 
monomeric unit is presented in a different colour. 
  
 

-gal is commonly used as a reporter gene in molecular biology to 
monitor transfected gene expression levels (Serebriiskii and Golemis, 2000). 
Its usefulness in molecular biology extended further with the discovery of -
complementation where the gene is split into two sequences each producing 
a peptide, denoted LacZ and LacZ; when expressed together in the same 
transfected cell these will produce a functional -gal, but separately they are 
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non functional. This has been used as the basis for blue/white colony 
screening for plasmid transfection into E.coli (Fung, et. al., 2006). Bacteria 
are grown on agar plates containing X-gal which produces a blue colour when 
cleaved by functional -gal, giving a clear indication of successfully 
transfected colonies. 
 
5.1.2 Senescence associated -galactosidase (SA -gal)

In 1995 Dimri et. al. identified what they believed to be a new isoform 
of -gal which was detectable at pH 6.0, unlike other isoforms which were 
readily detectable at pH 4.2 and not at pH 6.0 (Dimri, et. al., 1995). This 
novel activity is associated with senescent cells and it appeared to increase 
with age in human skin samples from people of different ages. This novel 
biomarker was termed senescence associated -galactosidase (SA -gal) 
(Dimri, et. al., 1995; Gorbunova, et. al., 2002), and new assays for its 
detection were implemented. It has now been shown that this activity is 
attributable to lysosomal -gal accumulation (Lee, et. al., 2006) and is 
accompanied by an increase in lysosomal mass (Kurz, et. al., 2000), which is 
activated in response to several different cellular stresses (Severino, et. al., 
2000). Despite some claims that this renders the assay non-specific (Krishna, 
et. al., 1999), it is still widely used and is deemed by most to be accurate 
(Satyanarayana and Rudolph, 2004). Reports continue to demonstrate the 
association between SA -gal and ageing (Melk, et. al., 2003). However, it has 
been demonstrated in astrocytes that SA -gal accumulation during 
senescence is dependent on the presence of functional pRb and that there 
may be a p21WAF1 senescence pathway that is independent of SA -gal 
expression (Fanton, et. al., 2001). The most commonly used assay for in situ 
detection of SA -gal is based on its ability to cleave the X-gal (5-bromo-4-
chloro-3-indolyl--D-galactopyranoside) galactopyranoside substrate at pH 6 
(Dimri, et. al., 1995), although other methods have been proposed using flow 
cytometry (Kurz, et. al., 2000), chemiluminescence (Bassaneze, et. al., 2008) 
and fluorogenic substrates (Gary and Kindell, 2005; Yang and Hu, 2004). 

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5.1.3 SA -gal expression in the brain
 
Most of the information available on SA -gal expression in the brain 
results from its use as a senescence marker, where it is used to determine 
whether a factor induces cellular senescence or not. For example, beta 
amyloid drives expression of p16INK4a and SA -gal, indicating a role for 
senescent astrocytes in the aetiology of AD (Bhat, et. al., 2012). While this 
information is not immediately useful it does suggest that this marker is not 
ubiquitously expressed. It can be predicted that -gal expression would 
increase overall in brain as it ages; this is due to the association of increasing 
levels of gangliosides during differentiation and their decrease in ageing, this 
decrease being the result of increased -gal activity (Aureli, et. al., 2011). In 
fact, it has been demonstrated that levels of SA -gal can increase rapidly 
with age in the hippocampus of normal rats (Geng, et. al., 2010). It has also 
been shown that levels of senescent neurons, and thus abundance of SA -gal 
increases with age (Jurk, et. al., 2012). Furthermore, due to this increasing 
expression with age SA -gal, is rapidly emerging as a potentially valuable 
marker in the investigation of neurodegenerative diseases; however no direct 
associations between its expression and occurrence of neurodegenerative 
diseases have thus far been discovered. 
 
The work in this chapter sought to investigate overall levels of SA -gal 
to confirm increased senescence with age. Given the highly accepted nature 
of this marker it provides a solid grounding for the interpretation of other 
data presented in this thesis. For example, it serves to confirm and validate 
the findings for both CDKN2A and the Sirtuins by demonstrating an increase in 
cellular senescence in conjunction with increased biological ageing and its 
associated metabolic stress/DNA damage.  
 
 
 
 
 
P a g e  | 5-150 
Ageing in the Mammalian Brain 
5.2 Materials and methods 
 
5.2.1 Animals used 
 
The animals used for these experiments were raised and sacrificed in 
accordance with all regulations, both national and local, and all animal 
husbandry/operations were performed by a qualified Home Office licence 
holder. Both strains of rat were fed a standard diet, with drinking water 
provided as required. Animals were reared and housed in the Joint Research 
Facility, University of Glasgow under standardised conditions – light/dark 
cycle 12/12 hours, temperature 22oC +/- 2oC, humidity 50% +/- 5% in plastic-
metal cages. 
A total of twenty four rats, six for each of the four experimental 
groups, were used. The experimental groups used were AS rats at 2 months 
old, AS rats at 12 months old, AS/AGU rats at 2 months old and AS/AGU rats 
at 12 months old. 
  
Sacrificed animals had their brains excised and rapidly frozen in 
Isopentane using liquid Nitrogen; these were then placed in a cryomold, 
clearly labelled and stored in Isopentane at -80oC until required. 
 
5.2.2 Immunohistochemical staining for SA -gal 
 
Slides were prepared as previously described (Chapter 2: Materials and 
Methods, section 2.3.3). The required slides were removed from 4oC and 
allowed to warm to RT before processing. They were then rehydrated in PBS 
(Gibco, Life Technologies, Paisley, UK) for 10 minutes. 
 
5.2.2.1 Preparation of specific pH solutions 
 
pH-specific base solutions were prepared by mixing 450ml of citric 
acid (400mM; Chapter 2: Materials and Methods 2.1.9) and 450ml of sodium 
phosphate (400mM; Chapter 2: Materials and Methods 2.1.10). The pH 4 base 
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solution was then made by taking half of this mix (450ml) and adjusting the 
pH to 4.0 by the addition of concentrated hydrochloric acid (to lower the 
pH) or concentrated sodium hydroxide (to increase the pH). The total 
volume was then made up to 500ml using a mixture of equal volumes citric 
acid (400mM) and sodium phosphate (400mM). The pH 6 base solution was 
made in the same manner using the other 450ml of citric acid/sodium 
phosphate and adjusting the pH to 6.0 using concentrated hydrochloric acid 
or sodium hydroxide.  
 
To make 10ml of the final pH specific solutions 1 ml of each of these 
solutions was mixed with 7.45ml of PBS (Gibco, Life Technologies, Paisley, 
UK), 200l of x-gal (50mg/ml stock solution; Sigma Aldrich, Dorset, UK), 
125l potassium ferricyanide (400mM; Chapter 2: Materials and Methods 
2.1.5), 125l potassium ferrocyanide (400mM; Chapter 2: Materials and 
Methods 2.1.6), 100l magnesium chloride (200mM; Chapter 2: Materials and 
Methods 2.1.7), 1ml sodium chloride (1.5M; Chapter2: Materials and Methods 
2.1.8) 
 
5.2.2.2 SA -gal staining 
 
Slides were carefully dried and the tissue section was circled with a 
hydrophobic barrier pen (DAKO Delimiting pen: S200230-2; DAKO, Ely, UK). 
200l of the appropriate final pH specific solution was added to each slide 
(pH6 for test slides and pH4 for positive controls). Slides were then 
incubated for 48 hours. 
 
Slides were then washed in running water to remove the SA -gal 
staining solutions, and counterstained by immersion in Nuclear Fast Red 
solution (Chapter 2: Materials and Methods 2.1.11) for 30 seconds. Slides 
were again washed in running water. 
 
Slides were dehydrated by immersing in 70% ethanol for 1 minute, 
then 90% ethanol for 1 minute followed by 2 immersions in 100% ethanol 
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each for 1 minute and finally 2 immersions in xylene each for 1 minute. 
Slides were then mounted with cover slips using DPX histology mounting 
medium (Sigma-Aldrich, Dorset, UK). 
 
The number of positive cells was then evaluated using a microscope 
and a histoscore for each slide. This was calculated by counting the number 
of positive cells compared to the number of negative cells in several visual 
fields. The percentage of positive cells was calculated and averaged for 
each slide before being collated and presented as a mean for each 
experimental group. 
 
5.3 Results 
 
5.3.1 SA -Gal expression in the brains of AS and AS/AGU rats aged 2 and 
12 months 
 
Expression levels of SA -Gal were measured in para-sagittal sections of 
rat brains from both strains (AS and AS/AGU) at two time points, 2 months 
and 12 months (Figure 5.3). A significant difference in the protein expression 
levels of SA -Gal in the brain was noted between 2 month and 12 month old 
AS/AGU rats (p=0.025); a trend was observed in AS rats but this was not quite 
significant at the 95% CI level (0=0.066). Additionally, no significant 
differences were noted between the strains at the different time points: 2 
months (p=0.791) and 12 months (p=0.627). 
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Figure 5.3 Senescence-associated -galactosidase (SA -gal) levels seen in 
sagittal sections of brain from AS and AS/AGU rat strains collected at 2 and 
12 months of age. A significant difference in protein expression levels was 
observed between SA -Gal  level  in AS/AGU brain sections between 2 and 12 
months old rats (p=0.025). Significance at the 95% CI level is denoted by *. 
 
 
5.3.2 Immunohistochemical analysis of SA -Gal expression in rat brains 
 
Immunohistochemical analysis of SA -Gal protein expression was 
conducted in the para-sagittal cut brain sections of both rat strains at two 
time points (2 months and 12 months). Example staining is shown in Figure 
5.4, demonstrating differences seen between the overall expression levels 
seen between the two points in both strains. This staining also shows the 
control groups at pH4 (Figure 5.4 panels A (AS rats) and D (AS/AGU rats) 
demonstrating normal -Gal activity compared with the specific activity of SA 
-Gal seen at pH6 in AS rats (Figure 5.4, panels B and C) and AS/AGU rats 
(Figure 5.4, panels E and F). 
P a g e  | 5-154 
Ageing in the Mammalian Brain 
Figure 5.4 Immunohistochemical staining for Senescence Associated  galactosidase (SA -Gal) activity at 100x magnification. 
A:12 months AS pH4 (control). B: 2months-AS pH6. C: 12months-AS pH6. D: 2months AS/AGU pH4 (control).E: 2months-AS/AGU 
pH6. F: 12months-AS/AGU pH6. Quantification of SA -Gal staining was performed using automated slide-path method aided by 
a microscope equipped to quantify the amount of indigo-blue staining within the cells (cytoplasm) in whole rat brain frozen 
brain section cut para-sagittally. Red staining indicates presence of SA -Gal. 
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5.4 Discussion 
 
5.4.1 Expression pattern of SA -gal found in the brains of AS and 
AS/AGU rats 
 
The expression of SA -gal in both rat strains appears to rise with 
age, but this is only significant in the AS/AGU rat. This trend is consistent 
with the current literature and understanding of ageing in the mammalian 
brain (Geng, et. al., 2010; Jurk, et. al., 2012). Interestingly, the 
differences between rat strains at each time point are non-significant 
indicating no real overall difference between the strains at each time 
point. However, the significant rise in AS/AGU rats suggests that the 
increase in expression levels between the two time points found in these 
rats is greater than the increase seen in AS rats. This would appear to 
indicate that levels rose faster in the AS/AGU rats, potentially indicating an 
increased rate of senescence and thus ageing in the brains of these AS/AGU 
rats.  
 
This marker is purely a marker of senescence (Dimri, et. al., 1995), 
but has become well established as a successful biomarker, particularly in 
post-mitotic tissues. It is not required for senescence, but is a result of the 
process making it an excellent marker for the presence of senescent cells 
(Lee, et. al., 2006). In this regard it would appear that AS/AGU rats have 
increased cellular senescence levels over the 10 month period examined 
here. A lack of power in the experiment may be at fault for no significant 
differences being seen in the AS rats. Further time points, monitoring of DA 
levels and observation of phenotypic variance would result in a more 
informative dataset, it may also allow investigation of the relationships 
between SA -gal expression and dopamine, ageing or the Parkinsonian 
phenotype of the AS/AGU rats. 
 
The results presented here in conjunction with previous results, 
particularly CDKN2A expression serve to confirm the accelerated ageing 
phenotype found in the AS/AGU rats. This data also confirms that cellular 
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senescence is concurrent with the ageing process, measured by CDKN2A, 
indicating that accelerated ageing is a direct result of increased cellular 
senescence and not apoptosis of neurons. In this regard, these results 
suggest that measurement of overall grey or white matter volume is 
unlikely to be a useful measurement for the level of ageing in the brain. 
However, as volume loss is apparent in the brain with advancing age it does 
suggest that the combination of senescence and apoptosis may combine to 
give an additive effect in regards to neurodegeneration associated with 
ageing.  
 
It has been shown that senescent cells produce high levels of ROS 
and contain higher levels of DNA damage due to this oxidative stress (Chen, 
et. al., 1995b; Song, et. al., 2005). In conjunction with the Sirtuins these 
results confirm that the changes in expression of the Sirtuins are most 
likely associated with cellular senescence and thus increasing age. 
Furthermore, this suggests that increased oxidative stress and DNA damage 
is the driving force behind the accelerated ageing. This also indicates that 
the increase in CDKN2A, Sirtuins and SA -gal are all driven by accelerated 
biological ageing and not directly by the PKC mutation in the mutant 
AS/AGU rats. 
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6. Global DNA Methylation levels in AS and AS/AGU rats at two time points 
(2 months and 12 months). 
 
6.1 Introduction 
 
DA may disrupt diet, however more importantly the aberrant 
expression of the Sirtuins may influence diet and clearly demonstrates a 
disruption in metabolism and nutrient storage/uptake in the AS/AGU rats. 
This disruption in the metabolic state suggests that there may be a critical 
impact on epigenetic markers. For these reasons global DNA methylation 
levels were investigated here to determine whether significant differences 
could be seen due to either the accelerated ageing phenotype or the 
metabolic disruption evident in AS/AGU rats. 
 
6.1.1 DNA methylation 
 
Methylation of DNA is rapidly emerging as a critical epigenetic 
modification, with far reaching implications. Originally believed to be a 
stable, inheritable and long-term form of gene silencing it now appears 
that DNA methylation levels can adjust quickly in response to several 
factors (Wu and Zhang, 2010). In fact methylation combined with histone 
modifications tightly control storage and expression of the information 
encoded by eukaryotic DNA (Portela and Esteller, 2010). This relatively 
simple chemical alteration to the DNA structure is implicated in epigenetic 
regulation of many genes. It has been clearly demonstrated that maternal 
diet can have far reaching effects for progeny in terms of epigenetic 
markers (Dominguez-Salas, et. al., 2014; Marco, et. al., 2014). For 
example, people conceived just before or during the Dutch Hunger Winter 
(1944-1945) have now been demonstrated to have significantly lower DNA 
methylation on specific genes than same-sex siblings who were not exposed 
to this event (Heijmans, et. al., 2008). Furthermore, the influence of diet 
and other socioeconomic factors have also been shown to influence global 
DNA methylation levels (McGuinness, et. al., 2012). These variations in 
levels have been shown to coincide with increased risk for age related 
diseases, for example CVD (McGuinness, et. al., 2012). It has also been 
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shown that global DNA methylation can be used to demonstrate ageing 
and/or senescence (Issa, 2014; Jin, et. al., 2014; Sidler, et. al., 2014).  
 
This epigenetic modification of DNA, catalysed by the DNA 
methyltransferases (DNMTs) in the presence of S-adenosyl methionine (SAM) 
(Goll and Bestor, 2005), occurs specifically at the Carbon 5 position on 
phosphorylated Cytosine (Cp) residues found in Dinucleotide pairs with 
Guanosine (G), i.e. CpG. This occurs most frequently in sites which contain 
high levels of CpG repeats, also known as CpG islands (Figure 6.1) (Dahl, et. 
al., 2011). The DNMTs fall into two categories, de novo (DNMT3A and 
DNMT3B) which establish the pattern of DNA methylation during 
embryogenesis (Okano, et. al., 1999) and maintenance (DNMT1) which 
replicates the methylation status of DNA during mitosis by favouring hemi-
methylated DNA (Hermann, et. al., 2004). Further modification of 5-
methylcytosine (5mC), by Ten-eleven translocation (TET) proteins in the 
presence of Oxygen (Iyer, et. al., 2009; Tahiliani, et. al., 2009), results in 
5-hydroxymethylcytosine (5hmC) which may facilitate demethylation of the 
Cytosine residue (Figure 6.1). Approximately 1% of all bases in mammalian 
genomes appear to be 5mC, which is around 4% of the cytosine content of 
DNA resulting in 75% of CpGs being methylated in humans (Dahl and 
Guldberg, 2003). Levels of 5hmC have been shown to be highest in neurons 
(Globisch, et. al., 2010). Several active mechanisms have been presented 
which may be responsible for demethylation of 5mC and 5hmC (Ooi and 
Bestor, 2008; Wu and Zhang, 2010), including enzyme activity, base 
excision repair (BER) and deamination. However, the most likely candidates 
appear to be the DNMTs themselves (Kangaspeska, et. al., 2008; Metivier, 
et. al., 2008). 
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Figure 6.1 Cytosine methylation and demethylation. Chemical schemata of 
the methylation, modification and demethylation of Cytosine residues by 
DNMTs and TET proteins (Dahl, et. al., 2011; Kangaspeska, et. al., 2008; 
Metivier, et. al., 2008).  
 
 
 
6.1.2 Physiological and pathological influence of DNA methylation 
 
The pattern of DNA methylation is established during embryonic 
development, in a tissue specific manner which is believed to influence 
cellular differentiation in tissues (Meissner, 2010). Therefore, disruption of 
this pattern can have serious implications for the organism. In fact 
disruption of DNMT function has been shown to be lethal during 
embryogenesis or shortly after term (Okano, et. al., 1999). Furthermore, 
many disease pathologies have now been linked to aberrant methylation 
patterns or disruption of the methylation machinery. For example, the 
neurodevelopment disorder, Rett syndrome, which causes mental 
retardation in females has been linked to a sex linked (X chromosome) 
mutation in the gene encoding methyl-CpG-binding protein 2 (MeCP2) 
(Amir, et. al., 1999). Genetic imprinting disorders are linked to both hypo 
and hyper-methylated sequences found in imprinting centres (ICs) within 
the genome. These ICs contain several genes which become methylated 
during embryonic development; aberrant methylation here has been 
demonstrated to be responsible for a variety of disorders. These include 
two diseases with opposing clinical features from the same IC, firstly 
Beckwith-Wiedemann syndrome (BWS) (Lim and Maher, 2010), which results 
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in overgrowth either pre or post-natally with a variety of clinical 
pathologies (Cooper, et. al., 2005; Elliott, et. al., 1994); Secondly, Silver-
Russell syndrome (SRS) (Abu-Amero, et. al., 2008) which demonstrates 
growth retardation. It has been shown that these opposing phenotypes can 
be the result of opposing epimutations with hypomethylation at the H19 
differentially methylated region (DMR) found in 60% of SRS cases and 
hypermethylation at the same site in 5% of BWS cases (Lim and Maher, 
2010). Transient neonatal diabetes mellitus, occurring within the first 6 
weeks post-natal and disappearing by 18 months, is also caused by 
hypomethylation at another DMR which contains the PLAGL1 gene (Lim and 
Maher, 2010). Furthermore, mutations in DNMT3B are responsible for 
immunodeficiency, centromere instability and facial anomalies, also known 
as ICF syndrome (Xu, et. al., 1999), it is characterised by low levels of 
serum antibodies which usually results in death by infection at a young age.  
 
Methylation is heavily linked to tumourigenesis, with a general loss 
of methylation globally resulting in hypomethylation but with highly 
localised increases (hypermethylation) of specific loci (Jones and Baylin, 
2007). For example, hypermethylation of gene trap locus 2 (GTL2) 
promoter or the associated DMR has been shown in neuroblastoma, 
phaechromocytoma, Wilm‟s tumours (WT) (Astuti, et. al., 2005) and 
pituitary adenomas (Gejman, et. al., 2008; Zhao, et. al., 2005). 
Additionally, hypermethylation of the PLAGL1 promoter has been linked to 
several forms of cancer including breast (Bilanges, et. al., 1999), ovarian 
(Kamikihara, et. al., 2005), pituitary adenomas (Pagotto, et. al., 2000) and 
basal cell carcinomas (Basyuk, et. al., 2005). However some tumours have 
been linked to hypomethylation, for example loss of imprinting, i.e. 
expression of both alleles at once due to hypomethylation, on the IGF2 
gene has been linked a broad range of sporadic embryonic and adult onset 
cancers (Jelinic and Shaw, 2007), as well as demonstrating specific ties to 
ovarian (Kamikihara, et. al., 2005), colorectal (Kaneda and Feinberg, 2005) 
cancers and WT (Yuan, et. al., 2005). Disruption of the methylation 
machinery has also been discovered in myeloid malignancies, where TET2 
was found to be mutated in many cases (Abdel-Wahab, et. al., 2009). 
Although whether these altered methylation patterns are a result or a 
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driver of tumourigenesis is still the subject of some debate (Baylin and 
Bestor, 2002). It has also been proposed that age-related methylation 
changes are highly similar to those found in cancer, leading to the 
possibility that changes in methylation are the drivers behind the increased 
cancer risk associated with ageing (Ahuja and Issa, 2000). Mapping of a 
large number of CpG sites (1505) in human samples revealed that there was 
a progressive hypermethylation in promoter based CpG islands and 
hypomethylation in non-CpG island promoters (Fernandez, et. al., 2011). 
 
6.1.3 Environmental influences on DNA methylation 
 
The influence of environmental factors on methylation patterns has 
been confirmed by studies comparing methylation patterns in monozygotic 
twins. Young twins show a large degree of homozygosity in terms of DNA 
methylation pattern, whereas older twins demonstrated a much higher 
level of heterogeneity (Fraga, et. al., 2005). Another Icelandic study 
measuring global DNA methylation levels in the same population on average 
11 years apart demonstrated less than 10% difference in 70% of 111 
individuals, the remaining 30% demonstrated more than 10% changes in DNA 
methylation levels (Bjornsson, et. al., 2008). This study confirms not only 
that DNA methylation changes over time but that it changes at different 
rates, this is most likely attributable to environmental influences. This 
variation appears to be restricted to very specific loci, a comparison of 
blood and buccal cells across a period of several years demonstrated 
significant variation in 3 of 8 examined sites (Talens, et. al., 2010). 
Examination of two imprinted sites (IGF2/H19 and IGF2R) over 20 years 
demonstrated no significant alterations in methylation pattern (Sandovici, 
et. al., 2003).  
In terms of dietary effects folate (Jacob, et. al., 1998); 
(Rampersaud, et. al., 2000); (Pufulete, et. al., 2005a) and alcohol ((Choi, 
et. al., 2009a); (Zhu, et. al., 2010)) have both been demonstrated to 
modulate DNA methylation levels via the one carbon metabolism system 
(Choi, et. al., 2009b). Physical exercise has also been linked to methylation 
of specific sites (Nakajima, et. al., 2010); (Alibegovic, et. al., 2010), 
although some express doubts over these connections due to lack of data. 
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Tentative data also exists showing that specific sites maybe related to 
obesity (Gemma, et. al., 2010), however one large scale study found no 
relationship between body mass index and global methylation of repeat 
elements (Zhu, et. al., 2010). Oestrogen intervention in post-menopausal 
women in a small pilot study (n=8) led to increased global methylation 
(Friso, et. al., 2007). 
DNA methylation levels have been shown to be lower in smokers than 
non-smokers in leukocytes (Monick, et. al., 2012) and the mucosa of the 
colon (Pufulete, et. al., 2005b). Other environmental factors have also be 
linked to fluctuations in methylation levels for example ionising radiation 
and some carcinogens (Mathers, et. al., 2010); (Pavanello, et. al., 2009). 
 
6.1.4 Role of DNA methylation in ageing 
 
DNA methylation has been demonstrated to change in accordance 
with increased age in general (Boyd-Kirkup, et. al., 2013) and at specific 
CpG sites (Issa, 2000). This has been demonstrated in several sites including 
endometrium (Kim, et. al., 2005b), colon (Yatabe, et. al., 2001) and the 
small intestine (Kim, et. al., 2005a). In general, it has been accepted that 
ageing induces global hypomethylation, with specific hypermethylation 
(van Otterdijk, et. al., 2013). Additionally, it has been demonstrated that 
global methylation levels are negatively correlated with measurements of 
frailty in the over 65s (Bellizzi, et. al., 2011). The direct measurement of 
age by DNA methylation is confounded by the discovery that global 
methylation levels vary according to mitochondrial DNA (mtDNA) haplotype, 
in particular haplotype J is different from non J haplotypes (Bellizzi, et. 
al., 2012). In fact, to demonstrate the utility of DNA methylation in 
determining age, a model measuring 353 CpG sites has been proposed that 
interprets methylation state in multiple tissue types as a measure of ageing 
(Horvath, 2013). However, it has been demonstrated that some sites do not 
demonstrate increases in methylation due to ageing in non-mitotic tissues 
(Chu, et. al., 2007). Despite this studies in the mouse hippocampal region 
have revealed an age-related increase in 5hmC levels which is independent 
of oxidative stress and is not associated with increased expression of the 
TET enzymes (Chen, et. al., 2012). Interestingly, it has been shown that 
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levels of 5hmC decrease in mitochondrial DNA found in the frontal cortex in 
association with age, but not in the cerebellum (Dzitoyeva, et. al., 2012), 
indicating that different regions of the brain age differently with respect to  
DNA methylation. This suggests that, at least in terms of DNA methylation, 
non-mitotic tissues do not exhibit normal ageing characteristics; this is 
consistent with these cells being senescent. Some believe that epigenetic 
drift, caused by errors in the maintenance of epigenetic marks as a result 
of ageing or senescence, leads to various pathologies including cancer (Issa, 
2014). This is certainly supported by a growing body of evidence 
underlining the role of 5mC (Esteller, 2005), 5hmC (Tan and Shi, 2012), 
DNMTs (Li, et. al., 2013a) and TET proteins (Bian, et. al., 2014) in the 
development and progression of tumours.  
 
The relationship between DNA methylation and diseases of ageing 
underscores the direct link between this epigenetic modification and the 
progression of time. From cancer (Esteller, 2005) to neurodegenerative 
disorders (Jakovcevski and Akbarian, 2012; Lu, et. al., 2013), methylation 
is rapidly becoming the critical genomic link that was missing. Other 
diseases which are now understood to be related to age have also been tied 
to aberrant DNA methylation, for example heart disease (Duygu, et. al., 
2013), metabolic syndrome (Bruce and Cagampang, 2011) and autoimmune 
disorders (Grolleau-Julius, et. al., 2009). 
 
6.1.5 Role of DNA methylation in the brain 
 
It is generally accepted that DNA methylation is critical for 
development in the embryo (Reik, et. al., 2001; Wossidlo, et. al., 2011); 
this is particularly true in the brain (Lister, et. al., 2013). A methylation 
map has now been published charting the changes in methylation patterns 
during different stages of brain development in mice and humans (Lister, 
et. al., 2013). The information gleaned from this study illustrates the role 
of methylation in directing and controlling brain development. This map 
also allows for new research into neurodegenerative diseases by comparing 
changes in methylation patterns. Studies have already began to show this in 
four major neurodegenerative disorders: AD, PD, HD and ALS (Lu, et. al., 
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2013), as well as others (Urdinguio, et. al., 2009). Other studies measuring 
methylation of CpG sites have confirmed this by demonstrating specific 
methylation fingerprints in neurological disorders (Fernandez, et. al., 
2011). In fact consistent changes in methylation patterns, involving 
hypermethylation of specific genomic regions resulting in silencing of three 
genes (TBXA2R, SORBS3 and SPTBN4), have been found in both mice and 
humans in relation to AD (Sanchez-Mut, et. al., 2013). In general it has 
been found that there is a general hypomethylation associated with AD, but 
with specific sites hypermethylated (Sung, et. al., 2011). However, one 
recent study has demonstrated overall global hypermethylation, when 
incorporating both 5mC and 5hmC, and that these levels were specifically 
raised in neurons (Coppieters, et. al., 2014). -synuclein, the main 
component of lewy bodies which are responsible for the PD pathology, has 
also been shown to be related to DNA methylation albeit in studies of 
alcoholism (Bonsch, et. al., 2005). This link has now been established 
directly in Parkinson‟s disease (Jowaed, et. al., 2010). Furthermore, 
hypomethylation was detected in the substantia nigra of Parkinson‟s 
disease patients, post mortem (Matsumoto, et. al., 2010); reduction of 
nuclear DNMT1 levels was also observed in post-mortem brain samples 
(Desplats, et. al., 2011). Another potential influence of methylation on the 
aetiology of Parkinson‟s disease may be related to hypomethylation of the 
tumour necrosis factor alpha (TNF promoter region in SN cells (Pieper, 
et. al., 2008). In Huntington‟s disease studies have revealed that 5mC may 
increase the expansion of triplet repeat sequences (CTG/CAG) which result 
in Huntington‟s disease (Behn-Krappa and Doerfler, 1994). This is supported 
by other studies which demonstrated global hypomethylation could make 
these triplet repeats unstable (Gorbunova, et. al., 2004). Substantial 
changes in methylation levels have also been recently linked with 
expression of the huntingtin protein (Ng, et. al., 2013a), which is heavily 
implicated in the pathology of Huntington‟s disease. Amyotrophic lateral 
sclerosis may also be linked to changes in DNA methylation, altered DNA 
methylation on specific genes has been found in the brains of individuals 
with sporadic ALS (Morahan, et. al., 2009). Additionally, methylation in the 
ATXN2 gene promoter region may be linked to the pathogenesis of ALS 
(Lahut, et. al., 2012). 
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5hmC is found in relatively high levels in Purkinje neurons (0.6%) and 
granule cells (0.2%) (Kriaucionis and Heintz, 2009). The high levels found in 
the brain suggest a role for 5hmC in neuronal function via epigenetic 
regulation (Kriaucionis and Heintz, 2009). An alternative theory has also 
been proposed, where 5hmC marks sites during developmental stages which 
will later be demethylated (Lister, et. al., 2013). This was discovered in 
foetal brains; however there is no reason why this could not be possible in 
adult brains at a lower or less plastic level. Interestingly, it appears that 
DNA methylation is also involved in memory formation (Miller and Sweatt, 
2007) and synaptic plasticity in conjunction with histone acetylation 
(Miller, et. al., 2008). Further studies have demonstrated that it may also 
affect neuronal function resulting in altered behavioural patterns (Day, et. 
al., 2013; Day and Sweatt, 2010). The DNMTs have also been linked to 
learning, memory and synaptic plasticity through their ability to maintain 
methylation integrity and modulate neural gene expression (Feng, et. al., 
2010). It has also been demonstrated that CpG methylation is significantly 
more prevalent in CpG island shores in neurons (Kozlenkov, et. al., 2013).   
 
Previous studies have demonstrated differential methylation 
patterns according to brain region, which is believed to be associated to 
specialised function in each region (Ladd-Acosta, et. al., 2007), although 
this may be attributable to initial or ongoing brain development. Previous 
studies have linked global methylation content, as a simple physical 
measure of overall epigenetic status, to healthspan and ageing in humans. 
 
In this thesis, it was decided to see if this was observable in the 
AS/AGU rat and AS rat and if there was any difference in the physical 
quantity of methylated DNA that might reflect poorer healthspan and more 
rapid ageing in the AS/AGU rat brain tied to the loss of PKC function. 
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6.2 Materials and Methods 
 
6.2.1 Animals used 
 
The animals used for these experiments were raised and sacrificed in 
accordance with all regulations, both national and local, and all animal 
husbandry/operations were performed by a qualified Home Office licence 
holder. Both strains of rat were fed a standard diet, with drinking water 
provided as required. Animals were reared and housed in the Joint 
Research Facility, University of Glasgow under standardised conditions – 
light/dark cycle 12/12 hours, temperature 22oC +/- 2oC, humidity 50% +/- 
5% in plastic-metal cages. 
 
A total of twenty four rats, six for each of the four experimental 
groups were used. The experimental groups used were AS rats at 2 months 
old, AS rats at 12 months old, AS/AGU rats at 2 months old and AS/AGU rats 
at 12 months old. 
  
Sacrificed animals had their brains excised and rapidly frozen in 
Isopentane using liquid Nitrogen, these were then placed in a cryomold, 
clearly labelled and stored in Isopentane at -80oC until required. 
 
6.2.2 Measuring global DNA methylation levels 
 
DNA global methylation levels were measured using the MethylampTM 
Global DNA Methylation Quantification Ultra Kit (Epigentek, Farmingdale, 
NY, USA). ELISA plates were coated with samples by adding 2 l of a 100 
g/ml genomic DNA sample (i.e. 200 ng) and 28 l of DNA binding solution 
(Solution GU2 provided in the MethylampTM Global DNA Methylation 
Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA) to each well, 
ensuring the entire bottom surface of the well was covered by liquid. 
Samples, negative control (solution NC provided in the MethylampTM Global 
DNA Methylation Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA) 
and positive control (solution GU3 provided in the MethylampTM Global DNA 
Methylation Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA) 
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were all run in duplicate, whereas the standard curve points were ran in 
triplicate. The standard curve was obtained by serial dilution of the 
positive control provided (solution GU3 provided in the MethylampTM Global 
DNA Methylation Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA) 
into six distinct concentration points: 0.4, 1, 2, 5, 10 and 20 ng/well. 
Plates were then dried by 40 minute incubation at 37oC, followed by a 60 
minute incubation at 60oC both in a hybridisation oven (low humidity 
environment). 
 
150 l of blocking solution (Solution GU4 provided in the 
MethylampTM Global DNA Methylation Quantification Ultra Kit; Epigentek, 
Farmingdale, NY, USA) was added to each well and plates were incubated 
for 30 minutes at 37oC. Plates were then washed in a 10x dilution of wash 
solution (solution GU1 provided in the MethylampTM Global DNA Methylation 
Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA) three times 
before adding 50 l of the primary antibody (solution GU5 provided in the 
MethylampTM Global DNA Methylation Quantification Ultra Kit; Epigentek, 
Farmingdale, NY, USA) at a 1:1000 dilution in diluted solution GU1 (final 
concentration was 1 g/ml) to each well. Plates were incubated for 60 
minutes at RT. Plates were washed in 150l of the diluted wash solution 
(GU1) four times before adding 50l per well of the secondary antibody 
(solution GU7 provided in the MethylampTM Global DNA Methylation 
Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA) diluted 1:5000 
with diluted wash solution (GU1) to a final concentration of 80 ng/ml, 
plates were incubated at RT for 30 minutes. Plates were then washed five 
times in 150 l of diluted wash solution (GU1), before the addition of 100 l 
of developing solution (solution GU8 provided in the MethylampTM Global 
DNA Methylation Quantification Ultra Kit; Epigentek, Farmingdale, NY, 
USA). Plates were kept in a darkened environment and monitored for the 
development of a blue colour at a medium density in the positive controls, 
at this point the reaction was stopped by addition of 50 l of the stop 
solution (solution GU9 provided in the MethylampTM Global DNA Methylation 
Quantification Ultra Kit; Epigentek, Farmingdale, NY, USA). At this point 
the colour changed from blue to yellow to indicate the reaction had 
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stopped, samples were then quantified by measuring absorbance at 450nm 
using a microplate reader within 15 minutes of stopping the reaction.  
 
The standard curve was generated by plotting final concentration of 
the positive control (GU3) against the Optical Density at 450nm (OD450nm) 
obtained. This gives a slope measuring OD450nm/ng. This slope value was 
then used in the following equation to determine the amount of 
methylated DNA in each sample (x): 
 
Methylated DNA in sample (ng) = xOD450nm – negative control 
       Slope 
 
The percentage of methylated DNA in each sample was calculated by 
correcting for the GC content of normal genomic DNA, which is 42% in rats 
(value provided by manufacturer, Epigentek for use with this kit and 
protocol), using the following formula: 
 
% methylated DNA in sample = Methylated DNA in sample (ng)/0.42 * 100% 
         Sample DNA Amount Added (200ng) 
 
6.2.3 Statistics 
 
All datasets were tested for normality using the Kilmagorov-Smirnoff 
test, all datasets presented herein passed this normality test and were 
deemed of normal distribution for all further analyses. 
 
The unpaired t test (2-tailed) was used to demonstrate differences 
between the means of experimental groups and between brain regions; p 
values are presented to 3 decimal places. A 95% CI (p<0.05) was used 
throughout to determine significance, however significance at the 99% CI 
(p<0.01) and 99.9% CI levels (p<0.001) are also denoted where appropriate. 
All analyses and graphs were completed and prepared using 
Graphpad®Prizm Software (GraphPad Software Inc., La Jolla, CA, USA). 
 
 
P a g e  | 6-170 
Ageing in the Mammalian Brain 
6.3 Results 
 
6.3.1 Global DNA methylation levels at 2 months of age in AS and 
AS/AGU rats 
 
Global DNA Methylation levels in the forebrain were not significantly 
different in the AS/AGU rats compared with AS rats (cerebral cortex, 
p=0.0624, basal ganglia, p=0.110, cerebellum (p=0.057) and brainstem 
(p=0.595) (Figure 6.2). 
 
 
Figure 6.2 Global DNA methylation levels found in both AS and AS/AGU 
rats at 2 months in four different brain regions.  
Box and whisker plot demonstrating the distribution and mean 
levels. Global DNA methylation levels from AS and AS/AGU rat brains in 
four regions (cerebellum, brainstem, cerebral cortex and basal ganglia) at 2 
months old are presented. 
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6.3.2 Levels of global DNA methylation at 12 months of age in AS and 
AS/AGU rats 
 
At 12 months of age levels of global DNA methylation are almost 
equivalent in all areas of the brain, showing no differences (cerebellum, 
p=0.505; brainstem, p=0.301; cerebral cortex, p=0.647; and basal ganglia, 
p=0.775), with no comparison within areas being significantly different 
between the AS and AS/AGU rats and no obvious directional trends 
noticeable (Figure 6.3).  
 
Figure 6.3 Global DNA methylation levels found in both AS and AS/AGU 
rats at 12 months in four different brain regions.  
Box and whisker plot demonstrating the distribution and mean 
levels. Global DNA methylation levels from AS and AS/AGU rat brains in 
four regions (cerebellum, brainstem, cerebral cortex and basal ganglia) at 
12 months old are presented. 
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6.3.3 Comparison of global DNA methylation levels in AS rats between 2 
months old and 12 months old 
 
In the AS rat strain global DNA methylation levels increase 
throughout between 2 months and 12 months of age (Figure 6.4). These 
rises are significant in the cerebellum (p=0.016) and basal ganglia 
(p=0.028), but not in the brainstem (p=0.916) or the cerebral cortex 
(p=0.107).  
 
Figure 6.4 Global DNA methylation levels found in AS rats at both 2 months 
and 12 months old in four different brain regions.  
Box and whisker plot demonstrating the distribution and mean 
levels. Global DNA methylation levels from AS rat brains in four regions 
(cerebellum, brainstem, cerebral cortex and basal ganglia) at both 2 
months and 12 months old are presented. Results significant at the 95% CI 
level (p<0.05) are marked with *. 
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6.3.4 Comparison of global DNA methylation levels in AS/AGU rats 
between 2 months old and 12 months old 
 
There appears to be no difference in global DNA methylation levels 
in the forebrain (Figure 6.5), cerebral cortex (p=0.0628) and basal ganglia 
(p=0.676). However levels appear to increase in the other areas of the 
brain, although these are not significant at the 95% CI level, cerebellum 
(p=0.064) and brainstem (p=0.091). 
 
Figure 6.5 Global DNA methylation levels found in AS/AGU rats at both 2 
months and 12 months old in four different brain regions.  
Box and whisker plot demonstrating the distribution and mean 
levels. Global DNA methylation levels from AS/AGU rat brains in four 
regions (cerebellum, brainstem, cerebral cortex and basal ganglia) at 2 
months and 12 months old are presented.  
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6.4 Discussion 
 
6.4.1 Global DNA methylation levels associated with increased age in AS 
and AS/AGU rats 
 
Although no significant differences between the strains were 
apparent, the results did demonstrate a general trend. At 2 months 
methylation was higher in the cerebellum and brainstem (the hindbrain) of 
AS rats compared to AS/AGU. This was reversed in the midbrain and 
forebrain (basal ganglia and cerebral cortex) where levels were higher in 
the AS/AGU rats. It is possible that the lower levels found in the hindbrain 
of AS/AGU rats is symptomatic of accelerated ageing. Furthermore, higher 
levels found in the basal ganglia may be characteristic of the AS/AGU rat 
strain resulting in disruption of the substantia nigra and thus dopamine 
production, as methylation has been shown to be critical in this area 
(Pieper, et. al., 2008; Smidt, et. al., 2004). 
 
At 12 months very little difference is seen in the levels of DNA 
methylation in any region. Given that significant differences are apparent 
when comparing time periods in AS rats it is most likely that this 
equalisation effect is as a result of changes in the AS rats. This suggests 
that levels in the AS/AGU rats may have reached a plateau which the AS 
rats catch up with 10 months later. In order to examine this more closely 
further time points would be required, possibly 6 and 18 months, to 
determine any further differences and fully examine the trends involved. 
The data presented here is sufficient to say that levels appear to rise with 
age and that they may plateau once a certain age has been reached. 
Whether methylation levels begin to decline at advanced age points would 
have to be evaluated in a future study. 
 
The data presented here involving two rat strains, which were raised 
in the same environment allowing a fair comparison of the two strains. 
However, it should be noted that dopamine affects mood and food uptake, 
this introduces potential confounding factors. Although, dietary intake 
initially seems irrelevant it can have far reaching consequences by 
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providing altered nutrient flow, even in the brain, thus influencing the 
immediate neural environment tested here. Additionally, mood has a 
dramatic effect on brain chemistry once again providing for potential 
disruption to the local environment. Even considering both of these factors 
both strains demonstrated hypermethylation over time and although the 
influence of these environmental exposures cannot be ruled out in terms of 
differences in magnitude or individual areas they were not sufficient to 
completely disrupt the overall pattern of hypermethylation in the AS or 
AS/AGU rats . 
 
6.4.2 Differences in global DNA methylation levels in AS rats between 2 
months and 12 months old 
 
There were significant increases in global DNA methylation levels 
detected in the cerebellum and basal ganglia of AS rats between 2 months 
old and 12 months old. Very little is known about specific methylation 
patterns in the cerebellum or basal ganglia, in fact this is the first study to 
show differences related to age in these regions. The levels in the cerebral 
cortex also tended towards higher levels, although this failed to reach the 
cut-off significance value for 95% CI. These results show a general 
hypermethylation across all of the sites measured in the AS strain, although 
no real differences were seen in the brainstem over time. This is not 
consistent with the general belief that global hypomethylation is associated 
with age (van Otterdijk, et. al., 2013), nor is it consistent with the 
hypothesis that methylation is relatively stable in brain tissues (Gravina, 
et. al., 2013). However, it is consistent with the notion that specific sites 
may be hypermethylated, a phenomenon that would vary depending on the 
tissue or cell type being examined (Reinius, et. al., 2012) and any 
environmental exposures. The differences in cell types/tissues may also 
explain the differences in methylation found in each of the brain regions. 
The differing functions of these regions may also explain some of the 
differences seen here. For example, the role of methylation in memory and 
learning (Miller and Sweatt, 2007) may result in changes in methylation 
pattern in the cerebral cortex. 
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6.4.3 Differences in global DNA methylation levels in AS/AGU rats 
between 2 months and 12 months old 
 
The AS/AGU rats demonstrated increases in DNA methylation in the 
cerebellum, however this was not significant. The AS/AGU rats also 
demonstrated a trend towards higher DNA methylation levels in the 
brainstem with age, indicating a general increase in the hindbrain, whereas 
levels in the forebrain and midbrain did not vary significantly, which is 
consistent with reports of stable epigenetic marks in the brain (Gravina, et. 
al., 2013). The trends of increased methylation in the Cerebellum and 
brainstem is not consistent with the general hypomethylation seen as a 
result of increased age (van Otterdijk, et. al., 2013). However it is 
consistent with reports that non-mitotic cells do not demonstrate some of 
the age related changes in methylation (Chu, et. al., 2007). It should be 
noted however that the differences shown here did not reach significant 
levels. 
 
The AS/AGU rats did not demonstrate the anticipated 
hypomethylation in the basal ganglia. It was expected that levels here 
would decrease for two reasons, firstly ageing should induce a global 
hypomethylation (van Otterdijk, et. al., 2013) which in this accelerated 
ageing model should have been exacerbated; and secondly PD 
demonstrates a global DNA hypomethylation (Jowaed, et. al., 2010). 
Although it has been suggested that methylation patterns in post-mitotic 
tissues are relatively stable over time (Gravina, et. al., 2013). It is possible 
that aberrant DNA methylation patterns in the basal ganglia, or more 
specifically the SN, may be related to silencing the expression of paired-
like homeodomain transcription factor 3, via methylation of brain–derived 
neurotrophic factor (Martinowich, et. al., 2003), which is responsible for 
the development of Mesodiencephalic dopaminergic (mdDA) neurons 
specifically in the SN (Jacobs, et. al., 2011; Smidt, et. al., 2004). 
Furthermore, a critical enzyme in the generation of DA from tyrosine, 
tyrosine hydroxylase (Th), is regulated by tissue specific methylation of 
CpG sites (Okuse, et. al., 1993). This raises the possibility that the 
Parkinsonian phenotype seen in the AS/AGU rats is a result of aberrant 
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methylation during development or maturation. The lack of variation of 
levels in the brainstem would appear to suggest that the ongoing 
suppression of Th is a distinct possibility. This is supported by the lack of a 
reduction in levels from 2 months to 12 months as this would be more likely 
to result from high levels disrupting development of the SN. Furthermore, 
the fact that no reduction in levels is evident, unlike PD, suggests that the 
methylation levels may be an integral and continuous component of the 
phenotype. However, the SN represents only one part of the basal ganglia, 
therefore it is entirely possible that hypermethylation in the other 
components masks hypomethylation in this region. Further studies looking 
directly at the SN alone would be required to confirm whether methylation 
patterns are similar to those found in PD.  
 
Further studies measuring levels of 5hmC would provide more 
valuable information about the state of global methylation levels in the 
brain. For example, if these demonstrated a global decrease in 5hmC levels 
then it may be speculated that 5hmC is being reduced to 5mC resulting in 
the increased levels associated with age seen here. Alternatively, the same 
decrease in levels may be the result of deamination resulting in DNA 
mismatches, which are then repaired from Uracil to Cytosine in the genetic 
code by mismatch repair enzymes whereupon the Cytosine residues would 
be remethylated by DNMTs.  
 
The lack of differences seen in the cerebral cortex is again 
unexpected, as this is the area the ageing phenotype would be most likely 
to be apparent. More recent studies have demonstrated a similar finding by 
analysing 100 CpG sites in the brain and found that DNA methylation is 
stable over time (Gravina, et. al., 2013). 
 
6.4.4 The relationship of DNA methylation and ageing in brain regions of 
AS and AS/AGU rats 
 
As very little information is available on the region specific levels of 
DNA methylation this study represents a step forward. Not only does it 
present data related to four key areas of the brain, it also demonstrates 
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the changes seen in these regions over a 10 month period. Furthermore, 
this study has measured these levels in two related strains which reinforces 
the findings and also grants an insight into the differences between these 
strains. Ultimately, these data demonstrate that a general 
hypermethylation is evident with increasing age in the four brain regions 
studied as seen in the AS rats. The lack of increases seen in the cerebral 
cortex and basal ganglia in AS/AGU rats may be evident of an increased 
ageing phenotype where levels stabilise or plateau with age. Further 
studies involving additional time points would be required to determine 
whether this is true or not. The alternative possibility is that these lack of 
changes in levels are a cause/result of the parkinsonian phenotype evident 
in these rats, this may include impairment of dopamine production or 
modulation by dopamine, or lack thereof. It is not possible that the 
disruption of one gene, and thus the epigenetic marks on that gene, is 
responsible for the differences seen in methylation patterns between the 
AS and AS/AGU rats. The only possibility in regards to this is that the gene 
itself has a direct effect on the methylation pattern of the animal, to date 
there are no studies demonstrating any direct methylation abilities for 
PKC, therefore it must be concluded that these differences are a result of 
the accelerated ageing phenotype and not a direct result of the mutation 
present in AS/AGU rats. 
 
Histones are also responsible for epigenetic changes to gene 
transcription, these can be mediated through the actions of the Sirtuins. 
Histones are key regulators of gene transcription and modification of these 
can make them more or less stable. The Sirtuins all possess histone 
deacetylase (HDAC) activity this allows them to regulate gene 
transcription, particularly in response to changes in metabolism. Recently, 
succinylation and malonylation sites have been identified on histones (Xie, 
et. al., 2012). This suggests that Sirt5 may play an even more critical role 
in the regulation of histones as it possesses both desuccinylation and 
demalonylation enzyme activities (Du, et. al., 2011). 
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6.5 Overall Conclusions 
 
Ultimately, the lack of significant differences between brain regions, 
time points and rat strains leaves the data here difficult to interpret. The 
previous discussion is based mostly on trends and possible explanations, but 
in conclusion the number of animals used represents insufficient statistical 
power to interpret the lack of difference between groups, due to an 
inability to reject the null hypothesis. Further measurement is required in a 
larger group to increase the statistical power and allow these findings to be 
investigated and interpreted fully. In conclusion, these results are 
intriguing and provide an excellent basis for further investigation, but do 
not provide a solid basis for further conclusions. 
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7. Conclusions 
 
7.1 An enhanced ageing phenotype is apparent in AS/AGU rats when 
compared with AS rats 
 
CDKN2A, or more precisely p16INK4A, is now a well established 
biomarker of ageing (Collado, et. al., 2007; Krishnamurthy, et. al., 2004), 
proving to be more accurate than more traditional biomarkers including 
telomeres (Gingell-Littlejohn, et. al., 2013; McGlynn, et. al., 2009; Shiels, 
2010). In fact this biomarker has been shown to associate with senescence 
and age even when telomeres demonstrate no shortening (Melk, et. al., 
2003). This biomarker has been demonstrated and validated in multiple 
human tissues including skin (Ressler, et. al., 2006), kidney (Chkhotua, et. 
al., 2003; Melk, et. al., 2004), thymus (Kanavaros, et. al., 2001), fibroblasts 
(Alcorta, et. al., 1996) and T cells (Liu, et. al., 2009) as well as in several 
mouse and rat tissues (Krishnamurthy, et. al., 2004). The expression of 
p16INK4A within the tissues of the body is also highly selective, being confined 
to cells which are not involved in replenishment or replacement of dead 
cells (Nielsen, et. al., 1999), this further reinforces the tight relationship 
between its expression and cellular senescence. Evidence also suggests that 
the senescence-associated secretory phenotype is not linked to p16INK4A 
expression (Coppe, et. al., 2011); indicating that p16INK4A expression is likely 
to be an early event in cellular senescence improving its use as a biomarker 
through the potential for early detection of senescence. However there are 
some studies which suggest that the increased levels of CDKN2A associated 
with age may not be as apparent as some researchers believe, in fact one 
such study claims that CDKN2A only increased in cardiac tissue and actually 
decreased in the cortex in association with advancing age in mice (Swindell, 
2009). Replicative cellular senescence can be divided into two categories 
(Jeyapalan and Sedivy, 2008), the first involving telomere shortening or 
dysfunction or other stress leading to DNA damage and is mediated via p53 
(d'Adda di Fagagna, et. al., 2004; Herbig, et. al., 2004); the second involves 
p16INK4A, which can be induced by a variety of stresses, this may represent a 
more natural phenomenon resulting directly from ageing rather than 
damage. 
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Probably the most widely used senescence marker is SA -gal (Dimri, 
et. al., 1995; Itahana, et. al., 2007), however there have been some reports 
of non-senescent cells being stained using this method (Cristofalo, 2005; 
Severino, et. al., 2000; Yang and Hu, 2005) potentially leading to false 
positives. Despite this it is still one of the most relied upon and accurate 
markers of cellular senescence available to date. 
 
The raised levels of both CDKN2A (presented in chapter 3) and SA -
gal (presented in chapter 5) in whole brain sections indicate that cellular 
senescence increases overall in rat brains in association with increased age. 
The concurrent use of these markers to demonstrate senescence has been 
used in the past, for example in pancreatic islet cells (Halvorsen, et. al., 
2000). Furthermore, this increase appears to occur at an earlier time point 
in AS/AGU rats, i.e. is accelerated compared to the background AS strain. 
These data taken together suggest that an accelerated ageing phenotype is 
present in the brains of AS/AGU rats. Dual staining for both p16INK4A and SA 
-gal may further enhance the data presented here by confirming the 
presence of both in the same cell population; however the increase seen for 
both in accordance with increasing age is highly convincing alone given what 
is known about both of these markers. 
 
Sirtuin 5 has been suggested to be involved in the cellular stress 
response (McGuinness, et. al., 2011), the high levels of this transcript seen 
at the earlier age point (2 months) in AS/AGU rats (presented in chapter 4) 
may indicate greater stress or genomic instability which has the potential to 
manifest as accelerated ageing. Furthermore this may be a progenitor to the 
increase in p16INK4A seen in the older AS/AGU rats. The higher levels seen at 
the older age point (12 months) in the AS rats (presented in chapter 4) may 
indicate that they have reached a similarly critical age point which would 
ultimately lead to a similar ageing phenotype as seen in the younger AS/AGU 
rats. The influence of both Sirtuins 6 and 7 on genomic stability 
(McGuinness, et. al., 2011) suggests that they may have the potential to be 
early warning signs for oncoming cellular senescence and thus ageing. Higher 
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levels seen at the earlier age point (2 months) in AS/AGU rats (presented in 
chapter 4) would appear to suggest that this possibility has some merit.  
 
Differential expression of CDKN2A (presented in chapter 3) throughout 
the brain (in the four regions evaluated here) suggests that different areas 
of the brain age at different rates. The similarities in regional expression 
between 2 month old AS/AGU rats and 12 month old AS rats suggests that 
the brains of these young AS/AGU rats are of a similar bio-age to the older 
AS rats. This provides further evidence for an accelerated ageing phenotype 
in AS/AGU brains. This data also suggests that this accelerated ageing occurs 
throughout the brain and is not isolated to specific regions; for example 
areas that differ between strains (e.g. the basal ganglia), areas that are 
susceptible to PKC KOs (e.g. the cerebellum), or areas that are known to 
show differences with age (e.g. the cerebral cortex, basal ganglia and the 
cerebellum) all demonstrate the same accelerated ageing phenotype. This 
indicates that the enhanced ageing phenomenon seen here is not simply the 
result of strain differences, PKC mutation or normal ageing. Given the 
ubiquitous nature of this accelerated ageing phenomenon in AS/AGU rat 
brains it is reasonable to assume that this may occur in other post-mitotic 
tissues as well, for example cardiac tissue or skeletal muscle, however this 
would require further rigorous examination to determine if this is the case. 
Investigating this would determine whether this model combination (AS and 
AS/AGU rats) is a general accelerated ageing model, i.e. throughout the 
entire organism, or if this phenomenon is present only in the brain. 
  
PKC disruption/down regulation has been shown to be involved in the 
pathology of neurodegenerative disorders (Battaini and Pascale, 2005). 
Although one experiment in rabbits suggests that disruption of subcellular 
localisation is enough to induce memory impairment (Van der Zee, et. al., 
2004). This is similar to the disruption seen in the AS/AGU rats, however in 
neurodegenerative disorders this is accompanied by neuronal cell death. This 
does not appear to be the case in these rats; it appears that there is an 
increase in senescent cells as shown by SA -gal and to a lesser extent by the 
increases in CDKN2A levels. This would suggest that the accelerated ageing 
seen in these rats is not directly related to the PKC mutation. Furthermore, 
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the appearance of symptoms and physiology at a very early age (Clarke and 
Payne, 1994), combined with the low levels of extracellular DA (Campbell, 
et. al., 1998), mean that it is unlikely that any progressive change in 
markers is due to loss of DA or 5-HT. In addition , no obvious direct links 
exist between DA levels and transcription of the markers measured herein 
indicating that disruption of DA is unlikely to be linked to the accelerated 
ageing phenotype. 
 
The similarities between AS rats at 12 months and AS/AGU rats at 2 
months also suggests that ageing in these rats is accelerated and not 
disrupted, in other words the method of ageing is the same its just faster in 
AS/AGU rats. This suggests that this is simply a case of accelerated ageing 
and not a disruption to the ageing mechanisms induced by the PKC 
mutation. 
 
7.2 Metabolic disruption and DNA damage accumulation as measured by 
Sirtuin levels in the brain may be part of the accelerated ageing 
phenotype seen in AS/AGU rats 
 
The critical role for Sirt5 in the urea cycle modulating CPS-1, by 
deacetylation (Nakagawa, et. al., 2009), demalonylation and desuccinylation 
(Du, et. al., 2011), which catalyses the reaction converting ammonia to urea 
has the potential to reduce cellular levels of ammonium which promotes 
oxidative stress. Therefore Sirt5 has a critical role in the reduction of 
oxidative stress and thus reduces the potential for DNA damage 
accumulation, as well as having a more direct role in the modulation of 
metabolism.  
 
It has been demonstrated that levels of cellular NAD+ can fluctuate 
dramatically dependent on tissue type during CR (Chen, et. al., 2008). This 
suggests that the activity and expression of Sirtuins is tissue specific. Sirt1 
overexpression can mimic many of the phenotypes associated with CR from 
lower body weight to greater metabolic activity (Bordone, et. al., 2007). 
The close ties between Sirt1 and Sirt6 implicates this DNA repair related 
Sirtuin with metabolic disruption and stress. In fact Sirt6 has been directly 
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related to metabolic homeostasis, particularly glucose uptake and glycolysis 
(Zhong, et. al., 2010). This raises the possibility that increased levels of 
Sirt6 in young (2 month old) AS/AGU rats is associated with reduced glucose 
uptake which may be involved in the lower body mass and lower glucose 
usage seen in these rats (Lam, et. al., 1998). Although this does not appear 
to fit well with reports that a mouse model with neural deletion of Sirt6 
results in early growth retardation; it does fit with ultimate outcome of 
these neuronally deleted mice in that they ultimately become obese 
(Schwer, et. al., 2010), whereas the AS/AGU rats remain underweight 
throughout. However, overexpression of Sirt6 has been shown to extend 
lifespan in mice (Kanfi, et. al., 2012), this is clearly not the case in the 
AS/AGU rats, although the reduction seen in older rats (12 months) with a 
rise seen in the controls may indicate that this Sirtuin still has a role to play 
in the determination of lifespan. Overexpression of Sirt6 has also been 
associated with increased fatty acid oxidation (in liver cells), additionally 
liver specific deletion leads to fatty liver disease (Kim, et. al., 2010). 
Overexpression also reduced the accumulation of visceral fat when on a 
high-fat diet (Kanfi, et. al., 2010). Although this is not immediately 
applicable to the brain it demonstrates the potential for metabolic 
disruption from this particular Sirtuin. The major role for Sirt6 involves 
modulation of DNA repair mechanisms which presents a direct role for this 
Sirtuin in the prevention of DNA damage accumulation. The early increased 
levels of this Sirtuin in AS/AGU rats may represent an increase in activity in 
the DNA damage repair mechanisms, suggesting instability is present. Lower 
later levels suggest an age-related reduction in DNA damage repair either 
resulting from or due to accelerated ageing.  
 
Sirt7 has been demonstrated to possess a role in protection against 
stress in cardiomyocytes (Vakhrusheva, et. al., 2008b) and in activation of 
RNA polymerase 1 (Ford, et. al., 2006). This indicates a role for Sirt7 in the 
maintenance of DNA integrity and prevention of DNA damage.  
 
The Histone deacetylase function of all Sirtuins has been suggested to 
be an important factor in the DNA repair mechanisms, indicating that 
expression of all Sirtuins may be linked to DNA damage accumulation 
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(Kruszewski and Szumiel, 2005). Due to the dependence of all Sirtuins on the 
presence of NAD+ they can all be considered metabolic sensors which 
respond to the metabolic status of the cell (Leibiger and Berggren, 2006). 
Taken together these factors make the Sirtuins ideal sensors for the damage 
or disruption that may lead to accelerated ageing. 
 
The decreased later levels of Sirtuins seen in this study are consistent 
with reports that all Sirtuins decrease with age (Ren, et. al., 2013). The data 
presented here would suggest that levels of the three Sirtuins examined 
start low, build through life, and then reach a tipping point where 
expression wanes in response to old age. This reduction may be indicative of 
DNA damage accumulation and may be a precursor to apoptosis in heavily 
affected cells. Data on apoptotic markers in these cells would provide 
confirmation as to whether this hypothesis is plausible or not. 
 
Overall, the expression of Sirtuins appears to follow a pattern which 
suggests that expression in AS/AGU rats is increased early in life. Given the 
roles of these three Sirtuins in the prevention of oxidative stress, repair of 
DNA damage and modulation of metabolism it is highly suggestive that at 
least one of these factors is involved in the accelerated ageing phenotype of 
the AS/AGU rats. Further data involving the generation of ROS or the 
metabolic state would be required to verify this conclusion.   
 
The data presented here for the Sirtuins, in combination with CDKN2A 
and SA -gal, strongly indicates that the AS/AGU rats are more advanced in 
age, biologically speaking, at both time points. This further indicates that 
the three components of the MTR trinity are also involved. Early Sirt5 
elevation potentially indicates an increase in mitochondrial activity, 
particularly within the urea cycle. This may in turn indicate increased energy 
generation from the citric acid cycle and thus a large increase in ROS 
activity. This activity may result in more oxidative stress from the 
mitochondria, in conjunction with early elevation in Sirt7, this suggests that 
ribosomal activity is also increased. Again this suggests an increase in energy 
usage and thus greater levels of ROS. Finally the elevation in Sirt6 suggests 
increased DNA damage and a reduction of telomere lengths. Taken together 
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this confirms the accelerated ageing phenotype and the involvement of the 
MTR trinity. It is unlikely that this is a direct result the PKC mutation, 
however it is not possible to rule out a potential influence by a more 
circuitous route – alteration of dietary intake via DA disruption. CR or 
disruption to diet is well known to alter the expression of Sirtuins in general. 
Further experimentation involving metabolic cages would be required to 
completely rule out this possibility. 
 
7.3 The accelerated ageing phenotype seen in AS/AGU rats is concurrent 
with DNA methylation changes at the global level. 
 
The global DNA methylation data generated within this project is 
inconclusive, with very few differences reaching significance. The general 
trends are interesting but drawing solid conclusions from these given the 
insignificance of the data is impossible. Further and more refined studies 
would be required to fully explore this research question and determine the 
full methylation status in regards to age. 
 
The lack of change seen here is consistent with some reports which 
suggest that methylation in the brain can be relatively stable over time 
(Gravina, et. al., 2013). Furthermore, it is entirely possible that a general 
hypomethylation associated with advancing age (van Otterdijk, et. al., 2013) 
may be masked by specific hypermethylation of selected sites (Reinius, et. 
al., 2012). Specific genes can demonstrate highly variable methylation levels 
throughout the lifespan, for example methylation of the Sirt6 promoter is 
relatively low during the early (<19) and late phases (>85) of human life and 
peaks in between (Sahin, et. al., 2014). More focused and specific 
investigation of methylation will be required to determine whether the 
trends demonstrated here are indicative of the true nature of accelerated 
ageing in the AS/AGU rat strain. 
 
7.4 Final conclusions 
 
Overall, this study demonstrated that an accelerated ageing 
phenotype is present in the AS/AGU rats compared with their parent strain 
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the AS rat. This ageing phenotype manifests itself with increased cellular 
senescence and a molecular response by the Sirtuins to at least one major 
driver of ageing: DNA damage accumulation or metabolic disruption. 
Attempts to measure the epigenetic effects of this accelerated ageing 
phenotype were inconclusive. The presence of this phenotype is consistent 
with the known PD phenotype of these rats; it also confirms the usefulness 
of this model as an animal model for the development and progression of PD. 
This work provides scope for future work further categorising and developing 
our knowledge of both ageing and PD. 
 
7.5 Future directions 
 
The data presented here leads to great potential for further research 
in new and novel directions. These potential studies fall into two categories, 
firstly improvements or enhancements to the data provided herein and 
secondly novel projects leading from these results. A brief summary of the 
potential in both categories is provided here. 
 
7.5.1 Improvements and enhancements to the current study 
 
First and foremost a further age point would greatly enhance all of 
the data presented here, it would provide linearity to the results and an 
improved view of the data with regards to changes associated with ageing. 
The optimal configuration would be to use 3-4 monthly sampling points 
however this may prove to be prohibitive due to the number of animals 
that would be required to achieve.  
 
Another improvement to this study would be to use dual staining to 
demonstrate the concurrence of increased levels of p16INK4a and SA -gal. 
This method of multiple staining could also enhance the Sirtuin results by 
showing where high levels of each occur and whether these are linked or 
independent.  
 
Incorporation of metabolic studies with Sirtuin expression studies 
would determine whether changes in diet, intake or glucose usage result in 
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altered Sirtuin expression. Furthermore, this would give valuable insight 
into the effects of metabolic factors on not only the expression of Sirtuins 
but also on the effects of Sirtuin expression on lifespan in this particular 
model.  
 
Further co-localisation studies involving the co-expression of the 
three Sirtuins investigated here would provide and insight into whether the 
changes in expression seen are in the same locations or whether these 
alterations occur in adjacent/distant cells. Furthermore, co-localisation 
with p16INK4a and/or SA -gal would determine whether changes in 
expression levels are associated with cellular senescence or not. 
 
Further enhancements include conducting investigations in more 
brain regions, or more localised brain regions for example looking at the 
SNC independently rather than as a component of the basal ganglia. 
However, this requires extreme precision and equipment that may only be 
within the grasp of a few labs in the world. 
 
Measurement of specific sites for methylation (Koch, et. al., 2012) 
would further enhance the data on senescence, it might also provide early 
insight into the initiation of senescence. Measurement of 5hmC may also 
provide insights into the true nature of the methylation changes seen here. 
 
Site specific methylation studies and measurement of 5hmC would 
improve the data received from this study and provide valuable insight into 
the level and nature of DNA methylation in this ageing model. 
 
A repeat of this experimental setup, with additional measurements 
of DA and glucose usage with female rats would provide a much more 
complete dataset. This may also allow further examination of the 
differences between the sexes in regard to ageing. Furthermore, it would 
provide valuable information on the AS/AGU model in general allowing for 
further experimentation with this rat model. 
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7.5.2 Potential research projects 
 
With the demonstration of altered p16INK4a expression from the 
CDKN2A locus it becomes apparent that the products of this locus may be 
involved in the phenotypes present in this rat strain. Therefore it would be 
prudent to incorporate the other products (p14ARF and p12) of this gene 
locus in further studies. Furthermore, it may also be advisable to 
incorporate relating genes and loci into future studies including CDKN2B, 
Rb and p53 to generate a more complete picture of the status of ageing in 
these rats. This data would also provide invaluable insight into the 
pathways involved in the PD phenotype if it was coupled with a more in 
depth investigation of localization, for example by examining key locales of 
the Basal ganglia to determine expression differences associated with the 
Dopamine disruption. 
 
The obvious differences seen in the expression of the three Sirtuins 
examined here warrants further investigation. An expanded study involving 
all seven mammalian Sirtuins may reveal more interactions between these 
molecules and would enhance our understanding of the action and effect of 
these molecules with regard to ageing and PD. The high level of 
information available for Sirt1 in these contexts would also provide a 
necessary guideline for a more complete and accurate evaluation of the 
role of the other Sirtuins. This study may also involve a greater number of 
smaller areas of the brain in order to determine micro-differences in 
expression patterns, particularly focused around the SN. 
 
More complete and thorough investigation of the methylation status 
throughout would require a completely new study aimed at elucidating the 
presence and effects of epigenetic changes with regards to the accelerated 
ageing phenotype demonstrated in the AS/AGU rat. This study should 
incorporate multiple time points and more accurate methodology for 
example bisulphate sequencing, which would allow the analysis of 
individual promoters as well as a more accurate measurement of global 
DNA methylation levels (Chatterjee, et. al., 2012). Another possibility is to 
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use Methylated DNA immunoprecipitation (MeDIP) methods to enrich 
methylated sequences (Weber, et. al., 2005). 
 
The presence of an accelerated ageing phenotype within the AS/AGU 
rat opens numerous possibilities for future studies, particularly related to 
the PD phenotype it also presents with. In fact, these are more than likely 
closely related however further studies that conclusively demonstrate this 
would be required. More accurate methylation data specifically within the 
Basal ganglia would provide a greater insight into localized changes. 
Determination of the metabolic status of these animals in relation to age-
related changes would also enhance our knowledge of the ageing process as 
it manifests in this rat strain. Once these studies have been completed it 
would be possible to examine the effects of L-Dopa in the context of 
altering expression of Sirtuins, p16INK4a and methylation status to determine 
whether this effective treatment for PD has any effect on the ageing 
phenotype or whether it merely overcomes and masks the effects of the 
loss of DA.  
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8.1 Appendix 1 
 
8.1.1 Appendix 1a – CDKN2A 
8.1.2 Appendix 1b - Sirtuins 
Gene 
Symbol 
Assay ID 
Gene Name and 
Alternative 
names 
Gene 
Aliases 
N
C
B
I 
C
h
ro
m
o
so
m
a
l 
L
o
c
a
tio
n
 
O
rg
a
n
ism
 
Forward primer 
DNA sequence 5’-3’ 
Reverse primer 
DNA sequence 3’-5’ 
CDKN2A 
R
n
0
0
5
8
0
6
6
4
_
m
1
 
cyclin-dependent 
kinase inhibitor 2A 
(CDKN2A);  
p16; 
ARF;  
MTS1;  
INK4A;  
p19ARF;  
 
Arf, 
INK4A, 
MTS1, 
p16, 
p16Cdkn
2a, 
p19ARF 
5q32 Rat ATGGAGTCCTCTGCAGATAGA ATCGGGGGTACGACCGAAAGTGTT 
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8.1.3 Appendix 1c – Housekeeping gene (reference gene) 
Gene 
Symbol 
Assay ID 
Gene Name and 
Alternative 
names 
Gene 
Aliases 
N
C
B
I 
C
h
ro
m
o
so
m
a
l 
L
o
c
a
tio
n
 
O
rg
a
n
ism
 
Forward primer 
DNA sequence 5’-3’ 
Reverse primer 
DNA sequence 3’-5’ 
Sirt5 
 
R
n
0
1
4
5
0
5
5
9
_
m
l 
Sirtuin 5 - 17p12 Rat 
GTCTTTCCCAAGATGCAAAGGT 
GACGGTTTCAGGATCACAACAG 
Sirt6 
R
n
0
1
4
0
8
2
4
9
_
m
l 
Sirtuin 6 
- 7q11 
Rat GCAGTGGTGTGTGGAGTGTGTA ACACCCAGTGTTCAGCACAGTT 
Sirt7 
R
n
0
1
4
7
1
4
2
0
_
m
l 
Sirtuin 7 - 10q32.
3 
Rat GCCGCATACCCAATACAGAAA CAAGGACACCTCCATCCTATCC 
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Gene 
Symbol 
Assay ID 
Gene Name and 
Alternative 
names 
Gene 
Aliases 
N
C
B
I 
C
h
ro
m
o
so
m
a
l 
L
o
c
a
tio
n
 
O
rg
a
n
ism
 
Forward primer 
DNA sequence 5’-3’ 
Reverse primer 
DNA sequence 3’-5’ 
Gapdh 
R
n
0
1
7
7
5
7
6
3
_
g
1
 
Glyceraldehyde-3-
Phosphate 
dehydrogenase 
 
Gapd 4q42 Rat 
TGATGACATCAAGAAGGTGGTG
AG 
 TTCTTGGAGGCCATGTAGGCCAT 
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